Genomics
for Good
Illumina Corporate Social
Responsibility Report 2023

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix22023 CSR Report

At Illumina, we are
driven by the powerof genomics topositively impact theworld and shape amore sustainable andequitable future for all.
Our fifth annual report documents
the evolution and performance of our
Corporate Social Responsibility (CSR)
program from January 1 throughDecember 31, 2023.

TA B L E O F C O N T E N T S
A message from our CEO
Introduction
5 2023 CSR highlights
6 Celebrating 25 years of Illumina
7 Recognition
8 About Illumina
9 Business overview
CSR at Illumina
11 CSR governance
12 CSR strategy
14 Materiality
15 Engaging our stakeholders
16 Progress on our 2030 targets

This document reflects the progress
we have made and looks to
the future with our continued
commitment to deepen our impact
on human health by serving
as a champion for patients, ourcommunities, our people, andour planet.
Learn more about this report

Accelerate access to genomics
18 Strategic approach and impact
19 Innovation
21 Affordability
22 Reach
27 Impact in action
Nurture our people and communities
29 Strategic approach and impact
30 Our people
31 Practice diversity, equity, and inclusion
33 Attract extraordinary talent
34 Invest in our people
36 Employee health, safety, and well-being
38 Employee engagement and community impact
39 Impact in action

Integrate sustainability
41 Strategic approach and impact
42 Driving climate action across our value chain
44 Operate sustainable facilities
46 Develop sustainable products
47 Leveraging genomics for sustainability applications
49 Impact in action
Operate responsibly
51 Strategic approach and impact
52 Practice strong corporate governance
55 Business ethics and integrity
58 Data privacy and cybersecurity
60 Responsible supply chain
63 Product quality and safety
Appendix
65 About this report
66 Progress on our 2030 targets
67 Key performance indicators
81 Indices (GRI, SASB, TCFD, UNGC)
89 Assurance statements
90 Disclosures

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix32023 CSR Report

Message from our CEO
Since joining Illumina, I’ve witnessed the passion ourcustomers, employees, and partners share around
improving human health by unlocking the power ofthe genome. As an industry leader, Illumina is uniquely
positioned to advance the adoption of genomics
across the life sciences ecosystem with our innovative
products, services, and solutions.
Despite challenging market conditions, we’vemaintained our steadfast commitment to serving
customers and supporting our environmental, social,and governance priorities. Aligned with our businessstrategy and core Illumina values, we continue
taking bold, meaningful steps to accelerate accessto genomics, empower our communities, integrate
environmental sustainability, nurture our people, andoperate responsibly.

Make our customers the heroes in their labs
Our customers' ambition to solve humanity's biggest
challenges inspires us to push the boundaries of what
is possible and create the genomics tools that canturn big ideas into life-changing discoveries. Our goal
is to make them the heroes in their labs, armed with acomprehensive portfolio of core sequencing innovation,
sample-to-answer solutions, and lab services.

Accelerate access to genomics
Bringing the benefits of genomics to more people
requires driving down the cost of sequencing,
expanding into new markets, and increasing thediversity of genomic data. In 2023, we trained morethan 27,000 health care professionals and increased thenumber of patients covered for genomic testing from
1.2 billion to 1.3 billion. In Canada, we helped fund a
new project aimed at bridging the diagnosis gap for theregion’s Indigenous children, just one of many initiatives
we support to increase diversity in human genetics.

We also launched several new products, including
the NovaSeq™ X Systems, powered by XLEAP-SBS™
chemistry; our TruSight™ Oncology 500 ctDNA v2
research assay, enabling comprehensive genomic
profiling from liquid biopsy samples; and the 25B flow
cell, which can generate tens of thousands of wholegenomes per year at the lowest cost per sample ofany Illumina platform.

Our customers' ambition to solve
humanity's biggest challenges
inspires us to push the boundaries
of what is possible and create thegenomics tools that can turn big
ideas into life-changing discoveries.”

Jacob Thaysen
Chief Executive Officer

Jacob Thaysen
Chief Executive Officer

Nurture our people and help them thrive
I’m incredibly proud of our global team. We share apassion for improving the world around us throughgenomics, and believe in the power of an inclusive,
collaborative, and caring workplace. In 2023, we
maintained a zero net pay gap for the fifth consecutive year; and reached 45% female workforce
representation, with a 5% increase in female leadershiproles over the last three years. Nearly 60% of ourglobal employees participated in charitable giving
and volunteering during the year.

Integrate environmental stewardship into
our business and innovations
We know improving human health is tied to creatinga healthier planet. Making bold environmental
commitments, and helping customers achieve their*Using onsite solar, purchased renewable energy, and renewable energy credits.

sustainability goals, is part of our role as an industry
leader. Launched in 2023, our NovaSeq X instruments
improve the sustainability of reagents with 90% lesspackaging, 50% less plastic, and a 61% reduction inclimate change impact. Additionally, in 2023 weachieved 100% renewable electricity* for a second
consecutive year.

Operate responsibly in all that we doEvery minute, approximately 7.5 human genomes aresequenced on an Illumina platform. That impact comeswith great responsibility. We're committed to operatingwith integrity and adhering to high ethics, privacy,
and security standards. In 2023, 100% of Illumina corefacilities participated in third-party audit programs. In
addition, we expanded our ISO data privacy certification
to include additional products and completed the

EU-US and Swiss-US Data Privacy Framework selfcertification and ISO 27701 certification.

Our next 25 years of innovation
Founded in 1998, Illumina has proven time and timeagain how unlocking the power of the genome can
exponentially improve the human condition. The futureis bright for Illumina and our industry, as we consider
the role genomics can play in improving the health ofthe planet and its people. Thank you to our customers,
partners, and employees around the world for helping
bring our mission to life. I look forward to continuing ourjourney as we build a stronger, healthier world together.
Jacob Thaysen
Chief Executive Officer

Table of contents
2023 CSR Report

2023 CSR highlights

CEO message
Celebrating 25 years of Illumina

Introduction
Recognition

Introduction

CSR at Illumina
About Illumina

AccessBusiness overview

PeopleSustainability

Responsibility

Appendix4

Table of contents
2023 CSR Report

2023 CSR highlights

CEO message
Celebrating 25 years of Illumina

Introduction
Recognition

CSR at Illumina
About Illumina

AccessPeopleSustainability

Responsibility

5

Business overview

2023 CSR highlights
AC C E L E R AT E AC C E S S
TO G E N O M I C S

1.3 billion
lives covered

N U R T U R E O U R P EO P L E
AND COMMUNITIES

Zero

net pay gap maintainedfor fifth consecutive year

100%

100%

of global electricity consumption
came from renewable sourcesof Illumina core facilities participatedin third-party audit programs

less packaging weight and waste
in NovaSeqTM X Series reagents

90%

11%

352

5%

increase in female executive
leadership representation in
the last three years

100%of our strategic supplierscommitted to minimize theirenvironmental footprint

Completed> 27,000

58%

8%

91%

enabled for liquid biopsy
samples‡ launched

NovaSeq X Series instruments
enabling whole-genome
sequencing (WGS) at $200 USD
genome* shippedTM

health care professional
learners reachedemployee participation in giving
and volunteer programs

decrease in water consumption(YoY) at core sites†*$200 USD genome on NovaSeq X Series is delivered at list price on 25B flow cell. Data on file.
†Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, the Netherlands, and Singapore Woodlands.

‡

O P E R AT E
R E S P O N S I B LY

minority representation in
the US workforce

Comprehensive
genomic profiling52%

I N T EG R AT E
S U S TA I N A B I L I T YWith our new TruSight™ Oncology 500 ctDNA v2 research assay.

Appendix

diverse supplier spend

The EU-US and Swiss-US
Data Privacy Framework (DPF)
Self-Certification and ISO 27701
Certification

independent Board of
Directors (all independent
with exception of CEO)

Table of contents
2023 CSR Report

2023 CSR highlights

CEO message

Introduction

Celebrating 25 years of Illumina

Recognition

Celebrating
25 years of
Illumina

CSR at Illumina
About Illumina

AccessPeopleSustainability

Responsibility

Appendix
6

Business overview

2019

Researchers used the MiniSeqTM
System to sequence a sample of
COVID-19 in Wuhan and enabled
partners to develop the vaccines
without a live virus.

2017

Since its inception in 2017, our market
access team has been working withconsortia, governments, payers, andothers to increase insurance coveragefor genetic testing. 1.3 billion lives are
now covered. Learn more

2023

2008

Illumina completed the first-eversequencing of an African humangenome. From the very beginning,
we have prioritized increasing
genomic data diversity.

2001

2020

2018

We launched our first
product.

[image of first
product – array
technology]

2010

On June 9, we received
the first FDA Emergency
Use Authorization fora sequencing-based
COVID-19 diagnostic test.

We began shipping the NovaSeq
X Series, our most powerful andsustainable high-throughput NGS
systems, resulting in the ~$200
genome* and a 61% reduction inclimate change impact†

We introduced a pan-cancer assay
designed to identify known andemerging tumor biomarkers, helping
to accelerate the field of precisiononcology with comprehensive
genomic profiling.

We brought the cost of sequencing
a human genome from $150,000 to$10,000 with the Illumina HiSeqTM 2000.
Learn more about how we’re making
genomics more affordable.

2007
1998

Illumina was founded.

We launched the Genome AnalyzerTM,
introducing the world to Illumina
sequencing by synthesis (SBS)
chemistry, advancing sequencing
chemistry to be faster, more accurate,
and more stable.

*$200 USD genome on NovaSeq X Series is delivered at list price on 25B flow
cell. Data on file.
†

Compared with NovaSeq 6000 reagents.

Table of contents
2023 CSR Report

2023 CSR highlights

CEO message

Introduction

Celebrating 25 years of Illumina

Recognition

CSR at Illumina
About Illumina

AccessBusiness overview

Recognition 2023
•3BL 100 Best Corporate Citizens•AmCham Corporate and Societal Action:
Recognition for Excellence in Singapore(CARES)•Military Times Best for Vets
•MSCI CSR (AA)•Newsweek America's Greatest
Workplaces for Diversity••Community Chest Singapore Charity Silver•Disability Equality Index, Best Places to Work•Newsweek America’s Greenest•Dow Jones Sustainability Indices•EcoVadis Silver Sustainability Rating•Fast Company’s Innovation by Design•Newsweek Excellence Index•Refinitiv Top 100 Global Diversity

CDP Supporter

for Disability Inclusion

Awards for the NovaSeq X Series (Honoree)•Fast Company’s World Changing Ideas

Awards for the NovaSeq X Series (Honoree)•Forbes America's Best-In-State Employers•Forbes World's Best Employers•Forbes World’s Top Companies for Women•FTSE4Good Index•IBO Gold Award for Design for the NovaSeq
X Series••JLens CSR Awards•Just Capital and CNBC America's
ISS CSR 1 | 1 | 10

Most Just Companies

Companies•Newsweek America’s Most Responsible
Companies

and Inclusion Index•S&P Global's Sustainability Yearbook
Member•SANDAG iCommute Diamond Awards•Sustainalytics Morning Star | Industry Top
Rated CSR

•The Straits Times Singapore's Best
Employers•TIME World's Best Companies•U.S. News & World Report Best
Companies To Work For•Workplace Safety and Health Council
Silver Award (Singapore)

PeopleSustainability

Responsibility

Appendix7

Table of contents
2023 CSR Report

2023 CSR highlights

CEO message
Celebrating 25 years of Illumina

Introduction
Recognition

CSR at Illumina
About Illumina

AccessPeopleSustainability

Responsibility

Appendix
8

Business overview

About Illumina

We are a global genomics and human health leader innovating the future of precision health. Unlocking the power of genomics
is exponentially improving the human condition. This is why we are committed to driving continuous innovation and deep
collaboration that will enable positive and impactful people- and planet-healing solutions.
O U R PR O M I S E

OUR MISSIONO U R PU R P OS E

To improve human healthby unlocking the powerof the genome.

Drive the positive progressof genomics to make it
useful for all.

We deliver breakthroughs that
redefine what’s possible in genomics
and accelerate impactful healthadvances globally.

O U R PR I N C I PLES

Accelerating
accessRedefining
possible

Leading purposefuladvances

Broadening impact
with collaborations

Acting with integrity tobenefit humanity

Making genomics accessible is critical inrealizing its potential to save and improve
lives. That’s why we are committed to driving
down the cost of sequencing, expanding
access to advanced technology, andincreasing the diversity of genomic data.

The genome has the potential to solve
humanity's biggest challenges. Our
industry-leading technology enables
researchers and clinicians to turnbig dreams into impactful genomic
discoveries that improve lives andchange the course of diseases globally.

Our passion for supporting customers andhelping them achieve their goals guides what
we do. Inspired by deep customer insights, welead the way in delivering purposeful advancesthat address critical needs and support
researchers and clinicians as they make lifechanging breakthroughs and decisions.

Improving health at scale requires visionand collaboration with changemakers
across the ecosystem. Together,
we're finding answers to life's biggest
questions and broadening the positive
impact of genomics around the world.

Doing the right thing is core to
who we are and what we do. We
have an unrelenting dedication
to genomics for good, and holdourselves to the highest standardsin ethics, privacy, and security.

O U R VA LU ES

Innovation
is in our DNA

We are relentlessin the creation ofgreat products

We collaborate
deeplyWe move fast andembrace change

We are open

The power of genomics
What causes a cancer cell to mutate? How do we identify a novel
virus and create a vaccine? How do we diagnose a rare genetic
disease? How do we safeguard the world’s food supply? What effectdoes climate change have on biodiversity? The answer to these andthousands more of life’s most pressing questions can be found in theworld of genomics.

Table of contents
2023 CSR Report

CEO message

2023 CSR highlights

Introduction

Celebrating 25 years of Illumina

Recognition

CSR at Illumina
About Illumina

AccessPeopleSustainability

Responsibility

Appendix
9

Business overview

Business overview
C O R E I L LU M I N A AT A G L A N C E

1998

~9300

founding year

employees$1 billion+~9500

in R&D (GAAP)

customers

450,000+

9893

sequencing publications

patents worldwide

C O R E I L LU M I N A R E V E N U E$4.44 billion

6% 5-Core Illumina 2023 revenue

25,000+

YEAR

CAGR

$4.5B
$3.3B

$3.5B

$4.6B

$4.4B

70%

Consumables

$3.2B

16%

instruments installed

Instruments

160+

countries receive our products

2018

2019

2020

2021

2022

2023

14%

Service and OtherM A R K E T S EG M E N T S

Oncology

Reproductive Health

Genetic Disease

Research/Applied Genomics

Infectious Disease

Drug Discovery

Multi-Omics

S EQ U EN C I N G SYSTEM S
LOW-THROUGHPUT

MiSeqTMMiniSeqTM

MID-THROUGHPUT

iSeqTM 100

NextSeqTM 500

NextSeqTM 550

NextSeqTM 1000/2000

HIGH-THROUGHPUT

NovaSeqTM 6000

NovaSeqTM X Series

DIAGNOSTIC

MiSeqTM Dx

NextSeqTM 550Dx

NovaSeqTM 6000Dx

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

Introduction

CSR at Illumina

Engaging our stakeholders

CSR at Illumina

AccessProgress on our 2030 targets

PeopleSustainability

Responsibility

Appendix10

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

Introduction

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
11

Progress on our 2030 targets

CSR governance
CSR is integral to how we do business. Our governance structure
facilitates accountability, transparency, and continuous improvement.
1

1
Board
of Directors

2
Nominating/Corporate
Governance Board Committee

3
CSR Executive Steering Committee

4
Philanthropy Governing Board

5
External Ethics Advisory Board

6
CSR Functional Group

7

The Board of Directors governs the managementof our material CSR issues and receives updates
on current performance and future strategic plansat least annually or more frequently if materialchanges occur.

2 The Nominating/Corporate GovernanceCommittee assists the Board in overseeing
the company’s material CSR issues, except as
specifically delegated to another Board committee(the Compensation Committee oversees DEI and
the Audit Committee oversees cybersecurity).
3 The CSR Executive Steering Committee provides
guidance on CSR strategic plans and practices,
approves major programs, and monitors progress
toward targets. It comprises senior leaders,
including the general counsel, chief of global
operations, chief people officer, chief technology
officer, chief marketing officer, vice president ofinvestor relations, and global head of CSR.
4 Philanthropy Governing Board
The Illumina Corporate Citizenship Steering
Committee has oversight on philanthropic
contributions from Illumina. The Illumina Corporate
Foundation Board governs the philanthropy
associated with the Illumina Corporate Foundation,
a separate entity and private foundation.

5

The External Ethics Advisory Board
provides guidance on a range of strategic
issues, including recommendations
on emerging ethics matters, policies,and regulations that are relevant to the
genomics industry.

6

The CSR Functional Group is responsible
for strategy development, program
implementation, and CSR reporting.

7

Supporting CSR Working Groups:

8

Employee Engagement Groups:•Executive Diversity Council•EHS Steering Committee•Quality Council•Sustainable Product Core Team
•Supplier Diversity Committee•Privacy Steering Committee•Sustainability Green Teams•Illumina Cares Volunteer Ambassadors•Employee Resource Groups (ERGs)

Working Groups

8
Employee Engagement Groups

Select CSR targets are included in annual corporate goals and influence executive compensation
through the management performance scorecard.
Learn more about our Board governance, member tenure, independence, and diversity.

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

CSR integration
into our business
Our CSR strategy is guided by our businessstrategy and the voice of our stakeholders.
It provides a lens to evaluate risks andopportunities to foster and promote long-term
shared value.
Governed by our Board of Directors, our CSR strategy
promotes the sustainable stewardship of our business byfocusing on accelerating access to genomics, nurturing ourpeople and communities, integrating sustainability into our
products and operations, and operating responsibly.
AccessWith our mission to improve human health by unlocking
the power of the genome, we are committed to making our
products more affordable, accessible, and sustainable.
PeopleThe success of our mission relies on engaging extraordinary
talent and helping them thrive. Putting people first and doing
the right thing is core to who we are and what we do.
Sustainability
Genomics has the potential to solve humanity’s biggest
challenges and the planet’s most pressing issues. We
integrate sustainability in our operations, products, and value
chain with recognition that human health and the health of ourenvironment are intertwined.
Responsibility
As genomic pioneers, we hold ourselves to the highest
standards in our actions, ensuring that the technology wecreate and the data we collect are used safely, ethically,
and responsibly. We are committed to transparency andconnected by a dedication to genomics for good.

Introduction

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
12

Progress on our 2030 targets

By embedding our CSR strategy into our business, we are driving
positive stakeholder impact and long-term shareholder value.

ImpactNurture our people
and communities

Integrate
sustainability

Accelerate accessto genomics

Operateresponsibly

CSR vision
Deepen our impact on humanhealth by serving as a champion
for patients, our communities,
our people, and our planet.

PurposeDrive the positive
progress of genomics tomake it useful for all.

MissionImprove humanhealth by unlocking
the power of thehuman genome.

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

Introduction

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
13

Progress on our 2030 targets

CSR strategy
We are deepening our impact on human health by serving as achampion for patients, our communities, our people, and our planet.

Accelerate access to genomics

Nurture our people and communities

Integrate sustainability

Operate responsibly•Be the engine of genomic innovation•Drive down the cost of sequencing•Expand the reach of genomics•Practice diversity, equity, and inclusion•Attract extraordinary talent•Invest in our people•Support employee health, well-being, and safety•Engage our employees and communities•Drive climate action•Operate sustainable facilities•Develop sustainable products•Leverage genomics for sustainability applications•Practice strong corporate governance

UN SDGUN SDGUN SDGand compliance•Act ethically and with integrity•Uphold high standards for data security
and privacy•Foster a responsible supply chain•Advance product quality and safety
UN SDGTable of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Introduction

Materiality

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
14

Progress on our 2030 targets

Materiality
We prioritize action on our most material* environmental, social, and governance(ESG) issues, supported by robust governance, transparency, and accountability.
Through managing the risks and opportunities related to each material ESG issue, we
execute on our purpose and deliver the greatest positive impact to our business, ourstakeholders, and the planet.

Reporting frameworks and external benchmarking

Our materiality assessments guide our CSR strategy by understanding whichmaterial issues matter most to our business, our stakeholders, and society. In 2021,
we refreshed our 2018 baseline materiality assessment, which further refinedand validated our priorities and focus areas. The updated materiality assessment
incorporated principles of a double materiality approach by understanding which
topics could have a potential impact on our business and which topics have apotential impact on external stakeholders, society, and the environment.
In this report, we outline our management approach, targets, connection to the United
Nations Sustainable Development Goals (UN SDG), and performance for each ofour material CSR topics. Our reporting efforts align with the leading frameworks andexternal benchmarking tools.

Material CSR topics

Employees

ENVIRONMENTSOCIALG OV E R N A N C E•Climate action•Sustainable facilities•Sustainable products•Access, innovation,•Supply chain management•Data privacy

and affordability•Human capitalmanagement†

and cybersecurity•Corporate governance•Business ethics•Product quality and safety

Customers

Suppliers

Investors

Nonprofits

Distributors

We engagewith a wide
range ofstakeholders

Channelpartners*In this report, we use the terms “material” and “materiality” to refer to topics that reflect the meaningful environmental,social, and governance impact of Illumina. The use of such terms shall not be deemed to constitute an admission as tothe materiality of any information in this report for purposes of applicable securities laws or any other laws of the UnitedStates, nor are we using them as they are used in the context of financial statements and financial reporting.
The human capital management topic includes the following themes: DEI, recruitment, development, engagement,
safety, and wellness.

†

CSR peergroupsCommunity partners

Industry leaders

Health care providers

Governments & regulatory

We routinely gather feedback on
ESG topics from our stakeholders
and work to create an open
dialogue. We are committed tooperating with transparency andopen communication to develop
trusted relationships with all
our stakeholders. Stakeholder
feedback is embedded into our
CSR strategy and programming.

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

Introduction

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
15

Progress on our 2030 targets

Engaging our stakeholders
Stakeholder
groups

How we engage

How we respond

Investors

Investor Day, CSR Virtual Investor Event, quarterly and annual reports, regular meetings, andcommunication via phone, email, and website.

Based on feedback for increased accessibility of data, we created an CSR data hub on our website that promotes
quick access to our CSR targets, policies, and performance.

Customers

Our Customer Experience team regularly surveys customers to understand how we can improve. We
conduct quarterly relationship surveys, leverage machine-learning tools, and provide an open channel
for customer feedback from our field employees. In 2023, we achieved a Customer Net Promoter
Score of 54, and 9 out of 10 customers find it easy to do business with our team.

We received feedback from customers on the sustainability of our products and on decreasing the amount of
packaging we use. With the launch of the NovaSeq X Series, we were able to reduce packaging by 90% and achieve
a 61% reduction in climate impact.* Learn more

We partner with patients, families, and organizations that represent communities to help raiseawareness, build hope, and create change.

Work from scientists at Illumina and our collaborators has shown that patients who get access to whole-genome
sequencing (WGS) are twice as likely to have a change in management and are more likely to get the precision carethey need. As of 2023, over 1.3 billion lives are covered for genomic testing. Learn more

Patients

Through evidence generation, education, and community outreach, Illumina is committed to
advocating for health care coverage and accelerating the adoption of genomics as a diagnostic tool.
We engage and communicate with our employees via regular pulse surveys, virtual and in-personcompany meetings, email, internal events, performance reviews, training, ERGs, recognition, and otherinternal platforms.

We received feedback that leaders wanted development opportunities, which resulted in delivering global leadershipprograms targeted to every leadership level in 2023. Learn more

Suppliers

Our procurement and supply chain management team engages suppliers through tenders, training,surveys, meetings, and questionnaires.

In 2023, we expanded our current practices to protect and promote the right to freedom from forced labor andmodern slavery by engaging with a third party to help us initiate human rights due diligence of our supply chain.
Learn more

Health care providers

We aim to increase genomic literacy by engaging health care professionals through podcasts, online
education, roundtables, conferences, and meetings.

In 2023, through independent medical education partnerships with professional societies and the medical
community, we provided education across all clinical segments, reaching 27,000 learners and measuring a 99%
increase in participant knowledge and a 98% increase in competence reported. Learn more

Community investment grant recipients complete both a mid-grant and final impact survey following
completion of their projects to help guide future opportunities and provide feedback.

In 2023, a STEM nonprofit grantee working to create a mobile lab experience communicated delays in construction
when they filed their mid-year grant surveys. This feedback enabled us to adjust the launch activation of their exhibit
and find alternative volunteer options onsite for our employees while the mobile lab was being completed.
Learn more

Illumina connects with governments and organizations around the world to engage and educate
policymakers and key stakeholders on issues that impact our mission and business.

In 2023, we focused engagement with public-policy stakeholders around advancement of precision medicine;
adoption and reimbursement for genetic testing; adoption and reimbursement for noninvasive prenatal testing;adoption and funding for genomic infectious disease surveillance; and promotion of STEM opportunities.

We seek guidance from our Ethics Advisory Board quarterly on a range of strategic issues.

The Ethics Advisory Board’s work includes providing strategic advice to Illumina about emerging policies andregulations relevant to the genomic industry and the company’s interests, and ethical issues arising from specifictechnology or products.

Employees

Community partners

Government andregulators

Ethics Advisory Board*Based on end market assessment NY, US.

Table of contents
2023 CSR Report

CSR governanceCEO message
CSR strategy

Materiality

Introduction

CSR at Illumina

Engaging our stakeholders

AccessPeopleSustainability

Responsibility

Appendix
16

Progress on our 2030 targets

Progress on our 2030 targets
Our focus areas

Objectives

Accelerateaccess to
genomics

2 Drive down the cost of sequencing

2030 Targets

1 Be the engine of genomic innovation

Achieved

In Progress

2023 Progress

Achieve 2 billion covered lives by 2026
Reach at least 25,000 medical education learners annually
Reach 5 million STEM learners

3 Expand the reach of genomics

1.3 billion lives covered>27,000 medical education learners reached
1.6 million STEM learners reached from 2019 baseline

SDG Alignment
Targets: 3.d, 17.6, 17.7, 17.16

Nurture ourpeople andcommunities

Increase gender representation in global leadership*
Maintain zero net pay gap
Increase minorities** in executive leadership‡ (US)Increase underrepresented minorities§ in US workforce and leadership*
Reduce recordable injury and illness rate
Donate 100,000+ volunteer hours
Achieve 50% employee participation in giving and volunteering

1 Practice diversity, equity, and inclusion
2 Attract extraordinary talent
3 Invest in our people
4 Support employee health, safety, and well-being
5 Engage our employees and communities

4% increase from 2019 baseline
Maintained for 5th consecutive year
8% increase from 2019 baseline
2% increase in leadership; 1% increase in workforce from 2019 baseline
48% decrease from 2019 baseline
47,130 volunteer hours donated from 2019 baseline
58% employee participation

SDG Alignment
Targets: 10.3, 5.bIntegrate
sustainability

1 Drive climate action
2 Operate sustainable facilities

Deliver net zero emissions (Scope 1,2,3) by 2050
Reduce emissions by 46% (Scope 1,2)
Reduce emissions by 46% (Scope 3)
Achieve 100% renewable electricity
Reach 90% landfill diversion at core sites
Reach 10% reduction in water intensity at core sites
Reduce packaging by 75%

3 Develop sustainable products
4 Leverage genomics for sustainability applications

In progress
48% decrease from 2019 baseline†
16% increase from 2019 baseline; 24% decrease YoY
100% renewable electricity†
56% landfill diversion at core sites
2.6% increase in water intensity at core sites; 8.3% decrease YoY in total water consumption
53% reduction from 2019 baseline

SDG Alignment
Targets: 12.2, 12.5, 13.2

Operateresponsibly

1 Practice strong corporate governance and compliance
2 Act ethically and with integrity
3 Uphold high standards for data security and privacy
4 Foster a responsible supply chain

Through onsite generation, purchased renewable electricity, renewable energy
credits, and Green-e certified nature-based carbon credits.

†

100% strategic suppliers committed to reducing their environmental footprint
11% spend with diverse suppliers (US)Top industry rating for DJSI, Sustainalytics, Just Capital, and others

SDG Alignment
Targets: 9.2, 10.3, 17.16

5 Advance product quality and safety
Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison,
UK Illumina Centre, the Netherlands, and Singapore Woodlands.

Ensure 100% strategic suppliers committed to reducing their environmental footprint
Achieve 20% spend with diverse suppliers (US)Achieve top industry CSR ratings

Leadership: manager, equivalent, and above.

*

Executive leadership: director, equivalent, and above.

‡

Underrepresented minorities (US): Black, Native, Pacific Islander, Hispanic or Latino, two or more.
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.

§**

As our business evolves and matures, we consistently evaluate our CSR strategy, targets and theconnection to our business priorities. Changes in leadership and macroeconomic trends have led toprioritization of our 2023 targets listed here. A deeper review with a double materiality lens is planned
for future inclusion and evaluation.

Table of contents
2023 CSR ReportInnovation

Affordability

CEO message
Reach

Introduction

CSR at Illumina

Access

Impact in action

Accelerate accessto genomics

PeopleSustainability

Responsibility

Appendix17

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

We are committed to accelerating access togenomics to realize health equity for billions
of people around the world. Making genomics
available to all is critical in realizing its potential
to save and improve lives. That’s why we are
driving down the cost of sequencing, expanding
access to advanced technology, and increasing
the diversity of genomics data.
K E Y O B J ECT I V E S

Be the engine of genomic innovation

2

Drive down the cost of sequencing

3

Expand the reach of genomics

2023 H I G H L I G H T S

UN SDGS

211

352

335

1.3 billion

new patent applications in 2023,
totaling 9893 patents issued
worldwide by end of 2023

patients supported throughphilanthropic iHope programming

units of new breakthrough
NovaSeq X series shipped

lives covered> 27,000 health care professional learners reached

PeopleSustainability

Responsibility

Appendix
18

Impact in action

Strategic approachand impact

1

AccessTable of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix19

Impact in action

Innovation
Our mission is urgent because we understandthat today’s discoveries have the potential tohelp tomorrow’s patients and address some of
the world’s most pressing challenges.
Every technological breakthrough that reduces cost, improves
throughput, decreases turnaround time, or improves ease ofuse helps us realize our potential, improving more lives andprotecting our planet.

~7.5

human genomes
were sequenced on
our platforms every
minute in 2023

Innovation is key to our continued growth as a company andthe scale of impact created by our products and services.
Inspired by deep customer insights, we lead the way indelivering purposeful advances that address critical needs andsupport researchers and clinicians as they make life-changing
breakthroughs and decisions.

Product innovation highlights
Change the world with the NovaSeq X Series
The first NovaSeq X andNovaSeq X Plus shipments weredelivered in early 2023. Powered
by XLEAP-SBS chemistry—aneven faster, higher quality,
and more robust version of ourproven SBS chemistry—theydeliver extraordinary throughput
and accuracy to perform
data-intensive applications at
production scale.

DRAGENTM technology, available
onboard or in the cloud, provides
award-winning accuracy for
rapid, easy-to-use, and efficientgenomic data analysis.
The NovaSeq X and NovaSeq
X Plus Systems were purposedesigned to be our mostsustainable sequencing systems
yet. Learn more

AWA R D S R EC E I V E D:

•2023 IBO Gold Award
for Design•Fast Company’s 2023

World Changing Ideas
Awards (Honoree)•Fast Company’s 2023
Innovation by DesignAwards (Honoree)

Enabling comprehensive genomic
profiling of solid tumors

Greater throughput at ourlowest cost per gigabase

The most trusted benchtop
sequencing systems

Announced in
2023, the new
TruSight Oncology
500 ctDNA v2 is a
research assaythat enables
noninvasive
comprehensive
genomic profiling (CGP) of circulatingtumor DNA (ctDNA) from blood.

In 2023, Illumina launchedthe 25B flow cell (300-cyclekit) and software updatev1.2 for the NovaSeq X
Series, enabling the $200
genome and continuing ourjourney of making genome
sequencing more accessible and powering
more expansive sequencing projects.
Customers can now sequence 2.5× morecells in half the time* with the 25B flow cellon NovaSeq X Plus. Learn more

The NextSeq 1000
and NextSeq 2000
Sequencing Systems
are flexible andscalable, empoweringscientists to explore
current and emerging
applications, like single-cell, whole-exome,
and RNA sequencing. Redesigned fromthe ground up, these easy-to-use systems
feature an improved user experience withsimplified run setup, minimal touchpoints,
and flexible informatics solutions, including
onboard DRAGEN. Their breakthroughsystem design uses integrated reagent
cartridges to minimize waste volume andimprove recyclability.

*Compared with the NovaSeq 6000 S4 200-cycle kit.

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Investing in strategic
collaborations
Together with changemakers across theecosystem, we’re finding answers to life’s biggest
questions and broadening the positive impact ofgenomics around the world.
See the full list of collaborations.

Introduction

CSR at Illumina

74

$1B+

93%

47%

startups launchedstartups raised capital*
In 2023, Illumina Accelerator relaunched as part of Illumina® Ventures
Labs. Read the press release.

Responsibility

Appendix20

Illumina provides a wide range of global, in-language
support including remote technical support 24/5, onsite
training, instrument qualification, and customized
onboarding solutions. Because of this, 9 out of 10
customers find it easy to do business with our team.

96%

3000+

97%

15+

<1

600+

day mean time to repair

trainings per year

Illumina Solution
Centers

support personnel

2-dayaverage field service engineer response time

Alliance for Genomic Discovery

VC funding secured

female founders

Sustainability

Comprehensive support for our customersof calls answeredin < 30 seconds

Genomic startups are playing an increasingly importantrole internationally in the expansion of the genomic
ecosystem. Illumina for Startups is our way ofaccelerating innovation in the entrepreneurial
community by partnering with leading venture capital
investors and entrepreneurs to create, launch, andgrow genomic startups. In 2023, we transitioned
operations of the Illumina Accelerator to Illumina
Ventures Labs to further expand the program and build
on success to date.

PeopleImpact in action

customer satisfaction

Supporting genomic startups*

AccessNovaSeqX arrives at deCODE genetics

The Alliance for Genomic Discovery (AGD) is a multiyear agreement that aims
to accelerate therapeutic development and expand the diversity of genomic
data through the inclusion of more samples from currently underrepresented
ancestries. In 2023, AGD announced its five biopharma members: AbbVie, Amgen,
AstraZeneca, Bayer, and Merck. The members will cofund the whole-genome
sequencing of 250,000 samples and have access to the resulting data for use in
drug discovery and therapeutic development. Learn more

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix21

Impact in action

Affordability
Pricing transparency

Driving down the cost of sequencing
At Illumina, we are focused on lowering the cost of sequencing
and enhancing the value beyond the cost per genome.
Since 2001, the cost of DNA sequencing has dropped by more than 100,000×,from $100 million USD per human genome to $200 USD on the NovaSeq X Series
using the 25B flow cell.

Sequencing more samples with the same budget
N U M B E R O F E XO M E SA M P L E S

Comparison chart
NovaSeq 6000

To support our customers and increase access, Illumina has:

NovaSeq X•Launched the NovaSeq X, a new production-scale

3×
14000

sequencing system that will push the limits of what’s
possible with genomic medicine, enabling faster, more
powerful, and more sustainable sequencing

12000

2001

$100M

•Created an emerging markets pricebook to enable

10000

differential pricing for products with more significant impact
and relevance to low- and middle-income countries

8000
6000

2010

$10,000
HiSeqTM 2000

4000
2000
0

2014

$1000
HiSeqTM X

2020

$600
NovaSeqTM 6000
v 1.5 Reagent Kit

2022

$200*
NovaSeqTM X*$200 USD genome on NovaSeq X Series is delivered atlist price on 25B flow cell. Data on file.

Illumina is committed to offering prices that enable broad
access to genomic technology. We maintain a responsible
approach to pricing our products. We negotiate and partnerwith health care systems, payers, and research institutions tomake our products available at a fair net price.

SP

S1

S2

S4

S5

S6

S7

Exome sequencing was performed on the NovaSeq X Plus
System with 25B flow cells and on the NovaSeq 6000 Systemwith S4 flow cells using the same total project budget. This
analysis is based on sequencing 8 Gb per exome.

Illumina sets and adjusts list prices based on several factors,
including cost, inflation, and market dynamics. Prices areavailable to customers through their account managers or
online at myillumina.com. Prices are also visible to customers
on their invoices and billing statements. As in past years,
Illumina price increases were at or below inflationary indiceswhile absorbing many of the temporary cost increases driven
by global supply chain issues. For example, in the US in 2023,
the Illumina annual price change was below the US Consumer
Price Index. Illumina pricing reflects its value propositionand enables the company to continue to innovate for ourcustomers and accelerate access to genomics for all.

Illumina launches Global Health Access Initiative to support
acceleration of pathogen sequencing in low- and middle-income
countries
With the launch of the Global Health Access Initiative, we aim to support access to pathogen
sequencing tools for public health in low- and middle-income countries (LMICs). The
program, developed with guidance from customers, funders, and market facilitators including
the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products
from Illumina to qualified global health funding entities and address key international logistics
and supply chain challenges. Learn more

Table of contents
2023 CSR ReportInnovation

Affordability

CEO message
Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix
22

Impact in action

Reach
Democratizing and increasing the reachof genomics and genomic sequencing canenable families, communities, and whole
populations to harness the benefits of nextgeneration sequencing (NGS). Realizing thepotential of the genome requires global
data that is representative of the diversityof our populations.
Broaden the impact of genomics

Increase genomic
data diversity

Advance genomic
literacyChampionpatients

Initiatives to increase genomic data diversity
We are proud to support efforts to increase diversity in human genetics and ensure thatgenomic representation is part of equitable health care for generations to come.

SAMPLE INITIATIVES

Qatar Genome Program
Egyptian Genome Project
WeGene Collaboration
Singapore’s SG100K project
Human Heredity & Health in Africa
African Centre of Excellence for
Genomics of Infectious Diseases(ACEGID)
The New York Genome Center’s
Polyethnic–1000 project
Native BioData Consortium
Alliance for Genomic Discovery

Increase genomic data diversity

Australia’s OurDNA initiative

Genomics has been integrated into clinical practice at a fasterrate than almost any innovation in the history of medicine,but inequities still exist. Implementation has been almost
entirely restricted to more developed nations, and 78% of
people included in genomic studies of disease risk are ofEuropean ancestry.

The Silent Genomes Project

To ensure that genomes can be interpreted in the appropriate
context of global diversity, we aim to increase the equitable
representation of genomic data. This allows for therapies
and solutions to be attuned to a broader set of genomes,
decreasing this bias in our medicine for the future.

Bridging the diagnosis gap for Canada’s Indigenous children
The Silent Genomes Project is building a first-of-its-kind variant library for First
Nations, Inuit, and Métis populations. The lack of reference data for Canada’s
Indigenous groups leaves clinicians with hundreds of thousands of variantsof unknown significance, creating health care inequity as Indigenous patients
face more difficult and uncertain paths to diagnosis. The project is correcting
this inequity through sustained, concerted partnerships between researchers,
clinicians, and Indigenous communities across Canada. Learn more

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix
23

Impact in action

Advance genomic literacy
To accelerate access to genomics, we need to boost awareness and adoption. We advance genomic literacy by supporting health care
professionals and by driving equitable access to STEM education to inspire the next generation of scientists, innovators, and trailblazers.

Health care professionals

Future workforce

We are committed to expanding understanding andaccess to genomic testing through our outreach tocommunity health systems. In our third year of supporting
the American Society of Human Genetics, we backed
online education for genetics professionals. This support
reached more than 900 learners in 2023 alone andmore than 2500 since July 2021. Additionally, we havecontinued to support the growing trend of reachinglearners through medical education podcasts with morethan 50,000 podcast listens in 2023, many of which
focused on genomics in cardiology.

The future of our mission relies on nurturing and equipping the next generation.
Through direct programming, nonprofit partners, and employee engagement, we
aim to enable educators to be advocates of genomics and inspire learners of allages to envision themselves as future leaders in STEM.
Learn more about how we are nurturing a diverse and inclusive STEM
workforce for the future and for our company.

Our STEM strategy
We work to integrate STEM and genomics into the education ecosystem where
educators and students have access to resources.
AUDIENCE

TACTICSRESULTS

98%

Educators

1. Provide direct
resources andcurriculum

Empowered tobe advocates ofgenomics

99%

Students

2023 PR O G R ES S

2030 TA R G E T>95%

supported medical education
programs and increase inparticipant knowledge andcompetence2030 TA R G E T

25,000+health care
professional learners
reached annuallyof learners reported
increased competence

2. Work with
nonprofit partnersof learners reported
increased knowledge

health care professional
learners reached

Inspiredto envision
themselves as
future leaders

SD2’s H. Puentes and student Alejandro
Pliego visiting Illumina headquarters

Alejandro Pliego’s journey into STEM
2023 PR O G R ES S

2023 PR O G R ES S

>27,000

3. Engage our
employees

2030 TA R G E T

5 million

STEM learners reachedglobally~1.6 million

STEM learners reachedglobally since 2019 baseline

Alejandro Pliego is a fellow of the yearlong mentorship program
offered by San Diego Squared (SD2) and a recipient of theIllumina SD2 STEM Scholar Award. SD2, a grant recipient of theIllumina Corporate Foundation, connects high school students
from underrepresented communities to hands-on STEM education,
mentorship, and other resources. Alejandro is attending Princeton,class of 2027, and is the first member of his family to go to a fouryear college. He plans to focus his studies on molecular biology
and public policy. Read more about Alejandro’s journey.

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix
24

Impact in action

Champion patients

Increasing access to molecular testing forpatients with ovarian cancer

Transforming patient outcomes epitomizes the heart of our mission. We partnerwith patients, families, and organizations that represent communities to help raiseawareness, build hope, and create change.

iHope
iHope is a philanthropic effort that provides clinical whole-genome sequencing (cWGS) to
underserved families around the globe. It was created in 2017, bringing together a wide rangeof organizations aiming to shorten the diagnostic journey and inspire hope.

2312

patients impacted
since inception

43%

of patients receive
diagnosis after cWGS

26

iHope clinicalsites worldwide

68%of cases received in
2023 from LMIC sites
Our expansion of the iHope program includes
iHope Genetic Health program under the
auspices of the nonprofit Genetic Allianceand iHope China with March of Dimes.

A notable example ofchange of management
includes a 13-year-old
boy from Lima, Peru, withtreatment-refractory epilepsy,
developmental delays, amoderate cognitive deficit,
muscular atrophy, andsubclinical hypothyroidism,
who first presented with seizures at two months of age. The
only available testing locally was karyotype and methylation
analysis for Prader-Willi syndrome, which were pursued, andthe results were normal. Trio-based genome sequencing
identified a diagnosis of GLUT1 deficiency syndrome, forwhich a ketogenic diet is the recommended treatment. He
began a ketogenic diet, which resulted in near complete
cessation of his seizures.

2023 P R O G R E S S

2030 TA R G E T

50,000+patients supported throughiHope programming

2312

patients supported

Pathogen genomics
surveillance in low- andmiddle-income countries
We are proud to be part of the
Pathogen Genomics Initiative(PGI), a multi-sector collaboration
with global funders, industry,
nongovernmental organizations,and public health agencies toenhance disease surveillance andpublic health through integrated,cross-continent laboratory
networks equipped with thetools, human resources, and data
infrastructure to fully leverage
critical genomic-sequencing
technologies. Illumina committed$60 million to support the initiativewith in-kind donations, including
NGS platforms, reagents, andtraining. PGI will bring us closer
to the vision of an early warning
system to detect new epidemics
and apply genomics to benefit all.

Left to right: Anne McDonnell (Major Gifts Officer, Clearity
Foundation), Ilianna Vargas (Marketing and iLatinX ERG Chair,
Illumina), Hillary Theakston (Executive Director, Clearity Foundation),
Lorena Gurule-Montes (Community Engagement, Clearity
Foundation), Shirlene Badger (Patient Advocacy, Illumina), and Emily
Dalton (Medical Affairs, Illumina)

An estimated 19,710 people in the US werediagnosed with ovarian cancer in 2023, according
to the National Cancer Institute’s Surveillance,
Epidemiology, and End Results Program. Most learnof their condition only after the cancer has spreadbeyond the ovaries or fallopian tubes, making thedisease difficult to treat and manage.
Illumina and the Clearity Foundation, a nonprofit
organization dedicated to improving survival andquality of life for ovarian cancer patients, launched
an innovative program to address inequities in
education, information, and access to molecular
testing and clinical trials. Its mission is to actively
learn about the experiences of Latin Americans
and Black Americans diagnosed with ovariancancer, increase access to the highest attainable
personalized care available, and support patients’agency to achieve improved cancer experiences.
This partnership supports our efforts to increase
diversity, equity, and inclusion in health care andresearch, further democratizing access to genomics.
Learn more

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleUS Coverage Data (EOY 2023)
Noninvasive prenatal testing(NIPT)

Comprehensive genomic
profiling (CGP)

Whole-exome and genome sequencing(Genetic disease)

Total insured lives 265.2M

Total insured lives 325.1M

Total insured lives 265.2M

Only high-riskcoveredNot covered

All pregnancies
covered

20.7M
8%

31.8M
10%

243.1M92%

CGP covered in all
solid tumor types
272.6M84%

Not covered
41.7M
16%

   WES & WGS covered
143.2M54%

CGP covered insome tumor types
20.2M
6%

2 Education of health care providers and government
representatives

Not covered

3 Expanded reimbursement and payer engagement

1.4M
1%

Only WES
covered

4 Increased adoption

SamuelPrincipal Scientist

Appendix25

1 Evidence generation for clinical utility

The products I work on as an Illumina scientist
are used globally by many labs to diagnosepatients with rare diseases, cancer, and otherconditions every day. This feels like my work is
amplified; rather than doing one test at a time,
I can impact many families across the world!”

Responsibility

Impact in action

Patient coverage and reimbursement
Enabling innovation and driving affordability go beyond
delivering sequencers and data. It includes delivering
insights and accelerating the paradigm shift toward
genomic sequencing as a standard of care to improve
patient outcomes and drive down overall health carecosts. Through evidence generation, education, andcommunity outreach, Illumina is committed to advocating
for health care coverage and accelerating the adoptionof genomics as a diagnostic tool.

Sustainability

80.3M
30%

Global coverage snapshot*
2023 P R O G R E S S

2023 P R O G R E S S

2023 P R O G R E S S

1.02 Billion

745 Million

613 Million↑33 Million YoY growth↑61 Million YoY growth↑76 Million YoY growth2023 P R O G R E S S
2030 TA R G E T

2 Billion
covered lives globallyby 2026

1.3 Billion
covered lives

1.02B lives covered for NIPT
translates to>9M

eligible pregnancies per year

Based on coverage and reimbursement of NIPT, CGP in advanced cancer, or WES/WGS in genetic disease.
Global coverage numbers represent our tracking of 19 countries globally (US, Canada, Belgium, Czech Rep, Denmark,France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, UK, Israel, Japan, S Korea, Australia, China, Brazil).
*Table of contents
2023 CSR ReportInnovation

Affordability

CEO message
Reach

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility

Appendix
26

Impact in action

Demonstrating the clinical utility of genomics internationally
Below are some strategic evidence projects and coalitions formed to engage healthsystems worldwide and demonstrate clinical utility:•Optum/United Healthcare Group (United•Omico (Australia): Omico enables patient access•Providence (United States): Illumina is•Baby Lion (Germany): Hannover Medical School,

States): This collaboration continues to generate
evidence across rare diseases, oncology,
and cardiovascular diseases, culminating in
2023 in the publication of multiple conference
presentations and manuscripts.
collaborating with Providence Health & Services
to generate evidence of the clinical and economic
utility of CGP in patients with advanced cancer.
The collaboration has resulted in more than
10 scientific congress presentations and fourmanuscripts in development.

to cancer genomic tests via clinical initiatives
in Australia. Illumina collaborates with Omico todemonstrate the clinical utility and economic
value of cancer genomic testing, which will informclinical practice and payer coverage decisions.
in collaboration with Illumina, is evaluating thebenefit of WGS in critically ill babies and infants
in intensive care settings (NICU/PICU) who arethought to have a genetic disorder.

•Baby Bambi (Israel): The results of this study

have now been published and following thecompletion of the project, Israel has commissioned
WGS in the NICU as a nationwide benefit.

•BALLETT (Belgium): This study has recruited

more than 900 metastatic cancer patients from
12 hospitals in Belgium, with testing in nine NGS
laboratories, to demonstrate the utility of CGP
within a nationalized single-payer system.

Explore more studies, projects, and coalitions:•QuicDNA (Wales)•IMPRESS (Norway)•CAPS (Coalition for Access to Prenatal Screening)•ACGP (Access to Comprehensive Genomic Profiling)•WGS (The Whole Genome Sequencing Alliance)•APACMed (Asia Pacific Medical Technology Association)

Illumina leads new European multi-stakeholder coalition
to accelerate the adoption of CGP
Illumina is a proud founding member of the European Coalition for Access toComprehensive Genomic Profiling (ECGP), launched in June 2023. ECGP aims to create
multi-stakeholder outputs to improve cancer care through increased routine clinicalaccess and reimbursement of CGP, with the ambition to deliver the right treatment to theright patient at the right time given widespread adoption of personalized medicine. Under
ECGP, patients, clinicians, pathologists, health economists, and industry leaders will
identify and share best practices and develop evidence-based policy recommendations
on the clinical and economic utility of CGP for payers and other decision-makers, basedon multi-stakeholder and multidisciplinary perspectives.

Table of contents
2023 CSR ReportInnovation

CEO message

Affordability

Reach

Introduction

CSR at Illumina

AccessPeopleResponsibility

Appendix
27

Impact in action

Impact in actionMore than 4500
students in Singapore
benefited from new
STEM partnership
In 2023, Illumina partneredwith the Science Centre
Board Singapore to run
a yearlong initiative where more than 4500 primary and secondary students
attended DNA-themed sessions at the Science Centre to learn about DNA andlife sciences through hands-on DNA extraction experiments. We expanded our
STEM education efforts across APAC in 2023, growing our outreach to 8500
from 1400 in 2022. Learn more

PrimateAI-3D: Improving genetic risk prediction anddrug target discovery using primate DNA and advanced
artificial intelligence
Each person carries millions of genetic
variants that underlie individual
differences in health and diseaserisk, but most of these variants arepresently of unknown function. To
help address this gap, scientists at
Illumina, in collaboration with specialists
from 24 countries, sequenced over
800 individuals from 233 species of
nonhuman primates, representing all 16
families and over 86% of living genera.
Leveraging the data from this study,
Illumina announced PrimateAI-3D, an
artificial intelligence algorithm thatpredicts disease-causing genetic
variants in patients with unprecedented accuracy. Learn more

Illumina and ACEGID to increase Africa’s genomics
capacity through establishment of a joint training academy
Illumina partnered with the African Centre of
Excellence for Genomics of Infectious Diseases(ACEGID) to increase Africa’s genomics capacity
through the establishment of a Joint Training
Academy. The objective is to establish a
Genomics and Bioinformatics training Academy
within ACEGID at Redeemer’s University, Ede,
Nigeria. Illumina and ACEGID will also explore theimplementation of a “mobile lab-in-container” thatwill enable real-time and on-the-move sequencing
for outbreak responses in West Africa. Learn more

Sustainability

Opening first Solutions Center in India
The new Illumina Solutions Center features a
fully equipped laboratory housing the latest NGS
and array technologies, and it is fully resourced
with field applications and service engineers
to offer Illumina partners and customers broad
genomic capabilities. The center will support
our growing number of channel partners in theregion by providing training and education toincrease local technical expertise and access togenomics. Learn more

Annual rare disease awarenesscampaign #IlluminatingRareDisease
Our employees are passionate about the rare diseasecommunity. They understand the power of genomics to
help end a patient’s diagnostic journey and support theircare management. Since 2008, Rare Disease Day events
have taken place around the world on the last day of February to raise awarenessabout rare diseases and highlight their impact on patients’ lives. Each year, ouremployees participate in a campaign and the Illumina Corporate Foundation
donates to the chosen charities in each region for the year.

A liquid biopsy study offers newhope for lung cancer patients
Lung cancer patients in Wales are about to get answers faster—and
potentially find out if they’re a match for targeted therapies.
In collaboration with Illumina and 13 other organizations, AWMGS,
the single provider of genetic services in NHS Wales, will make liquidbiopsies available to 1260 lung cancer patients consecutively across thecountry’s seven health boards, under a partnership named QuicDNA.
Rather than excising tissue from a patient, a liquid biopsy uses a simple
blood draw, since fragments of tumor DNA shed into the bloodstream.
The blood samples with circulating tumor DNA (ctDNA) are sequenced
on a 500-gene panel. The approach is known as comprehensive
genomic profiling (CGP) and it can assess multiple biomarkers innumerous tumor types in a single NGS assay. Learn more

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

Nurture our people
and communities

PeopleCommunity

Sustainability
Impact in action

Responsibility

Appendix28

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

Strategic approachand impact
We are committed to creating a workplace centered on
innovation and care that values the unique talents of theindividual, brings forward the best of the collective, anddelivers on the Illumina mission at a global scale.
We are also committed to giving back, creating shared value through our business,and seeking opportunities to engage our people to be agents of change.
Our extraordinary mission requires extraordinary people and leaders at every
level. By nurturing an inclusive and caring culture, we magnify the value ofcollaboration and building a community. Together our impact is amplified,and our potential is unlimited.
K E Y O B J ECT I V E S

1Practice diversity, equity, and inclusion

2

Attract extraordinary talent

3

Invest in our people

4

Support employee health, safety, and well-being

5

Engage our people and communities

2023 H I G H L I G H T S

45%female workforce
representation

52%

minority representationin the US workforce

5%

increase in female
executive leadership in
the last three years

58%

employee participation ingiving and volunteering

Zero net
pay gap
maintained for a fifth
consecutive year

350K

STEM learners
reached for 2023

UN SDGS

AccessWell-being and safety

PeopleCommunity

Sustainability
Impact in action

Responsibility

Appendix29

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Our people

Everyone at Illumina is driven by the powerof genomics to positively impact the world.
We seek opportunities. We embracechallenges. We work tirelessly to movegenomics and humanity forward.

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

5559 AMR

PeopleCommunity

1365 EMEA

Sustainability

Responsibility

Appendix30

Impact in action

G E N D E R R E P R E S E N TAT I O N (G LO B A L)

2384 APAC

54% 45%Male<1%

FemaleOther/undisclosed

E M P LOY E E AG E D I S T R I B U T I O N (G LO B A L)

17%

Under 30

9308

Total global employees (FTE)

67%

16%

30-50

Over 50

A D D I T I O N A L I D E N T I T I E S (U S)

3%
LGBTQ

2%

Veterans

10%

Persons with disabilities

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

Responsibility

Appendix
31

Impact in action

Practice diversity, equity, and inclusion
We relentlessly practice diversity and inclusion in all
we do to advance equity and belonging.

Pay equity
Our pay practices are designed to compensate employees based on
factors such as job performance, expertise, and experience relevant
to individual geography. We monitor our pay equity status and market
competitiveness on an annual basis.§ For a fifth consecutive year, weare proud to confirm a zero net gap in pay** regardless of gender,
race, age, ethnicity, sexual orientation, national origin, or any attributethat does not relate to the employee job and contribution.

DEI strategy
Our DEI program is anchored in the philosophy of practice, appreciating that
there is always more to learn. We embed our DEI efforts across our businessby acquiring and developing diverse talent, building inclusive leadership skills,
advancing equity in people processes, and cultivating a culture of belonging.

Expanding pay transparency
As part of our commitment to pay equity and equitable processes,
we provide salary range transparency on all US job postings. We also
provide all employees with access to the salary range for their current
position via our HR system.

Quarterly people
analytics dashboard,
implemented focus groupfeedback, salary range
transparency

18 global ERGs
representing 9
distinct communities

DiversetalentInclusive
leadership2030 TA R G E TS

Transparency
and awareness

Increase gender
representation in global
leadership*

Peopleprocess
innovation

350+ employees
completedstrengths training

25% roles filledwith internal
candidates

Increase minorities† inexecutive leadership (US)K E Y PR O G R A M S•Employee resource group (ERG) program •Strengths training•DEI Ambassador Program•Self-serve and hybrid DEI training

Increase underrepresented
minorities† in workforce andleadership*

4%•UN Global Compact•Disability:IN CEO Signatory

2030 TA R G E T

Maintainzero net
pay gap

Increase(2019 baseline)

8%

Increase(2019 baseline)

2%

Increase(2019 baseline)

As part of our commitment to DEI, we are the proud signatories of:•UN Women Empowerment Principles•CEO Action for Diversity and Inclusion

2023 PR O G R ES S

2023 PR O G R ES S

Leadership: manager, equivalent, and above.

Maintained

zero net pay gap
for a fifth consecutive year

Equal opportunity and nondiscrimination policies
We support the elimination of discriminatory practices in employment.
We are committed to fair and respectful treatment of all employees,
promoting equal opportunity and diversity in the workplace and all
aspects of our business. Our policies prohibit discrimination basedon race, color, age, gender, sexual orientation, marital status, gender
identity and expression, ethnicity, religion, physical or mental disability,
medical condition, genetic information, veteran status, national origin,
or any protected class.

*

Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino,
two or more.

†

Executive leadership: director, equivalent, and above.

‡

Equal pay refers to paying equal pay for equal work.

§

Zero net gap in pay means no statistically significant difference in pay for the same or**similar work, regardless of gender, ethnicity, or race.

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

Responsibility

Appendix
32

Impact in action

Employee resource groups (ERGs)
ERGs are a cornerstone of our DEI strategy and a key lever
to identify, develop, and retain talent. They deepen our
respectful, inclusive culture by engaging employees andproviding an opportunity to connect, celebrate, and learn
with peers and allies.

National Hispanic Heritage MonthTo kick-start the celebration of National Hispanic Heritage Monthin the US this year, the Illumina iLatinx ERG hosted Mariachi &Paletas, offering employees the chance to enjoy sweet treats andsocialize to the tunes of a live mariachi band at our San Diego
headquarters, and learn about the culture and community. The
iLatinx ERG planned this event to introduce themselves to thecommunity and bring people together in celebration of Latino andHispanic cultures.

I feel lucky to have this community. I havecreated connections and have grown withcolleagues in a way that has given me space
to be my authentic self and have genuine
connections. I love that our ERGs are here tohelp make sure everyone has a chance to findthat community.”
JordaniPride ERG leader

Our employee resource groups
B US I N ES S I M PACTCA R EER D E V ELO PM ENT

Enhance innovation withdiverse teams identifying andsolving business challenges

Focus on building the
careers and skills of diverse
employees into future leaders

Our ERG program pillars

C O M M U N IT Y S ERV I C E
Support our communities
by engaging with nonprofits
where we live and work

ED U CATI O NCreate more understanding
and deeper collaboration

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Attract
extraordinary
talentIntroduction
Talent attraction

CSR at Illumina
People investment

AccessPeopleWell-being and safety

Community

Sustainability

Responsibility

Appendix
33

Impact in action

University recruitment

The next generation of changemakers

Nurturing and investing in future talent is critical to the Illumina growth strategy.
Robust engagement with key universities allows us to create long-term
relationships with students, graduates, professors, and university faculty. We
create meaningful student experiences through special events, professional
development workshops, technical talks, and campus ambassador programs.
Our hybrid approach meets students where they are by offering both virtual andin-person sessions across multiple time zones.

We are committed to equitable access to STEM education, with the goal of
empowering students and enabling educators to inspire the next generationof scientists, innovators, and trailblazers for the workforce of the future.

Illumina is made up of extraordinary people anddedicated professionals who are all in on creating
a better world through genomics. Everyone sharesa commitment to our mission, and it shows in our
enthusiasm for the work we do together. Our sharedcuriosity to discover and our drive to achieve
create deep connections among our people as
we pursue world-changing innovations. In every
role, the feeling we get from working at Illumina isremarkable. The environment is motivating, and theexperience is unmatched.

Diverse talent

The talent acquisition strategy at Illumina plays acritical role in supporting our mission and fostering
our unique culture. As a global organization, ourrecruitment efforts seek exceptional talent withdiverse backgrounds and unique skill sets to deliveron the transformative power of genomics.

We know that students and graduates areinnovators, creators, and the future of Illumina.
Every year we welcome an extraordinary groupof interns, work experience students, andapprentices around the globe. Our programs
provide endless opportunities for meaningful
work, professional development, andcommunity impact projects.

As we invest in the future, one of our key
priorities continues to be supporting andengaging with underrepresented student
groups, including school chapters of the Societyof Women Engineers, the National Society ofBlack Engineers, and the Society of Hispanic
Professional Engineers, and many others.

Internship program

Intern cohort

63%
Women
(global)73%

Minorities*(US)*Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, two or more.

To do this, we collaborate with community partners and engage our employees
to reach and empower students of all backgrounds. We aim to inspire learners
to envision themselves as future leaders in STEM and at Illumina.

DNA Day STEM outreach: The Future Is Bright
In honor of DNA Day, celebrated annually on April 25, we host
The Future Is Bright, a genomic literacy initiative. Illumina
employees around the globe connect with students by hosting
career panels, implementing genomic curricula, and leading hands-on
experiments. Learn more
2023 FUTURE IS BRIGHT IMPACT

100,000+

71%

130+

2300

1600+

1500+

learners across six
countries and every US
state

donated strawberry DNA
extraction kitsof US classrooms wereTitle 1 schools where lowincome families make up atleast 40% of enrollment

community partners
and schools

eventsemployeevolunteer hours

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

Responsibility

Appendix
34

Impact in action

Invest in our people
At Illumina, everyone can achieve and become more than they thought possible.
We aim to create the opportunities and environment to unlock the full potential of
our people.
Development at Illumina is an intentional, everyday activity that prepares
employees for success in their work now and for opportunities in the future. It isavailable to all, accessible in many formats, and contributes to a meaningful career
experience at Illumina. Development is the catalyst for how we achieve successand become more than we ever thought possible—as individuals, as teams, and as
an organization. Regardless of work arrangement or location, opportunities exist forcontinuous learning and growth.
To ensure that our employees enjoy long and fulfilling careers at Illumina, we:•Provide leadership development for all levels of leaders as they grow their careers•Encourage everyone to give feedback and recognition•Enable employees to lead quarterly development discussions with
their managers and gain clarity on their priorities•Provide resources that build great teams and high performance•Provide access to professional development and on-the-job experiences
Guided and supported at every step
Development

Individuals own theirdevelopment and are empowered
to grow their strengths, learn
beyond their discipline, andpursue their own personal andprofessional growth path

Leaders guide and support
development by helping todefine the path, providing
access to resources, andgrowing individuals
through coaching

Illumina invests inexperiences, tools, andprograms that help people
achieve their aspirations
and create a cultureof development

Listening to our people
Illumina improves by deeply
understanding our people. Listening
to our employees allows us tocapture their feedback to take action
and improve their experience.

84%

90%

84%

91%

87%

82%

Engagement index

feel their manager
supports balancing
work and personal life

25%

Roles filled with internal candidates

23%

New hires referred by Illumina employees

Quarterly career development and performance conversations

are proud to workfor Illumina

feel they are a valued
member of their team

62
100%

would recommend
illumina as a great place
to workfeel they belong
at Illumina

Average hours of annual training per employee
of employees are provided opportunities for regularperformance and career development reviews

Semiannual promotion cycles

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

Responsibility

Appendix
35

Impact in action

Leadership development at Illumina
Leaders actively prepare for the future through a variety of formal development offerings.

•Elevate Leadership Development Programs –These address the key challenges facing leaders
at all levels of the organization and provide theneeded tools, mindsets, and coaching for success•Power Hours – A leadership development

program for frontline leaders, run by subject
matter experts, to develop the skills andknowledge required to lead teams effectively•Discussion and Lean In Circles – Our businessleaders host discussions on important topics,
such as Moving into Management and Managing
Your Career. We also support Lean In Circles
through our Women at Illumina Network(WIN) ERG.

•Mentoring Programs – The Horizons ERG

hosts buddy programs, connecting early career
professionals with seasoned employees, and WIN
offers a mentorship program called iMentor•Over 350 participants in theStrengths-Based Training Program•70% of leaders attend at least one

development program each yearwith an average satisfaction rate ofover 85%•Leaders have access to over 18,000
on-demand learning courses

I have been very fortunate to have fantastic
leadership in my time at Illumina. This has
inspired me to take on a leadership rolemyself. I am now a new people leader andcontinue to receive both formal and informal
leadership training to help me best support
my team.”Will
Manager, Laboratory Programs

Recognizing success
We have designed several programs to recognize employees’ outstanding achievements, including:•Innovation Award – Recognizes this core element of our culture and success by annuallycelebrating our pioneering scientists for their extraordinary contributions•Inventor Award – Annually recognizes employee inventors who contribute to our patentapplications•Values Award – Presented to individuals and teams nominated by their peers for
exemplifying our values

2023 I L LU M I N A I N V E N TO R S BY T H E N U M B E R S•Culture of Coaching – Our Coaching Learning

Path highlights a variety of options to help leaderslearn, practice, and build their coaching skills

453

163

42%

•Leaders in Action – Leaders helping leaders growTotal inventors

First-time inventors

US inventors are minorities•Thrive New Leader Orientation – Targeted to

26%

36%

40%

their skills and expand their impact

newly hired and promoted leaders at Illumina,
this provides insight into Illumina’s leadershipphilosophy•Ignite – This series brings external thought leaders
to speak on leadership topics to provide ongoing
and regular development•Strengths-Based Training Program – Using theCliftonStrengths Assessment, this program isdesigned to build self-awareness of strengths andan appreciation for what colleagues contribute,
helping drive DEI through our work

US inventors are women29%

UK inventors are women

Female inventors

Singapore inventors are women

2×

Illumina female inventors compared to thenational rate of women receiving patents

In 2023, Illumina employees filed a record 211 new patent applications.
Illumina has a total of 9893 issued patents worldwide.

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

Responsibility

Impact in action

Employee health, safety, and well-being
Building extraordinary teams and breakthrough innovations starts with caring forour employees and putting their welfare at the heart of all we do.

Employee benefits
We offer a world-class portfolio of benefits and well-being programs beyond thestandard medical benefits, and extend these benefits to employees, spouses, domestic
partners, and dependent children. Every day, our technology is being used to improve
human health—enabling advancements that were not possible just a few years ago. Our
employees receive access to these new technologies, such as workplace genomics,
reproductive health programs, and cancer testing, to help better inform their healthcare decisions. Our employee benefits, which vary by country and region, recognize thetremendous value our people bring to the business with an array of meaningful programs.

Workplace genomics program*

Supporting growing families*

Through our partner Genome Medical, we
provide access to genetic experts who canconsult, guide, and facilitate testing for
employees and their families. In addition,
we offer financial support for cancer tests,
reproductive health tests, and clinical wholegenome sequencing (cWGS) for rare andundiagnosed diseases.

Employees, their spouses, and their domestic
partners may be eligible for the companysponsored reproductive health program
either through insurance or financial support,
covering:

Cancer early detection testingThrough our partner Progyny, we offer acomprehensive fertility benefit program toeligible US-based employees that covers
fertility preservation, providing equitable
access to care for our diverse employees,
including those pursuing nontraditional paths
to parenthood.

The Galleri® multi-cancer early detection test
is available at no cost to eligible employees
in the US and their dependents as part of our
Workplace Genomics Program.

•Assisted reproductive technology•Pre-implantation genetic testing•Noninvasive prenatal testing

US employees also receive access to Cleo, acomprehensive family support system for theirjourneys to parenthood, returning to work, andmanaging life as a parent.

Providing time to recharge•Flexible time off
mental health program•Comprehensive•Two days of paid volunteer time off
for employees, dependents, and allhousehold members through Lyra Health•Minimum 10 days of holiday paid time off•Company-wide shutdowns in July and December
Investing for the future•Compassion and care time off•Employee stock purchase program
Fostering wellness inside•Retirement savings plansand out•Pensions (EMEA)•Life and accident insurance•Medical, dental, and vision coverage•Disability insurance•Pretax spending accounts  •Independent financial advice•Employee assistance program (EAP)  
Wellnessrooms
fornursing,
meditation,
and•Tuition assistance•prayer  •Business travel medical insurance  •Gym access or membership  
workstations, abundant natural light,•Ergonomic
and opportunities to work outdoors
offering sustainable, healthy food•Cafeterias
options, including vegetarian choices  •Genetic counseling  

Health solutions (US)support and expert advisory review•Cancerthrough AccessHope

guidance for diagnosis, treatment, or•Expertfinding the best physician through Included
Health (US)*Some services available in the US only.

musculoskeletal (MSK) physical•Digital
therapy care solution with Hinge Health

Additional perksand benefits

amenities, including•Site
car washing, dry cleaning,mobile salons, food service,mindfulness, and selfimprovement courses•Employee referral program•Donation matching program•Special interest clubs•Commuter support

Appendix36

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Workplace health and safety
We prioritize the safety and well-being of our employees, contractors, and the communities where we work. Our policies follow
a risk-based strategy that guides the assessment, evaluation, reduction, and management of environmental, health, and safety(EHS) risks while enhancing the overall effectiveness of our global operations.

EHS programs

Global EHS management system

Our vision is for every Illumina employee to be anenvironmental, health, and safety leader. We arededicated to fostering a culture of safety, promoting
continuous improvement and enhancing the maturityof our EHS programs.

We embrace our mission by establishing, implementing, andmaintaining an integrated global EHS management system. Our
Singapore site recently achieved recertification, demonstrating ourcommitment to upholding these voluntary standards, consistent with
ISO 14001 and ISO 45001. Learn more

Sustainability

Responsibility

Appendix
37

Impact in action

Prevention and preparedness
The Illumina EHS Global Injury and Illness Prevention Program (IIPP) describes basic
processes our employees can take to maintain a safe and compliant workplace.
Our Emergency Action teams work together to create awareness and lead regularpreparedness drills and activities. This precautionary approach† is embedded in ourrisk assessments, our environmental aspects/impacts, our EHS policy, our productstewardship, and the engagement of our people.
2023 SA F E T Y P E R FO R M A N C E

4135

Prevention
reports

43,067

Hours of EHSrelated training

E N V I R O N M E N TA L , H E A LT H ,A N D SA F E T Y T R E N D S

Recordable injury & illness rate
.342023 H I G H L I G H T S•Received the Workplace Safety and Health177

Council Silver Award from The Workplace Safety
and Health (WSH) Council at our Singapore site.

EHS riskassessmentscompleted globally•Implemented a new safety and risk management

best practice in our Americas operations with QR
codes posted at equipment linking to diagrams
and steps to safely deenergize.

184•Implemented an Industrial Athlete Programfor our Americas operations. Supported by anonsite industrial injury prevention specialist, thisprogram focuses on preventing and managing
work-related musculoskeletal disorders bytaking a sports medicine model and applying itto the workplace. The program rollout had 135
participants, 42% of whom reported preventive
measures helped minimize the potential
escalation of reported injury.

Ergonomic Champion
In 2023, we established a global ergonomic champions network.
Meet Sem Yeng, a dedicated member of the Illumina family
since 2010, currently serving as a senior supervisor in Instrument
Operations. Sem Yeng’s transformative journey, evolving from atechnician to leading a team of 25 employees, exemplifies not only
professional growth but underscores his unwavering commitment tocultivating a safer and healthier workplace.
Sem Yeng and his team’s proactive approach led to the in-house
design of several smart lifting solutions tailored to reduce physicalstrain during manual lifting. Notably, our instrument operations
team in Singapore boasts a remarkable record of zero ergonomicrelated injuries. The in-house design of smart, multi-directional
lifting solutions have also garnered recognition with two Gold Safety
Innovation Awards from the Singapore Manufacturing Federation andthe Workplace Safety Health Council Singapore.

Ergonomic
evaluations
completed

.54

.52

.23

.03

Increase in days
away, restricted, ortransferred rate*

.27

2019

EHS policy
14001 certificate
45001 certificate

2021 2022

2023

Lost time illness rate
.74

Recordable injury
and illness rate

LEARN MORE

2020

.27

.18
2019

2020

.23
2021

.12

.10

2022 2023

Days away, restricted,
or transferred (DART)
.43

.34

Injury and Illness Prevention
Program (IIPP)
2019

.20

.18

.17

2020

2021 2022 2023

UN Global Compact Principle 7 and Principle 15 state that in order to protect the environment, the precautionary
approach shall be applied.

†

Reduction reflects year-over-year comparison between 2022 and 2023.

*

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

PeopleCommunity

Sustainability

We strive to create a purpose-driven culture with opportunities for
employees to volunteer in their community with the organizations
that matter most to them. Guided by our CSR strategy focus areas,
we deploy our skills, time, and resources to create a positive impact
in our communities.

Employee giving and volunteer benefits$500
donationmatch

16hours paid
volunteertime off (VTO)

$25

$10

new hireseed donation
depositEmployee participation ingiving and volunteer programs

Volunteer rewards
donation earned for eachhour of volunteer work

Volunteering
GivingTotal participation

50%

47%

39%

20%

24%

31%

28%

We focus our community impact strategy on investments that support
our mission and most material CSR issues. We drive collective impact
and leverage our resources to help address local and global needs withphilanthropic activities and nonprofit partnerships.

We offer a variety of ways for employees to give back.
Employees can volunteer as individuals; with their families,
teams, local sites, or regions; with ERGs; and throughcorporate global opportunities.

2020
Since 2019 baseline

Community
investment*

Students from the L’Association FrancoLibanaise pour l’Education et la Culture wereinvited to the Dubai Illumina office to learn
and apply their knowledge about DNA and life
sciences through a fun escape room gamespecially designed by Illumina employees.
Employees from Illumina Korea partnered with
JUMP, a nonprofit educational social venturecompany, for the second year to host a groupof underserved students at our Illumina Solutions
Centre. Participants engaged in hands-on
activities to learn about DNA and life sciences.
Leaders and employees in Singapore
shaved their heads to raise awarenessand fundraise close to USD $65,000 forChildren’s Cancer Foundation.

Partnering with SEE Foundation, close to 50
employees and family members gathered at
the Dongtan Wetland on Chongming Islandin Shanghai, China, to clean up marine waste
for the migratory birds that will be coming tospend the winter in November.

31%

38

Community impact

10%

5%

1

26%

58%

Appendix

Impact in action

Employee engagement
and community impact
Engage our people to be agents of change

Responsibility

DEI

Sustainability andenvironmental justice

Equitable accessto genomics

AGGI

Africa PGIBlack climate week

Australia’s OurDNA
Initiative

Cal State East Bay
Green Biome
GRID Alternatives
iConserve
STREAM

China University
Scholarships
CHRF STEM,
Bangladesh
iHope MOD China
Methylation LMIC

2021

2022

2023

San Diego employees and their families
head to the beach to support the annual
International Coastal Clean Up day.

NativeBio

Local impact

China Gansu
earthquake relief
Holiday food drive
Israel and Gaza
humanitarian response
Maui fire relief
Ronald McDonald
House support
Toys for Tots
Turkey and Syria
earthquake relief
Ukraine humanitarian
response*
In order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations are then evaluated against 1,200 watch lists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that are also excluded frommatching eligibility. Illumina currently blocks charitable organizations that have been found to discriminate against a specific race, religion, ethnicity, sexual orientation, or gender identity.

Table of contents
2023 CSR Report

Our people

CEO message

Diversity, equity, inclusion

Introduction
Talent attraction

CSR at Illumina
People investment

AccessWell-being and safety

Impact in action

PeopleCommunity

Sustainability

Responsibility

39

Impact in action

UK STEM students get hands-on
lessons in biodiversity and genomics
Pedal the Cause“This year was my seventh year
participating in Pedal the Cause, a charity
ride with 100% of proceeds going tofunding cancer research in San Diegoarea. As scientist and a steminist, I’m
passionate about this cause and astrong believer in finding cures throughscience. There is an incredible energy
here of a community brought together
by the shared goal of stopping cancer. It
reminds me that there’s a path to a curewhen people come together. This is why I
ride—ride bicycles, fight cancer.”In 2023, Illumina partnered with the nonprofit
organization Engineering Development Trust(EDT) and Industrial Cadets to guide students
through genome-focused sustainability
projects. Volunteers from Illumina worked
with them on biodiversity assessments tolearn about genomic applications in ecologicalconservation. Learn more

Global Wellness Charity
Challenge: Virtual 5K
Around the WorldThis year we had more than 1500
participants across the globe
celebrate the 4th Annual Virtual
5K! The charity recipient was the
Leukemia & Lymphoma Society.

Misha
Associate Director, Scientific Research

Summiting Italy’s Stelvio Pass forcancer research

Q&A: An Illuminaintern’s shift fromacademia to industry
When Adee Newman
started her summer as a
research associate internat Illumina in June 2023,
she had no prior industry
experience. Originally from
Palo Alto, California, shespent two years at De Anza
College before transferring
to University of California, San Diego (UCSD). Currently, she
is a master’s student in biology with a research emphasis of
epigenetics and genomics at UCSD. Learn more

Appendix$25
In honor of the Illumina
25th anniversary, we
provided employeeswith $25 to donate toa cause that mattersto them.

On September 2, 11 Illumina teammates embarked
on a journey up the formidable Passo dello Stelvio
as part of the Stelvio for Life charity event. As theycycled, walked, and even ran their way up thischallenging mountain pass in the Italian Alps, they
did so with a singular purpose: to support Stelvio forLife Foundation, an organization working to advanceresearch into personalized cancer treatments.
This foundation is unwavering in its commitment to supporting the cancer research carried out
by the Center for Personalized Cancer Treatment (CPCT) in the Netherlands. In recent years,
the CPCT has conducted groundbreaking studies, including the Drug Rediscovery Protocol trial,a nationwide clinical research effort that matched patients with targeted therapies based on
specific DNA alterations identified through whole-genome sequencing (WGS) performed by the
Hartwig Medical Foundation. Learn more

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

Integrate
sustainability

AccessPeopleSustainability

Responsibility

Appendix40

Impact in action

Scott
Sr. Specialist, Ethics & Privacy
Summit of Mt. Whitney, CATable of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

Appendix
41

Impact in action

Strategic approachand impact
We are committed to integrating environmental stewardshipinto the fabric of how we operate. Human health and the healthof our environment are intertwined, which is why we prioritize
taking action on climate change and implementing sustainable
solutions in our facilities, in our products, and across our value
chain. As the world seeks innovative solutions to tackle climate
challenges and protect our natural capital, we recognize theincredible opportunity genomics and our technology provide.
K E Y O B J ECT I V E S

1Drive climate action across our value chain

2

Operate sustainable facilities

3

Develop sustainable products

4

Leverage genomics for sustainability applications

2023 H I G H L I G H T S

100%

53%

Carbon neutral8%

renewable electricity*

direct operations (Scope 1, 2)
beyond†‡ SBTi path

reduction in packaging (since 2019)

decrease in water usage (YoY)

Through onsite generation, purchased renewable electricity, and renewable energy credits.

*

SBTi Beyond Value Chain Mitigation.

†

Through onsite generation, purchased renewable electricity, renewable energy credits, andGreen-e certified nature-based carbon credits.

‡

UN SDGS

NovaSeqTM X Series

NovaSeqTM 6000

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

Our path to ascience-based
net-zero by 2050

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

42

Impact in action

Climate change represents a threat to human health, the environment, and theglobal economy. As a science-based organization, we aim to ground our climate
action in a science-based framework.
We were among the first companies in the world and the first genomic company
to receive verification of our 2050 net-zero emissions targets by the Science
Based Targets initiative (SBTi) Corporate Net-Zero Standard. Our Scope 1, 2, and3 emission targets are also externally verified by SBTi and aligned to the Paris
Agreement’s goal of keeping planetary warming to 1.5°C.

Managing climate risks and opportunities
To manage climate-related issues, we are incorporating climate resilience across ouroperations and value chain with a risk management structure, our EHS management
system, business continuity program management, supply chain risk reviews, andperiodic audits of related processes. As external conditions evolve, we will continue toevaluate our approach, recognizing that both physical risks, such as extreme weather,and transition risks, such as regulatory and technological developments, may affectour operations.
Learn more about how we manage climate risks and opportunities in our TCFD Index.

Illumina carbon footprint
Scope 1

Scope 2

Scope 3

Scope 3 emissions

18.9

350

10

20.3
6.0

9.8

SCOPE 3 CATEGORIES2019 BASELINE

17.9

300

12.5

19.1

21.9

16.9

8

358.7
323.7
299.0

200

150

100%

12
11.4

250

SBTI-APPROVED TARGETS

Emission intensity*

400

5.8

238.1

6

242.4
4.2

4

•

Our most material Scope 3 categories
of focus include:

Short-term emission
reduction

•
•
•
•
•
•

Capital goods (cat. 2)
Upstream transportation and distribution (cat. 4)

100

Business travel (cat. 6)

250

Renewable electricity

Based on our Scope 3 emission baseline
assessment, more than 87% of our global
emissions are attributable to our Scope
3 emissions, making it imperative for us to
manage our value chain and work with our
suppliers on their decarbonization efforts.
We assessed all 15 Scope 3 categories andidentified the most material contributors.
Categories that represented 7% or more
were defined as material and accounted for
92% of our total Scope 3 footprint.

Purchased goods and services (cat. 1)

4.1

Appendix

Increase annual sourcingof renewable electricity to
100% by 2030 from 2019baseline

0 GHG
Net zero

net-zero GHG emissions across•ReachIllumina's direct operations (Scope 1, 2)
and our value chain (Scope 3) by 2050
from 2019 baseline levels

↓90%

↓46%
absolute GHG•Reduceemissions from material

Scope 3 categories 46%
by 2030 from 2019baseline

Long-term emission reduction

Scope 1, 2 absolute GHG emissions•Reduce
90% by 2050 from 2019 baseline
absolute GHG emissions from
•Reducematerial Scope 3 categories 90% by 2050
from 2019 baseline

Employee commuting (cat. 7)
Investments (cat. 15)

2019

2020

2021

2022

2023

2030

2050

SBTi net-zero mitigation hierarchy

Net zero transition

Illumina follows the recommended mitigation hierarchy with our net-zero commitments. SBTi recommends science-based targets for the near and long term to address our value chain emissions and to implement
strategies to achieve these targets as a first order of priority, and then to invest in mitigation outside the value chains. Under the recommendations of the SBTi Corporate Net-Zero Standard, companies should go beyond
their near- and long-term science-based targets to further mitigate climate change by undertaking actions or making investments that generate additional co-benefits for people and nature. To further facilitate beyond
value chain mitigation, Illumina has invested in nature-based Green-e certified carbon offsets while on our journey to net zero. We have applied carbon offsets for our natural gas Scope 1 as a temporary mitigation.

As we work towards net zero, we're reducing emissions by
incorporating on-site energy generation and purchasing
renewable electricity, renewable energy credits, andGreen-e certified nature-based carbon credits.

Emissions in Kilotonnes.

Full emissions data here

*Scope 1 and 2 emission intensity per million dollars revenue.

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleImpact in action

Driving climate action across our value chain
We recognize that our environmental footprint extends beyond our facility walls,
and we engage in projects to further reduce emissions from our value chain.

Scope 3 management and reduction efforts•Sustainable upstream transportation and distribution

We have a bold program of mode shift initiatives that will havemeasurable impact in 2024 and will significantly scale in 20252030. Our mode shift initiatives are focused on shifting our
product movements to lower emission options, with our ocean
freight program remaining as the largest contributor.

•Ocean transportation – In 2023, we qualified oceantransportation for our internal Singapore-to-US supply
movements. In 2024 we will expand our routes and increase
our volumes for ocean freight to include Singapore to Eastand West coast US ports.

•Logistics Network Optimization – In 2023, we increased

our focus on network improvements, ensuring our products
are handled and transported more efficiently. In 2024 and2025, we will add significant digital transport management
capability to enable accelerated progress in this area.

•Sustainable investments – We modified our investments

policy to eliminate investing in energy and utilities sector bonds
unless the associated issuance is identified as a Green, Social or
Sustainability (GSS) bond. We were able to adjust our approachwithout any expected impact on our returns.

•Sustainable business travel – At Illumina, we enable employees
to effectively avert travel for business meetings with a host ofdigital and virtual tools, reducing carbon emissions associatedwith business travel. For our highest-traveled routes in 2023,
we contracted with an airline in a rebate model that drives apercentage of our spend towards the purchase of sustainableaviation fuel in $50k increments. We partner with an electric
car consortium called SWOOP that allows for electric cartransfers to and from our high-transfer routes of Chicago–
Madison and San Diego–Los Angeles. Additionally, in 2023 wechanged our primary preferred rental car provider, which has ahigher % of rental cars that are electric than other providers.

•Sustainable capital goods and purchased goods andservices – Through our CSR supplier program, we assess
environmental sustainability commitments made by our
suppliers. Our goal is to empower our suppliers to reduce
their collective carbon footprint and encourage transparent
reporting on their progress. In turn, this will help us to reduce
our overall Scope 3 emissions. Learn more about our CSR
supplier program.

•Sustainable employee commuting – We support employeeswith a variety of regional commuting options, including freeelectric vehicle charging, commuter shuttles, and subsidized
vanpools.

•Sustainable shipping – The breakthrough NovaSeq X Series

allows for ambient shipping and the elimination of cold-chaintransportation. In 2023, 352 NovaSeq X Systems shipped.
Learn more about our approach to sustainable products.

2023 E M E A O P E R AT I O N S

In 2023, our EMEA operations team oversaw a successful transition to a localized
cold-chain shipping system. Following a more than yearlong initiative to investigate andapply a localized approach, the team achieved:

14×

reduction in
CO2 emissions

Shortenedlead times for critical materials
from months to days

Reducedwarehousing andlabor expenses

Sustainability

Responsibility

Appendix43

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

Appendix
44

Impact in action

Operate sustainable facilities
We approach reducing the environmental footprint of our facilities
by focusing on green building design and optimizing our energy,
water, and waste management.

2023 P R O G R E S S

2023 initiatives

Green building design

Energy management

As a data-driven organization, we track key metrics
across our facilities that allow us to measure oursustainability performance and make changes. We
consistently identify and adopt strategies to manage
energy conservation, water usage, waste disposal,
and the use of sustainable materials.

We integrate sustainable principles into the design,
construction, and operation of our global real estate
portfolio.

We regularly evaluate energy efficiency measuresand renewable energy projects to reduce ouroperational carbon emissions. Each of our sites
maintains a pipeline of energy projects to contributeto emission reduction.

Buildings Scorecard Program – This program•Greenevaluates all new builds and renovations against LEED

criteria categories to assess energy, water, waste, andbuilding efficiency considerations.

(Water Efficiency Building) Award – Our Singapore•WEB
site completed a project that installed more than 80
control flow restrictors, water sensors, and water delay
timer fittings to improve water efficiency, conserving an
estimated 1 million gallons of water annually, earning a
WEB award from the Public Utilities Board in Singapore
in 2022.

waste recycling – Northern California, San•Organic
Diego, and Madison sites have taken proactive steps toalign with California Assembly Bill 1826, which requires
businesses to recycle their organic waste. The sites havepartnered with local waste haulers on a phased rolloutthat includes new containers for organics, standardized
instructional labels, and change management education
strategies.

Economy Plastics Pilot – Following a successful•Circularpilot of diverting consumables waste to be repurposedfor other plastic applications, we are currently exploring
internal processes for the collection of plastics andselecting a recycling partner for a global program.

Green Building Design LEED Certified Sites•San Diego, CA•Foster City, CA•Singapore, SG•Shanghai, China

Our Singapore North Coast building earned LEED Gold. By
engineering design with energy efficiency and sustainability
in mind, Illumina Singapore has not only reduced its
environmental impact, but has also enabled total energy
saved of 736K kWh per year, resulting in $126,000 yearlycost reduction. Best-in-class practices were achieved forinfrastructure energy and water efficiency, managementof recyclable waste, environmentally friendly construction
materials, and indoor environmental quality.
GREENING OUR LABS

We have partneredwith My Green Lab® toimprove the sustainabilityof our laboratories around the world. In 2023, sixof our labs continued the certification process bycompleting a baseline assessment to evaluatesustainable best practices. Participating labs
will discuss and implement improvements forreassessment and certification next year.

100%

through onsite generation,purchased renewableelectricity, and renewableenergy credits

2030 TA R G E T

100%

renewable electricity
achieved

upgrades and optimization – Our Singapore•HVAC
site began reconfiguring building HVAC system fansto achieve a more balanced air distribution, eliminate
energy transmission, and operate at a higher efficiency.
These upgrades will result in an annual energy savings of
188,340 kWh. Singapore also initiated a project that will
study building occupant activity HVAC trends to optimize
schedules and operate more efficiently, ensuringconsistent indoor air quality, and reducing the building’s
carbon footprint. These upgrades will result in an annual
energy savings of 70,080 kWh.

Renewable electricity*
100%

100%

2022

2023

59%

•

LED lighting replacements – Our Singapore site began
replacing fluorescent lights in manufacturing spaces
with more efficient LED lighting. The new LED lights
emit less heat, have a longer lifespan, and are moreenergy efficient compared to fluorescent lights, saving
approximately 109,697 kWh annually.

optimization – Our Europe facilities team has•Occupancy
been focused on a number of scheduling updates andbehavior change initiatives to power down equipment
and reduce airflow to fume hoods in unoccupied spaces.

automation analytics – Our San Diego site
•Buildinginitiated a project that will assess building-level data,

provide insights into energy and operational efficiency
improvements, and identify building HVAC control
and set point issues by leveraging advanced building
automation analytics and reports.

0.6%

2%

2019

2020

2021

*
Onsite generation, purchased renewable electricity,
renewable energy credits, and Green-e certified naturebased carbon credits.

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

Appendix
45

Impact in action

Water stewardship

Waste management

At our core sites*, we employ a variety of water conservation applications. We assess ourwater usage by comparing the locations of our sites with the baseline water stress risk
ranking according to the World Resources Institute and its Aqueduct Water Risk Atlas.
For facilities that have been identified as operating in water-stressed regions, we arecommitted to focusing additional efforts on water management planning.

We take a hierarchical approach to waste management, where source reduction is themost preferable option and landfill is the least preferable. We continue to prioritize
innovative waste management efforts as part of our 2030 landfill diversion target.

WATER RISK ASSESSMENTBY SITE

Extremely HighHigh
Medium-High
Low-Medium
Low

WATER RISK AT CORE SITE LOCATIONSMOST PREFERABLE
Avoid or Reduce

San Diego, CA

Foster City, CA

Singapore, SG

Reuse

Madison, WI

Cambridge, UK

Hayward, CA

RecycleSteenoven, NL

Incinerate

Following a complete analysis, including
pH levels, conductivity, hardness, andcorrosion levels, the team made key
adjustments to optimize chemical dosing,
reducing water wastage, and enhanceoverall system performance.

Additionally, the team identified
opportunities to optimize theblow-down process, preventing
unnecessary
water loss while
maintaining water
quality.
The optimization
effort resulted in a
total water savings of 3,800,000 liters
a year as well as a cost reduction.

L E AS T P R E F E R A B L E

Hazardous waste
Our hazardous waste management program isdesigned to minimize impact and manage materials
in the most environmentally responsible manner.
The process follows a hierarchy that specifies
reclamation/reuse, recycling, waste-to-energy
recovery, fuel blending, wastewater treatment,
incineration, autoclave, and landfill when alternatives
are not available.

Producer responsibility
2023 P R O G R E S S

2030 TA R G E T

Our San Diegolocationscontinue to utilize
reclaimed water
for landscaping,water features,and our cooling
towers.

10%

Through our waste management programs,
we aim to reduce the environmental impact
from electronic waste and ensure responsible
management at end of life. We partner with
e-Stewards, R2, and other certified recyclers
to refurbish, rebuild, and reuse devices to helporganizations around the world.

Landfill

Cooling Tower Optimization
In 2023, our Singapore facilities teamlaunched an initiative to review andoptimize the cooling towers to reduceoverall water usage without compromising
the efficiency of the system.

Responsible electronic
waste disposal

25%

increase in water intensity
at core sites from baseline(2% increase YoY)

reduction in water
intensity at core sites**Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, Netherlands, China, and Singapore.

We participate in required compliance schemes
for producer responsibility to ensure propercollection, management, and disposal. This includes
the recycling of packaging, batteries, and waste
electrical and electronic equipment (WEEE). Under
the European Union’s Batteries and Accumulators
Directive and Packaging Waste Directive andregulations in several EU member states, we comply
with requirements to finance the collection andrecycling of batteries and packaging supplied with our
products at end of life.

iRecycle – An employee-led program in
our Asia Pacific, Middle East, and Africa(AMEA) region, iRecycle aims to minimize
the environmental footprint associatedwith waste from the field service engineer
teams. Previously, product parts that were
not reparable by our service teams were
disposed of in landfills. With the launchof the program, these parts were sorted
and recycled in collaboration with key
partners. In the past year, the program
has expanded beyond its pilot phasein Australia to include service teamsin Singapore, Japan, and South Korea.
Mirroring the geographical expansion,
the volume of spare parts being recycled
has increased by 40% to 7000 kilogramsin 2023.
2023 P R O G R E S S

2030 TA R G E T

90%

landfill diversion at
all core sites*

56%

landfill diversion, a
5% improvement
since 2019

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina

AccessSustainability applications

PeopleSustainability

Responsibility

Appendix46

Impact in action

Develop sustainable products
We integrate the Design for the Environment (DfE)
approach into the core of our product development to findopportunities to shift to a circular economy, addressing
the full life cycle of materials and their end of life. We apply
environmental criteria to resource selection, design, energyuse, data processing efficiency, size, weight, stability,
packaging, shelf life, temperature requirements, end-of-life
management, and more.

1

1

2

6

2

Our approach to developing
sustainable products:•Integrate DfE
sequencing system power consumption and•Optimizeprocessing efficiency

3•

Reduce the amount of petroleum-based plastic in new
product designs

the use of chemicals of concern wherever•Replace
possible with greener alternatives

additional opportunities to engage in a circular•Seek
economy3

52023 P R O G R E S S
2030 TA R G E T

75%

53%

90%

of our secondary andtertiary packaging
will be recyclable,
reusable, orcompostable

Sustainable production – Through oursustainable facilities, we aim to makethe manufacturing process less energy
intensive, minimize the use of toxic
materials, and recycle waste from theproduction process where possible.
Sustainable logistics – We work to
make the transportation of our products
more efficient and sustainable.

5

Sustainable packaging – We invest
in making our packaging recyclable,
returnable, and reusable.
Returnable insulated containers:
Insulated containers used forrefrigerated and frozen in vitro
diagnostic (IVD) product shipments canbe returned to us for reuse.

reduction of packaging
from 2019 baseline

2030 TA R G E T

Sustainable resources – We arecommitted to sourcing sustainable
materials, including reducing theamount of petroleum-based plastic in
new product designs. We also actively
work to replace the use of chemicals ofconcern with greener alternatives.

4

4

reduction of
packaging

Sustainable end of life – We develop
innovations that serve our customers
long into the future and include design
planning to incorporate end-of-life of
our products.

•
2023 P R O G R E S S

70%of our secondary andtertiary packaging is
recyclable, reusable,or compostable

In 2022, we engaged a third party to complete a streamlined life cycle assessment‡ of the
NovaSeq X 10B 300 cycle kit compared to the NovaSeq 6000 S4 300 cycle kit and used
the functional unit of a per gigabase (Gb) of genetic code. Our findings demonstrated a
61% reduction in climate change impact† with the NovaSeq X kit. Armed with data on theholistic impact, we will use the information to address new opportunities in future designfor environment applications and sustainability product enhancements.

We launched a container reuseprogram where returned containers
are inspected, sterilized, reworked,
and used again

full implementation, these•At
containers reduce 1.43 metric tons of
CO2 emission each month

NovaSeqTM 6000

NovaSeqTM X

0.09 kg CO2 e

0.04 kg CO2 e

Recyclable insulated containers:
Moving to plant-based paperinsulated containers has resulted in a
100% curbside recyclable solution.*curbside recyclable and•100%
compostable containers use

standard paper recycling streams

insulated containers for frozen•Theand refrigerated shipping are
made with plant-based renewablematerials, which requires lessenergysolution diverts 250,000 cubic•Thisfeet of material from landfills per
100,000 containers

Reusable bulk sustainable
solutions: Insulated pallet shippers
for frozen and refrigerated products
are validated for multiple uses andreturnable for refurbishment andreuse. This supports the internal
movement network and customer bulk
orders.

return facilities inspect•Supplierand refurbish for return shipment toIllumina

are modular and break down
•Pallets
flat for easy return of multiple units
via land or ocean

6 Sustainable use – When designing

our innovations, we aim to create
products that are both more powerful
and more energy efficient.

100% recyclable in the US and widely recyclable globally.
Based on end market assessment NY, US
The project aligned with the methodological requirements and guidelines of the ISO standards ISO 14040 (2006a)
and ISO 14044 (2006b) on LCA and the GHG Protocol Product Life Cycle Accounting and Report Standard (WRI/
WBCSD, 2011). However, as it is a streamlined LCA study, it does not fulfill all of the reporting requirements ofthese standards.

*†

Emissions per
gigabase (Gb)container returned diverts 34•Everykilograms of waste from landfills‡

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

Appendix
47

Impact in action

Leveraging genomics forsustainability applications.

The positive power of genomics is helping to identify, measure, and solve some of the planet’s most challenging
and pressing sustainability issues. Our customers are leveraging the power of genomics for studies on biodiversity,
endangered species protection, ecosystem conservation, sustainable agricultural practices, and climate change research.

Naturalcapital andbiodiversity
As part of ourapproach tosustainable andresponsible
business
operations, we take a holistic look at natural
capital and diversity and have reviewed
potential risks and opportunities beyond our
climate footprint. We have also reviewed thelinks between our potential direct impacts
and dependencies on natural capital, using
the Taskforce on Nature-related Financial
Disclosures and the Kunming-Montreal
Global Biodiversity Framework. As theintersection between biodiversity, natural
capital, and the economy becomes moredefined, we recognize the opportunities forthe application of genomics and Illumina
sequencing to protect and innovate in futurenature-positive economies. Learn more about
how we manage climate risk.

Agrigenomics
Agricultural genomics, or agrigenomics, is driving sustainable productivity and offers solutions
to the mounting challenges of feeding a growing global population. Using modern technology,
farmers, breeders, and researchers can easily identify the genetic markers linked to desirable
traits, informing cultivation and breeding decisions.

Dedicated to making tangible contributions
Previous recipients
SENAI Innovation Institute for Biosynthetics, basedin Rio de Janeiro, Brazil, focuses on seaweed
cultivation to explore the genetic potential for
carbon sequestration and environmental services,and food security. Learn more

Launched in 2011 and awarded
annually, the Illumina Agricultural
Greater Good Initiative
grant spurs critically needed
research that will increase thesustainability, productivity, andnutritional density of agriculturally
important crop and livestock
species. Grantees receive
donations of Illumina products
to support their projects.

The International Institute of Tropical Agriculture (IITA)
focuses on developing genomic resources for yams, asignificant agricultural crop and a rich source of nutrition.
The IITA aims to conduct WGS of guinea yams from
Nigeria and Benin to investigate their evolutionary
development and to tap into specific genes for optimizing
hybrids in the breeding program. Learn more
Dr. Bertram Brenig, from the University of
Goettingen, Institute of Veterinary Medicine,leverages genomics to help understandvulnerabilities impacting the Western honey bee,
one of the most populous pollinators facing multiple
challenges and population decline. Learn more

Breeding better sugar with genomics
Scientist Jorge Da Silva, PhD, at Texas A&M
University is using genomics to produce
sugarcane that is sweeter; higher yield;
more resistant to cold, pests, and drought;
and more carbon neutral. Da Silva’s researchcomparing leaf chlorophyll content, leaf
temperature, and relative water content
in several different sugarcane genotypes
subjected to a 90-day drought cycle has
generated a wealth of data about which genes
are actually being expressed and controllingthese traits. Genetic samples, or germplasm,from these crops have already been sharedwith the International Society of Sugar
Cane Technologies, and the US government
recently awarded Da Silva’s program a grant
to turn their attention to “energy cane”—
sugarcane grown specifically to produce
bioethanol. Read the full story
The newest and most advanced Illumina
sequencing systems, NovaSeq X and NovaSeq
X Plus, use a biopolymer derived fromsugarcane in their reagent kit cartridges, which
can be recycled after use.

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

Responsibility

Appendix48

Impact in action

Conservation genomics

Biodiversity and eDNA sequencing

Conservation genomics focuses on characterizing the genetic diversity of endangered species andapplying molecular tools like Illumina sequencing to support sustainable management of threatened
species and populations.

Environmental DNA sequencing is a rapidly emerging method for studying biodiversity andmonitoring ecosystem changes. As organisms shed DNA into their environments, eDNA analysis
can provide clues about the species present without disrupting the ecosystem. Potential
applications of eDNA include port monitoring, biodiversity surveys, ballast water testing, soil
testing, and more. Scientists are utilizing our technology and eDNA to gain insights to develop
innovative environmental solutions.

iConserve initiatives
The Illumina iConserve program seeks to bring the community together to accelerate wildlife conservation.

Turning sport sailors into field scientists
New Zealand’s Cawthron Institute, led by Xavier
Pochon, specializes in science that supports
the environment and sustainable development.
Pochon’s team monitors natural ecosystems
using DNA metabarcoding, which inspects anenvironmental sample for both microbes andcells shed by larger organisms, whether thosespecies are previously known or novel. And whenit comes to marine biodiversity, Pochon saw apressing need for more data.
How genomics will support
gorilla conservation

Sequencing to savethe lemurs

Bottlenose dolphin genome
made available to researchers

A new genomic atlas could help
save endangered elephants

The iConserve koala retrovirus sequencing project
Illumina and the San Diego Zoo’s koala sequencing project will represent thelargest pedigree of any koala genomic database to date.
In 2021, the Australian Centre for Wildlife Genomics at the AustralianMuseum, hosted the Second Koala Retrovirus (KoRV) Workshop to facilitate
multidisciplinary discussions about KoRV and koala management.
One of that workshop’s ultimate recommendations recognized a need for
longitudinal studies, across multiple generations, to investigate the genetic
causation of these health conditions.
In 2023, the workshop hosts, the Illumina iConserve program, and the San
Diego Zoo engaged to begin just such a study. The San Diego Zoo preserves
genetic samples of most koalas in their care, including many from former
generations dating all the way back to the current population’s founders in the
1970s—and Illumina performed whole-genome sequencing on all of them. Thisdata, spanning five generations, was uniquely valuable. Learn more

Traditional oceanographic research methods
require direct visual observation or even physicalcapture of the species involved, which is slow,
expensive, and can be harmful to marine life.

Pochon came up with the idea to equip sport
sailing vessels with user-friendly tools and asimple procedure for taking seawater samples
at key points along their route—a faster, morereliable, and harmless way to track endangered
species, monitor pathogens and, over time,show how climate change is shifting species’
geographic range.
With support from Illumina, Sequench, and SmithRoot, Cawthron Institute’s molecular surveillanceteam was able to extract 4.7 million DNA
sequences identifying 11,000 species—
all in less than two weeks.
Learn more

Table of contents
2023 CSR Report

Climate action

CEO message
Sustainable facilities

Introduction
Sustainable products

CSR at Illumina
Sustainability applications

AccessPeopleSustainability

49

Future of sustainable mining
belongs to the microbe
Our relationship with the microcosmos is undergoinga paradigm shift as great as when we first discovered
it in the 17th century. We spent 300 years believing
microbes were either ubiquitous but harmlessstowaways or disease agents to be eradicated at all
costs. Now we’re finally starting to explore the ways
these tiny-but-mighty creatures could help us tackle
some of our biggest challenges. Learn more

51% diverted fromlandfill with red tag
program

The Illumina operational excellence team, incollaboration with the Madison Green Team
employee resource group, created the Red Tag
program, a pivotal surplus management initiative.
By efficiently tagging surplus items that are nolonger needed and making them available to all of
Illumina, the Red tag program improves our efforts
to become a more circular business, as well as
improve our bottom line.

Over 100 employees globally,in Singapore, Europe, and across the Americas,
volunteered to remove trash and protect our waterways
from pollution in celebration of International Coastal
Cleanup Day.

Appendix

Impact in action

Impact in action

Illumina employees celebrate coastal
cleanup day

Responsibility

In 2023, the Red Tag program in our Madison
location was able to divert 51% of materials—
ranging from equipment to lab consumables—fromthe landfill. Of this, 27% of the inventory was
returned to service in other lab spaces, while 24%
was donated to a nonprofit partner that provides
lab space and equipment for biotech startups.
These results were achieved primarily throughlocal redeployments. Today, Red Tag is integrated
with Illumina’s internal continuous improvement
platform—iImprove. This integration enables global
equipment redeployment, further advancing ourwaste diversion efforts.

Marine conservation and sequencing at sea
In 2022, Illumina and the Minderoo Foundation announced a three-year,$28 million partnership to improve surveillance of marine ecosystems
using the power of high-throughput sequencing with Illumina technology.
Watch the latest update.

A lesser-known application of genomics:
Reducing cow burp intensity
Methane is 28 times more
powerful a greenhouse gas
than carbon dioxide: It’s
responsible for a third ofglobal warming. A single cow
can produce up to 500 litersof methane a day, or 160
kilograms per year, mostly

SANDAG annual
iCommute diamondawardsFor the sixth consecutive
year, Illumina was awarded
the iCommute Diamond Award
for Excellence in Commute
Programs from the San Diego
Association of Governments(SANDAG). SANDAG’S annual
iCommute Diamond Awards
recognizes San Diego-area
employers who have madestrides to promote alternative
commute choices in theworkplace.

through eructation (that is,belching). Multiply that by theplanet’s 1.4 billion cattle, and it
might be a burp, not a butterfly
wing, that causes a hurricaneon the other side of the world.
Genomic sequencing has
enabled dairy farmers to makebreeding decisions much faster,with greater accuracy, basedon genomic breeding values.
No longer do they have to wait
to see how productive, fertile,or hardy a bull’s progeny are
before they decide whether
to use that bull for further
breeding: These genomic
breeding values can becalculated for animals as soon
as they’re born. This reduces
the time between generations
and, according to one estimate,saves bull breeding companies
up to 92% of their costs.
Learn more

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

Operateresponsibly

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

Product quality and safety

Responsibility

Appendix50

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

Strategic approachand impact
We are committed to conducting ourselves with honesty,
integrity, and respect for all. Our role as a genomics pioneer
brings with it the responsibility to enable innovation for good,
ensuring that the technology we create and the data wecollect are used safely, ethically, and responsibly. Doing theright thing is core to who we are, what we do, and how we
do it. We honor the trust placed in us by patients, customers,
employees, shareholders, and communities.
K E Y O B J ECT I V E S

1Practice strong corporate governance and compliance2

Act ethically and with integrity

3

Uphold high standards for data security and privacy

4

Foster a responsible supply chain

5

Advance product quality and safety2023 H I G H L I G H T S

3$94.1 million

100%

97%

board members are womenof Illumina core facilities* participatedin third-party audit programsin diverse supplier spend (US)employees trained on our code of conduct*Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre,
Netherlands, China, and Singapore Woodlands.

UN SDGS

AccessResponsible supply chain

PeopleSustainability

Product quality and safety

Responsibility

Appendix51

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessPeopleResponsible supply chain

Sustainability

Responsibility

Appendix
52

Product quality and safety

Practice strong
corporate governance

B OA R D O F D I R ECTO R S

By exercising strong corporate governance, we aim to inspire
confidence in the work we do and in our company’s future.
Board of directors

Diverse and independent board

Our Board of Directors is a diverse group of leaders whochampion scientific innovation. The Board’s aim is toensure the company is equipped with the tools it needs toaccelerate the power of genomics. The Board has adopted
Corporate Governance Guidelines that are founded on
a commitment to building shareholder value, with anemphasis on responsible governance. These guidelines,
together with the Code of Conduct and Board Committee
Charters, provide the framework for corporate governanceat Illumina.

As stipulated in our Corporate Governance Guidelines,
our company seeks to achieve a mix of Board membersthat represents a diversity of background and experience,
including with respect to age, gender, international
background, race, and specialized experience. The
guidelines also require that independent directors
constitute at least a majority of the Board. In order to be
independent directors of the company, directors must meetthe criteria for director independence established by the
Nasdaq Stock Market.

G OV E R N A N C E H I G H L I G H T S

Our Board has established four standing committees.
Learn more in each committee charter:•Independent Board chair
directors other than the CEO are•All
independentof standing committees are•75%
chaired by women
director changes, two•Sixdepartures, and four additions•New CEO selected••Compensation Committee•Nominating/Corporate Governance Committee•Science and Technology Committee
Audit Committee

Frances Arnold, PhD

Caroline Dorsa

Robert S. Epstein, MD

Scott Gottlieb, MD

Professor of Chemical Engineering,
Bioengineering & Biochemistry at
Caltech; Nobel Laureate

Former EVP & CFO,
Public Service
Enterprise Group

Former President & Chief
R&D Officer, Medco-UBC

Former Commissioner,
US FDA

Gary S. Guthart, PhD
President & CEO,Intuitive SurgicalPhilip Schiller

Former Apple Fellow,
Apple

Sue Siegel

Former Chief Innovation
Officer & CEO, GE Ventures

FO U R N E W D I R ECTO R S A D D E D I N 2023

Board CSR/ESG governance
The full Board provides CSR oversight, and in 2022
we expanded the remit of the Nominating/Corporate
Governance Committee to assist the Board in overseeing
the company’s material CSR matters, except as specificallydelegated to another Board committee. The Compensation
Committee continues to oversee and provide input tomanagement on diversity and inclusion matters, and the
Audit Committee continues to oversee cybersecurity.

Learn more in Governance

Stephen MacMillan

Jacob Thaysen, PhD

Chair of the Board, Illumina;
President and CEO, Hologic

CEO, Illumina

4year average tenure

More details about the Board can be found in our Proxy and on our corporate website.

3

Andrew Teno

Portfolio Manager,
Icahn Capital

female directors

Scott Ullem

CFO, Edwards
Lifesciences91%

independent

Table of contents
2023 CSR Report

Corporate governanceCEO message
Business ethics and integrity

Introduction

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

Compliance
At Illumina, our Code of Conduct and associated anti-bribery compliance policies and procedures areintended to promote honest and ethical conduct, compliance with applicable laws, and protection of ourbusiness interests. Our Anti-Bribery Compliance Program (“Compliance Program”) is built on the eightelements of an effective compliance program as recognized by the Office of Inspector General (OIG) of the
US Department of Health and Human Services and the Serious Fraud Office (SFO) of the UK. The Programprovides a comprehensive framework to detect and prevent violations of law and company policy.
The fundamental tenets of our Compliance Program are detailed below. Our Program has been structured
to meet the needs of Illumina’s unique position in the industry and address the risks our company faces.

1. Compliance policies and procedures

3. Training and education

Our Code of Conduct applies to all Illumina Board
members, employees, officers, contractors,
distributors, and other business partners, and isintended to provide personnel with a blueprint
for meeting Illumina’s high ethical standards andapplicable law. Illumina also has a set of associatedanti-bribery and anti-kickback compliance policies
and procedures to help us all operate in accordancewith relevant laws, industry codes, and our own
standards.

Illumina is committed to ensuring that all our
stakeholders have a clear understanding of thelaws, policies, and industry codes that apply to
our interactions with the health care community,
governmental bodies, patients, and the public atlarge. We provide employees with training andeducational content in a variety of formats andin multiple languages, which reflects the diverse
scope and nature of our business and employees.
Our training program and methodology are regularly
reviewed and revised as needed to address newand emerging risk areas.

2. Compliance program governance
The Illumina chief compliance officer and Global
Compliance Committee are responsible for theoversight of Illumina’s Compliance Program. The
Global Compliance Committee comprises a crossfunctional group of senior-level executives atIllumina, and our chief compliance officer serves
as the committee chair. Together, this team of
executives monitors the effectiveness of Illumina’s
Compliance Program and drives any necessary
Program enhancements to management andrelevant personnel.

PeopleSustainability

Responsibility

100% of employees* are assigned
training annually
97% completed the web-based training
and certified they have read andunderstand the code in 2023
*Including FTEs, contractors, consultants,
and interns

53

Product quality and safety

4. Reporting concerns

7. Disciplinary guidelines

Everyone at Illumina has an affirmative obligation
to report any suspected violations of applicable law
or any of our compliance policies. We encourage
everyone to raise concerns to their managers,
Human Resources, or the Compliance department
directly. There are several resources available to
make reports, including our Compliance and Fraud
Prevention Hotline, where reports can be madeanonymously (where permitted by law) 24 hours
a day, seven days a week. Our Code of Conduct
strictly prohibits any form of retaliation for anyone
who makes a good-faith report of a potential
violation of law or our policies.

Illumina requires adherence to our Code of Conduct
for continued employment or affiliation with ourcompany. We address discipline for policy violations
consistently without regard to a stakeholder’slevel, function, influence, or perceived value to thecompany. Our documented disciplinary guidelines
are clearly communicated and made readily available
to all employees.

5. Internal monitoring and auditing
Illumina monitors the effectiveness of ourCompliance Program through the development andimplementation of a monitoring and auditing plan
carried out every year. The extent and nature of thepolicies and interactions subject to this review varyfrom year to year based on Illumina’s risks and anychanges in the regulatory landscape.

6. Response to compliance violations
TRAINING

Appendix

Illumina takes all violations of our compliancepolicies seriously and we are committed to taking
corrective action when needed. Violations reported
internally and through the third-party hotline, as wellas those that are discovered through our monitoring
and auditing efforts, are promptly investigatedand remediated as appropriate. Moreover,violations inform our annual monitoring plan andany enhancements that may be required to our
educational content and policies.

8. Assessing risk
The effectiveness of Illumina’s Compliance Programis regularly assessed internally by our compliance
personnel using a variety of tools to uncover process
gaps and make modifications to respond to businesschanges and any shifts in the regulatory landscapegoverning our business. We regularly communicate
with all our stakeholders, including executives,
employees, distributors, and contractors, to ensure
our Program is modified, where necessary, toaddress Illumina’s major risk areas.

KEY POLICIES•Code of Conduct•Compliance Program Framework•Anti-Bribery and Anti-Corruption•Anti-Competitive Behavior
With Healthcare•Interactions
Professionals and Organizations•Compliance Information•Ethics Information•Ethics Advisory Board Charter•Ethics Advisory Board Members

Table of contents
2023 CSR Report

CEO message

Corporate governanceIntroduction

Business ethics and integrity

Risk management
Illumina has adopted a company-wide approach to assess andmanage risks. We endeavor to ensure that all employees adhere
to our ethics and compliance protocols. Our enterprise risk
management (ERM) framework has been established to anticipate,assess, monitor, manage, and report on risks that could impede
our business and identify emerging issues and opportunities.
We have implemented a corporate global business continuity
planning (BCP) program to reduce risk exposure and mitigate
negative events to business operations. The ISO 22301:2019
standard is used as a business continuity framework for thisprogram. Additionally, the Internal Audit Department independently
and objectively assesses risk and reports insights to the Audit
Committee of the Board of Directors quarterly.
Our risk assessments consider various quantitative and qualitative
inputs, including:Business and finance

Product quality

Operational

Employee

Legal and regulatory

Environmental, health, and safety

Brand and reputation

Climate (physical and transition)

Learn more about our risk factors in our 10K.

Climate resilience
At Illumina, we believe addressing climate change is one of the
key avenues to achieving a sustainable, just, and resilient future
for all. We are committed to climate action and the integration ofclimate resilience planning into our risk management program. See
the Integrate sustainability chapter for additional information and
the Appendix for additional details on our Task Force on Climaterelated Financial Disclosures (TCFD) index.

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

Product quality and safety

Responsibility

Appendix54

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

We are committed to reflecting the very best of our people, practices, andpurpose. Integrity and fairness are central to our values and how we operate in
the workplace and the marketplace.

Ethics advisory board

Ethical use of genomic technologies

We seek guidance from our Ethics Advisory Board on a range of ethicalissues, including recommendations on emerging technologies, policies,and regulations that are relevant to the genomic industry. We meetwith the Ethics Advisory Board quarterly; their work includes providing
strategic advice to Illumina about:

Illumina is steadfast in our commitment that genomic technologies
should be used to benefit humanity. Our Human Rights Policy andcustomer agreements outline our expectations regarding ethicalbusiness conduct, the use of our technology, and the steps we cantake in the event of a possible violation. We have expanded andenhanced our oversight and accountability processes to monitor andenforce these commitments and seek to prevent sales that could resultin misuse or human rights concerns before they happen. Illumina iscommitted to investigating potential reports of product misuse andwill not hesitate to cease sales to business partners in the event of aconfirmed ethics or human rights violation.

industry and the company’s interests•Ethical issues arising from specific technology or products

K E Y I N I T I AT I V E S

Clement Adebamowo,
BM, ChB, ScD,FWACS, FACS

Leslie Biesecker, MD

Glenn Cohen, JD

Charmaine Royal,
MS, PhD

Ethical artificial intelligence principles
Illumina is dedicated to improving human health by unlocking the powerof the genome. Our mission drives everything we do, including thetechnology we develop. Illumina creates and uses artificial intelligence(AI) systems to power industry-leading sequencing quality, fuel data
insights, improve understanding of genomic variation in relation to healthand disease, and advance genomic science. We define AI systems
to include machine learning, deep learning, and predictive modeling.
Illumina is committed to developing and using AI according to applicablelaws and the following guiding principles:•Transparency•Diversity, nondiscrimination,and fairness•Values-driven design•Accountability

LEARN MORE

Ethical Artificial Intelligence Principles

Ethical marketing
The claims we make about our products must be truthful and accurate.
All information we provide to our customers about our products,
including those that are involved in providing health care services, must
be consistent with the applicable label and consistent with local legal
and regulatory requirements.

our products and services
advertising and promotional•Represent•Allfairly, truthfully, and accurately, andmaterials must adhere to our•Generative Artificial Intelligence Committee•International Genomic Data Sharing by Health Technologies

not create, by statement or
not use messages or marketing•Do•Doomission, any misleading impressions
materials that have not been

Industries: Points to Consider Committee

Nita Farahany,
JD, PhD

55•Ethics Advisory Board•Human Rights Oversight and Accountability Framework•Human Rights Impact Assessment•Supply Chain Human Rights Assessment•Illumina Connected Analytics Impact Assessments(includes ethical AI, privacy, and human rights analysis)

Freda Lewis-Hall,
MD, DFAPA, MFPM

Appendix

Product quality and safety

Business ethics and integrity•Emerging policies and regulations relevant to the genomic

Responsibility

OUR RESPONSIBILITIES

promote them only for their approved
uses

Advertising and Promotional
Materials guidelines and policies

in any advertising, marketing, or sales
materials, or in any presentations

properly reviewed and approved
following company policy andprocedure

not overstate the efficacy of our•Doproducts, downplay or minimize therisks associated with our products,
or make false or illegal claims aboutor comparisons to the products orservices of a competitor

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

Product quality and safety

Upholding human rights for all stakeholders
We are committed to respecting human rights and treating every
stakeholder with dignity and respect.
Recognizing that only governments have the authority to becomea party to and to be bound by international agreements, Illumina
respects the fundamental principles contained in the International
Bill of Rights (that is, the United Nations Universal Declaration of
Human Rights, International Covenant on Civil and Political Rights,
and International Covenant on Economic, Social and Cultural Rights),
the International Labour Organization’s Declaration on Fundamental
Principles and Rights at Work, and the United Nations Guiding
Principles on Business and Human Rights. As a member of the United
Nations Global Compact, Illumina is committed to integrating theseprinciples into our strategy, our culture, our operations, and ourrelationships with business partners.
K E Y P L E D G E S O F O U R H U M A N R I G H T S P O L I CY

•Ethical business conduct•Protection of privacy•Supplier Code of Conduct•Safe workplace•Right to exercise freedom of association•Elimination of child labor, forced labor, and human trafficking•Equal opportunity and non-discrimination•Fair wages and working hours
Read the full Human Rights Policy.

KEY POLICIESHuman Rights Policy
Conflict-Free Minerals Policy
Illumina’s Modern Slavery Statement 2023

Human rights impact assessment
In 2022, we completed our first human rights impact assessment inalignment with the UN Guiding Principles. To do this we evaluatedinternal policies and external disclosures and worked to map actual andpotential salient human rights impacts. We then built on this evaluation
to identify the salient human rights impacts of Illumina, current practices
for protecting and promoting these rights, and ways in which Illumina
can continue to build on its human rights practices.
We reviewed the International Bill of Human Rights, the International
Labour Organization’s Declaration on Fundamental Principles and Rights
at Work, and the United Nations Guiding Principles on Business andHuman Rights.
We identified four salient human rights impacts:•Right to equality and non-discrimination•Right to privacy•Right of everyone to the highest attainable standard of health and toenjoy the benefits of scientific progress and its applications•Right to freedom from forced labor and modern slavery

In 2023, we continued to engage with internal stakeholders acrossIllumina’s departments to understand how Illumina impacts these salient
human rights and to identify opportunities for growth relevant to eacharea. We expanded our current practices to protect and promote theright to freedom from forced labor and modern slavery by engaging
with a third party to help us initiate human rights due diligence of
our supply chain. This due diligence helped us to identify higher-riskareas of our supply chain and opportunities for Illumina to engage with
suppliers to remediate human rights risks. Illumina is committed toworking directly with higher-risk suppliers to remediate their identified
human rights risks.
We will continue to work across the business to continuously improveand support existing efforts.

Responsibility

Appendix56

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessPeopleResponsible supply chain

Sustainability

Product quality and safety

Public policy
Proactive engagement with public policy stakeholders enables thesharing of accurate and reliable information about genomics andadvocacy for policies that ensure and promote broad access. Illumina
participates in the political and public policy process with governments
and organizations around the world to engage and educate
policymakers and key stakeholders on issues that impact our mission
and business.
Our interactions with policymakers must align with our core values,
ethical responsibilities, and legal obligations. The Illumina Nominating/Corporate Governance Committee of our Board of Directors oversees
our political policies and contribution practices. The committee
maintains responsibility for ensuring all Illumina political activities
promote ethical and transparent engagement, advance the company’s
mission, and comply with applicable laws and reporting requirements.
On an annual basis, we provide an update on our public policy
priorities, political contributions, lobbying expenditures, and information
about significant memberships. Our Global Government Affairs
team is responsible for advocacy activities. Illumina does not have apolitical action committee but does retain outside strategic advisors
who support our global engagement with policymakers and key
stakeholders. These advisors may also provide expertise on policy andspecific regional issues.
Illumina complies with all applicable laws and requirements inconnection with our global political and public policy activities. Theselaws generally require reporting on lobbying activities and compliancewith applicable gift laws.
Reports filed on behalf of Illumina are publicly available in the following
government-hosted databases:
Office of the Clerk, US House of Representatives
Secretary of the Senate, US Senate
Lobbying Disclosure, California Secretary of State
Transparency Register, European Commission
Texas Ethics Commission

Advocating for public policies that ensure and enable broad access togenomic technologies is a priority. In 2023, we focused engagementwith public policy stakeholders around:•Advancement of precision medicine•Adoption and reimbursement for genetic testing•Adoption and reimbursement for noninvasive prenatal testing•Adoption and funding for genomic infectious disease surveillance•Promoting STEM opportunities
Trade associations and memberships

Illumina participates in various trade associations for collaboration andthe exchange of ideas. We pay annual dues to a number of trade andindustry associations, some of which use a portion of their membershipdues for nondeductible state and federal lobbying and politicalexpenditures. We disclose memberships in trade associations for which
we contributed over $5000 in the immediately preceding year, as wellas the total amount of such dues.
For trade association payments in excess of $50,000, we also disclose
the portion of payments that are nondeductible under Section 162(e)(1)(B) of the Internal Revenue Code, such as payments to organizations
designated as 501(c)(4) and 501(c)(6).

LEARN MORE

Corporate Political Contribution Policy
Political Contributions Spend Report,
Trade Association and Significant
Membership Report

Responsibility

Appendix57

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

Data privacy
and cybersecurity
As we expand access to genomics around the world,
we must also respect and properly secure data privacy.
Genomics data is powering positive progressaround the world. We are committed todeveloping, upholding, and promoting highstandards for genomic data privacy. We develop,
implement, and review privacy-related policies,
practices, and contractual language and ensure
the integration of privacy as a priority throughout
the company. Our Privacy Policy defines the way
we use, maintain, protect, disclose, and transfer
personal information.
LEARN MORE

Privacy Policy
Privacy Principles
Privacy Transparency Report

Our privacy principles
We believe that responsible data stewardship, built
on a foundation of strong privacy and data security
protections, is essential to promote trust and support
innovation. Illumina is committed to handling personal
data according to applicable laws and the following
guiding principles:•Transparency•Ethical use•Responsible stewardship•Accountability

Key initiatives in 2023

•Led an Industry Core Group to produce theInternational Genomic Data Sharing by HealthTechnologies Industries: Points to Consider andpresented the work product to the Global Alliance for
Genomics and Health (GA4GH) plenary committee•Completed the EU-US and Swiss-U.S. Data Privacy
Framework (DPF) Self-Certification•Expanded the scope of products within our cloud
bioinformatics portfolio for the 2024 ISO 27701
privacy certification•Enrolled in the MedTech Europe Data Protection
Committee

PeopleSustainability

Product quality and safety

Responsibility

Appendix58

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

CSR at Illumina

Data privacy and cybersecurity

AccessPeopleResponsible supply chain

Sustainability

Responsibility

Appendix
59

Product quality and safety

Cybersecurity framework
Our technologies and services inherently involve
handling large amounts of genomic and healthdata that must be protected, making cybersecurity
integral to achieving our company’s mission.
LEARN MORE

Illumina Data Security and Privacy Statement

KEY REFERENCESCY B E R S EC U R I T Y E D U CAT I O N M O N T H•California Consumer Privacy Act•NIST Cybersecurity Framework•ISO 27001•ISO 13485•General Data Protection

Accountability Act (HIPAA)

Each October, we recognize Cybersecurity Education Month, whichheightens awareness of cybersecurity events, threats, attacks, and bestpractices that all employees can follow to help keep Illumina and its data
safe from cyber threats.

Amendments (CLIA)

There was an 8% increase in total participation and an 11% increasein unique participants compared to last year.

(CCPA)•Health Insurance Portability and•Clinical Laboratory Improvement

Regulation (GDPR)

The five pillars of our cybersecurity initiatives

1

2

Secure product design
and placement

Risk analysis andsecurity testing

Analysis Center (H-ISAC)•Led by chief product security officer•Continuously assess cybersecurity(DSAC)•Driving products towards secure by•Perform internal and external security

Program governance•Led by chief information security
officer (CISO)•Board of Directors’ Audit Committee
receives quarterly cybersecurity
updates•Annual assessment against

National Institute of Standards andTechnology (NIST) Cybersecurity
Framework*•Employees and contractors trained
annually•Third-party work requires

Partnerships•Healthcare Information Sharing and•Domestic Security Alliance Council•Information 2 Systems Security

Association International (ISSA)•Society for Information Management
San Diego (SIM)(CPSO)

design and secure in deployment
states•Implementing risk mitigations as partof product design and development
process•Chief Information Security Officer•Cloud-based products aligned with

•InfraGard•

cybersecurity risk assessment prior
to engagement*Limit to cloud products; does not apply to instruments.

4

3

Roundtable

ISO 27001 (security) and ISO 27701(privacy) certifications
Privacy by design and by default
initiative•Programs for hardening Illumina

software products to comply withindustry security practices

risk

testing for cloud software products•Regularly put cloud software products
through static analysis

5

Data protection•Data protected in compliance withapplicable laws and cybersecurity bestpractices*•Data privacy and data protection alignwith standards set by GDPR, CCPA,HIPAA, other regulations, and Illumina
privacy and data protection policies•Incident response plan and team

•CLIA laboratories ensure data quality•Internal vulnerability analysis•Backup capabilities encrypt and store

in place to handle cyber-related
disruption with business continuity
and contingency plans
conducted•Internal tests deployed to represent
simulated hacker attacks

with privacy, security, and regular
HIPAA framework assessments

data in immutable formats for data
confidentiality and integrity•Illumina connected software portfolio
provides enterprise-level protection
with a range of deployment options

Table of contents
2023 CSR Report

Corporate governanceCEO message
Business ethics and integrity

Introduction

CSR at Illumina

Data privacy and cybersecurity

Responsible
supply chain

The Illumina global supply chain consists ofsuppliers, subcontractors, channel partners,
manufacturing sites, distribution centers, andcustomers. We consider it business-critical towork with suppliers who share our commitment
to integrity and who support an ethical compliant
culture. We view our suppliers as partners in
our effort to work toward a more equitable andsustainable future for all.
What our suppliers provide ranges from off-theshelf packaging material to highly sophisticatedreagents. We define our supplier base, for both
direct and indirect, by categories, segments,and subcategories. Categories are defined by
specific commodity or service. Each category
has segments such as Strategic Suppliers.
Subcategories depend on the product, region,or service. We source components, software,equipment, and services from more than 75
countries.

PeopleResponsible supply chain

Sustainability

Responsibility

Appendix60

Product quality and safety

O U R S U P P LY C H A I N

4533

Our suppliers are critical to our mission. Together,
we magnify the positive impact to the customers
we serve and the communities where we operate.

Supply chain overview

Accesssuppliers acrossthe supply chain

Supplier code of conduct
We hold our suppliers to the same standards of business conduct that we
set for ourselves. We require them to comply with the standards of behavior
outlined in our Supplier Code of Conduct and exhibit social responsibility andenvironmental stewardship. All new suppliers are required to acknowledge theSupplier Code of Conduct to complete the onboarding process.
The Supplier Code of Conduct is consistent with commitments we made bothas a signatory of the United Nations Global Compact and as a member of the
Dow Jones Sustainability World Index.

We expect our suppliers to:•Comply with applicable, local, US, and international regulations•Uphold their employees’ human rights and the Illumina Human Rights Policy•Ensure a safe and healthy workplace•Demonstrate social and environmental responsibility•Conduct business in an ethical mannerSocial impact and environmental screening are included in our Request for
Information (RFI) tools when evaluating potential suppliers.
We embed the requirement for suppliers to commit to reducing theirenvironmental footprint in our Supplier Code of Conduct and require ourstrategic suppliers to accept this with issuance of any purchase order.

>$1B

estimated payments
to suppliers872

active diverse
suppliers$94.1M

diverse US supplierspend

Table of contents
2023 CSR Report

Corporate governanceCEO message
Business ethics and integrity

Introduction

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

Responsibility

Appendix
61

Product quality and safety

Modern slavery prevention

Verification and due process

Channel partners

Sustainable supply chain

Illumina is committed to conducting its businesslawfully and with integrity. We work to continuallystrengthen our practices to ensure no humantrafficking, slavery, or forced or compulsory labor(“modern slavery”) occurs in any part of our global
value chains and global operations. We also seek
to ensure that our global business partners do notuse modern slavery in any of its forms in providing
goods or services. In 2023, we updated ourModern Slavery Statement to include disclosures
for the Canadian Fighting Against Forced Labour
and Child Labour in Supply Chains Act. Additional
information is available in our Modern Slavery
Statement 2023.

We only build relationships with business partners
that share our commitment to fulfilling all legal
and ethical obligations. We never knowingly
conduct business with business partners that
employ underage individuals, employ forcedlabor, or use corporal punishment to discipline
employees, regardless of whether such practices
are permitted by law.

Our products are available around the globe
through a robust channel partner network. Our
partners not only offer critical access to our
products throughout the world but also provide
the same level of sales, marketing, service, andsupport that we offer to customers directly.
The Illumina Channel Partner Code of Conduct
requires that channel partners match the Illumina
commitment to business integrity, ethical conduct
in the marketplace, adherence to all applicablelaws, and the fundamental elements of humanrights. Illumina is a member of the Advanced
Medical Technology Association (AdvaMed) and
MedTech Europe. Channel partners are required
to adhere to the applicable provisions of the
AdvaMed Code of Ethics and MedTech Europe
Code of Ethical Business Practice.

We engage with strategic suppliers and business
partners on climate-related issues, holding themto the same high standards of business conductthat we set for ourselves. We require suppliers tocommit to reducing their environmental footprintin our Supplier Code of Conduct and require ourstrategic suppliers to accept this with issuance ofany purchase order.

Conflict-free minerals
Illumina supports international efforts to ensure
no conflict minerals directly or indirectly benefit
armed groups in the Democratic Republic ofCongo or adjoining countries. To this end,
Illumina expects all suppliers to commit to the
Responsible Business Alliance (RBA) Code of
Conduct. Through our Conflict-Free Minerals
Policy, we expect all our suppliers to establish
their own due diligence programs to ensure
supply chains are free of conflict minerals andto make those due diligence measures available
to us upon request. Illumina routinely evaluates
its suppliers to ensure they are adhering to our
expectations and values.

We perform due diligence on new business
partners to verify that they meet our standards.
This process involves conducting initial risk
assessments when onboarding new suppliers andconducting periodic assessments of performance.
In addition, for supply chain areas of higher risk,
we take steps to enhance our risk mitigation
strategies. Prior to engaging in business with any
supplier, we utilize tools that provide up-to-datesanction lists from governments around the worldthat identify companies and individuals involvedin criminal activities such as money laundering,financing paramilitary groups, etc. In addition, we
utilize tools to continuously monitor our supplierbase for potential risk elements such as financial
stability, leadership changes, global news, andothers.
We encourage all employees and business
partners to report potential violations or concerns
through a variety of formal channels, including
our Legal team and/or our Compliance and Fraud
Prevention Reporting website or hotline.

LEARN MORE

Channel Partner Code of Conduct
Illumina Modern Slavery Statement 2023
Conflict-Free Minerals Policy
Responsible Use of Stem Cells
Position Statement
Animal Testing Position Statement

2023 P R O G R E S S
2030 TA R G E T

100%of strategic supplierscommitted to reducing theirenvironmental footprint

100%

CSR supplier program
In 2023, we initiated an ongoing project tostrengthen our CSR supplier program by updating
our evaluation criteria for new suppliers. Throughanalysis of key regulations, reporting frameworks,
and third-party CSR raters’ methodologies, wedeveloped an evaluation assessment that will aid
in tracking our suppliers’ emission and CSR data
performance. By improving the measurement of
supplier CSR data, we can more accurately track
and report our CSR performance against shortand long-term goals. Going forward, we plan todeepen our engagement with key suppliers on their
CSR performance and collectively work towardshared targets.
We also expanded our current practices to protect
and promote the right to freedom from forced laborand modern slavery by engaging with a third party
to help us initiate human rights due diligence of our
supply chain.

Scope 3 emissions management
We recognize that our environmental footprint
extends beyond our facility walls, and we work with
relevant functional groups on projects to further
drive down emissions from our value chain. In 2021,
we assessed 100% of our supply chain as part ofour Scope 3 emission data collection. Review our
Scope 3 reduction efforts.

Table of contents
2023 CSR Report

Corporate governanceCEO message
Business ethics and integrity

Supplier diversity
Our supplier diversity efforts aim to cultivate a supplierbase that reflects the diversity of our communities,
customers, employees, and the local economies where
we operate.
We recognize that a diverse supplier base provides acompetitive business advantage by harnessing suppliers’
unique experiences and creative solutions. Our program,overseen by a Supplier Diversity Governance Committee,
promotes partnership opportunities for suppliers in the
US that are at least 51% owned, managed, and controlled
by a qualifying diverse group.
These include, but are not limited to:•LGBTQ owned•Woman owned•Socially and economically•Minority owned
disadvantaged owned•Veteran owned•Disabled person owned •Certified small businesses
Globally, we encourage the use of local businesses
wherever possible to support the economies where our
employees work and live.

As part of our operational controls to embed supplier
diversity in our supplier management, we require a
mandatory internal training certification on supplier
diversity for our procurement sourcing managers throughour learning management system (LMS). In 2023, weplan to include diversity screening in our Request for
Information and Request for Proposal process, further
strengthening the operational controls to support
diverse suppliers.
LEARN MORE

Supplier Code of Conduct
Supplier Diversity Program

Introduction

CSR at Illumina

Data privacy and cybersecurity

AccessResponsible supply chain

PeopleSustainability

Responsibility

Appendix
62

Product quality and safety

2030 TA R G E T

20%2023 P R O G R E S S

11%spend with diverse
suppliers (US)$18.2M

to women-owned businesses$52.7Mto minority-owned businesses

13.6%

of active diverse suppliers areminority owned

13.3%

of active diverse suppliers are
women owned$94.1M

Diverse supplier spend (US)The percentage of diverse suppliers in 2023 saw
a decline from 2022 as several suppliers originallycertified as “Small Business” under our diverse
definition experienced growth beyond the criteria
to maintain that label. We are excited to see theimpact and success for these organizations andare seeking additional ways to continue to expand
our diverse supplier ecosystem to compensate forthese types of changes as our program matures. We
also attribute the reduction to changes in the mix ofspend as we insource critical components as part of
supply continuity.

Table of contents
2023 CSR Report

Corporate governanceCEO message

Introduction

Business ethics and integrity

Product quality
and safety
Illumina is dedicated to being the leading provider of integrated
solutions that advance the understanding of genetics and health.
We achieve this through our focus on the customer experience,
our commitment to continual improvement, the effectiveness of
our quality management system, and compliance with regulatory
requirements.
During 2023, Illumina initiated one recall for cybersecurity vulnerability
that was reported to the US Food and Drug Administration (FDA).

Quality management systems
The following locations are certified to the ISO 13485 Standard,
which specifically covers the quality of medical devices:•San Diego, CA•Singapore•Hayward, CA•Shanghai, China•Madison, WI•Cambridge, UK•Eindhoven, Netherlands

100%

Illumina core facilities* participatedin third-party audit programs*
Core facilities: San Diego (i3, HQ, Distribution Center), Foster City, Hayward,
Madison, UK Illumina Centre, Netherlands, and Singapore Woodlands.

CSR at Illumina

Data privacy and cybersecurity

AccessPeopleResponsible supply chain

Product quality and safety

Supplier quality vision and values
The Illumina Supplier Quality Vision is to construct
and foster a leading supplier base that ensures safeand quality products every time.
The supplier quality management life cycle
incorporates the following phases:•Initial risk assessments•Qualification•Audits•Monitoring

Working with our suppliers, we focus on thecustomer experience, continual improvement,
effectiveness of our quality management system,
and compliance. All Illumina Direct Tier 1 suppliers
are subject to onboarding and qualification per
Illumina Purchasing Controls. All products havetraceability, and inventory is tracked via ourinventory management system, SAP. Products
may contain bar codes, lot numbers, and/or
unique identifiers.

Supplier quality management cycle
A quality management system is a critical aspect atevery stage of the product life cycle to ensure thatpolicies and objectives are in place and productquality standards are of the highest caliber.

•Supplier selection and evaluation•Supplier qualification•Supplier monitoring•Component qualification
LEARN MORE

Supplier Quality Manual
Quality Policy Statement

Sustainability

Responsibility

Appendix63

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

Appendix

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleAssurance statements

Sustainability
Disclosures

Responsibility

Appendix64

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleAssurance statements

Sustainability

Responsibility

65

Disclosures

About this report?

Our report has been designed to provide a comprehensive and integrated viewof our commitments, progress, and activities related to our corporate social
responsibility program and most material environmental, social, and governance(ESG) themes.

Boundaries and exclusions

Assurance

The boundary of this report includes only core
Illumina activities.

Limited assurance has been provided in accordancewith ISAE 3000 and ISAE 3410 on the following topics:

Reporting period
January 1, 2023, to December 31, 2023, unlessotherwise indicated.

Baseline year
2019, unless otherwise indicated.

Materiality
Based on the materiality assessment refreshedin 2021.

Currency references
US dollars

Re-statements
We conduct ongoing data review to ensure accuracy
and consistency. Any material data changes would
be identified. In 2023, there was one restatement ofwater data noted as a footnote on page 77.

•Scope 1, 2, and 3 GHG •Water data
emissions data
•Waste data
Energydata••Human capital data
Reporting frameworks•In accordance with the GRI standards•Sustainability Accounting Standards Board (SASB)•Task Force on Climate-related Financial
Disclosures (TCFD)•UN Sustainable Development Goals (SDGs)•UN Universal Declaration of Human Rights•Dow Jones Sustainability Index•CDP•Bloomberg Gender Equality Index•HRC Corporate Equality Index•ISO 26000 as reference to provide guidance for*

integration of social responsibility

To access Illumina’s public facing CDP submission Learn more.

*

UNGC Communication on Progress Illumina participant page.

†

Appendix

C O N TACT

We welcome your feedback at csr@illumina.com
LEARN MORE

Illumina ESG reporting hub

Signatory participation•United Nations Global Compact (UNGC)•We Mean Business Coalition 1.5ºC•UN Race to Zero•CEO Action for Diversity & Inclusion•UN Women Empowerment Principles•STEMM Opportunity Alliance†

Relevant memberships••World Economic Forum•Association of Corporate Citizenship

Business for Social Responsibility (BSR)

Professionals (ACCP)•Chief Executives for Corporate Purpose (CECP)•CSR Board.Org•World 50•Sustainable Packaging Coalition•My Green Lab

CSR appendix contents
65 About this report
66 2030 targets
67 Key performance indicators
67 About Illumina
67 Accelerate access to genomics
67 Nurture our people and communities
75 Integrate sustainability
78 Operate responsibly
81 GRI Index
84 SASB Index
85 TCFD Index
89 Assurance statements
90 Disclosures

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix66

Disclosures

Progress on our 2030 targets
Our focus areas

Objectives

Accelerateaccess to
genomics

2 Drive down the cost of sequencing

2030 Targets

1 Be the engine of genomic innovation

Achieved

In Progress

2023 Progress

Achieve 2 billion covered lives by 2026
Reach at least 25,000 medical education learners annually
Reach 5 million STEM learners

3 Expand the reach of genomics

1.3 billion lives covered>27,000 medical education learners reached
1.6 million STEM learners reached from 2019 baseline

SDG Alignment
Targets: 3.d, 17.6, 17.7, 17.16

Nurture ourpeople andcommunities

Increase gender representation in global leadership*
Maintain zero net pay gap
Increase minorities** in executive leadership‡ (US)Increase underrepresented minorities§ in US workforce and leadership*
Reduce recordable injury and illness rate
Donate 100,000+ volunteer hours
Achieve 50% employee participation in giving and volunteering

1 Practice diversity, equity, and inclusion
2 Attract extraordinary talent
3 Invest in our people
4 Support employee health, safety, and well-being
5 Engage our employees and communities

4% increase from 2019 baseline
Maintained for 5th consecutive year
8% increase from 2019 baseline
2% increase in leadership; 1% increase in workforce from 2019 baseline
48% decrease from 2019 baseline
47,130 volunteer hours donated from 2019 baseline
58% employee participation

SDG Alignment
Targets: 10.3, 5.bIntegrate
sustainability

1 Drive climate action
2 Operate sustainable facilities

Deliver net zero emissions (Scope 1,2,3) by 2050
Reduce emissions by 46% (Scope 1,2)
Reduce emissions by 46% (Scope 3)
Achieve 100% renewable electricity
Reach 90% landfill diversion at core sites
Reach 10% reduction in water intensity at core sites
Reduce packaging by 75%

3 Develop sustainable products
4 Leverage genomics for sustainability applications

In progress
48% decrease from 2019 baseline†
16% increase from 2019 baseline; 24% decrease YoY
100% renewable electricity†
56% landfill diversion at core sites
2.6% increase in water intensity at core sites; 8.3% decrease YoY in total water consumption
53% reduction from 2019 baseline

SDG Alignment
Targets: 12.2, 12.5, 13.2

Operateresponsibly

1 Practice strong corporate governance and compliance
2 Act ethically and with integrity
3 Uphold high standards for data security and privacy
4 Foster a responsible supply chain

Through onsite generation, purchased renewable electricity, renewable energy
credits, and Green-e certified nature-based carbon credits.

†

100% strategic suppliers committed to reducing their environmental footprint
11% spend with diverse suppliers (US)Top industry rating for DJSI, Sustainalytics, Just Capital, and others

SDG Alignment
Targets: 9.2, 10.3, 17.16

5 Advance product quality and safety
Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison,
UK Illumina Centre, the Netherlands, and Singapore Woodlands.

Ensure 100% strategic suppliers committed to reducing their environmental footprint
Achieve 20% spend with diverse suppliers (US)Achieve top industry CSR ratings

Leadership: manager, equivalent, and above.

*

Executive leadership: director, equivalent, and above.

‡

Underrepresented minorities (US): Black, Native, Pacific Islander, Hispanic or Latino, two or more.
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.

§**

As our business evolves and matures, we consistently evaluate our CSR strategy, targets and theconnection to our business priorities. Changes in leadership and macroeconomic trends have led toprioritization of our 2023 targets listed here. A deeper review with a double materiality lens is planned
for future inclusion and evaluation.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix67

Disclosures

Key performance indicators
Introduction
GeneralNurture our people and communities
2023

Name of organization
Location of headquarters
Number of global locations
Nature of ownership and legal form
Core Illumina revenue
Total capitalization (stockholder’s equity) market value
as of 12/31 of reporting year

Illumina, Inc.
San Diego, California, US
2023 10-K$4.44 billion$5.7 billion
6%

10Y CAGR

12%

R&D % revenue investment (GAAP)

23%

R&D spend (GAAP)$1.03 billion

Building footprinta

2,560,913 square feet

Facility additions

1

Facility closuresd

2

2021

2022

2023

$1,185,088$14,966,331$18,239,858$9,223,443

Illumina, Inc. + Illumina Corporate Foundation$873,088$14,446,500$17,676,194$8,899,992

1021

1345

1747

2281

2019 baseline

2021

2022

2023

$560,088$9,409,966$12,379,381$8,899,992

2019 baseline

2021

2022

2023

$312,000$519,831$563,664$323,451

19%

26%

28%

47%

Charitable grants$105,000$4,489,650$4,887,885$3,737,249

Total Foundation giving (not including employees)$313,000$5,036,534$5,860,477$4,237,544

2019 baseline

2021

2022

2023

13,9808772

20,142

20,506

29%

10%

39%

31%

Number of causes supportedg

Illumina, Inc. giving
In-kind product donations + cash grants

Illumina Corporate Foundation giving
Employee giving
Employee participation (giving)

Volunteer hours
Employee hours (including intern hours)

Accelerate access to genomics

Employee volunteering

Access to genomics

2023

Cost per genomee~$200

iHope™ patients supportedf

330

Total iHope™ patients supported since program inceptionf

2312

Clinical iHope™ network sites

2019 baseline

Illumina, Inc. + Illumina Corporate Foundation + employee giving

Public Corporation

5Y CAGRb,c

Total giving

26

Professional health care learners>27,000

NGS coverage outlook: total insured lives

1.3 billion

Employee participation

2019 baseline

2021

2022

2023

Total employee participation (giving + volunteering)

40%

31%

50%

58%

Summary of international giving (outside US)

2019 baseline

2021

2022

2023

Illumina, Inc.

NA

$7,044,842$5,994,599$960,571

Illumina Corporate Foundation

NA$1,089,892$1,980,646$1,363,411

Number of countries

24

44

46

63

2019 baseline

2021

2022

2023

306,170

315,000

396,865

348,691

Footnotes:
Average square feet during reporting year.
Added commercial facilities in India.
c
Acquired new facility through acquisition.
d
Closed San Diego i3 site. Moved Israel Office.
eAnnounced launch in 2022 based on US list price, assuming 120 Gb/genome, compared to NovaSeqTM 6000.
f
Families with multiple affected children are considered one case.
gIn order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations arethen evaluated against 1,200 watch lists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that are also
excluded from matching eligibility. Illumina currently blocks charitable organizations that have been found to discriminate
against a specific race, religion, ethnicity, sexual orientation, or gender identity.
a

b

STEM
Number of teachers and students engaged in Illumina STEM programs

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix68

Disclosures

Key performance indicators

Nurture our people and communities continued
Workforce data

2019 baseline

2021*

2022*

2023*

Gender data
Workforce

Total employees

7802

9191

10,2579308

Full-time employees

7749

9137

10,1959254

Part-time employees

53

54

62

54

Contingent workers

1247

1647

1578

1375

Age group
Employees under 30
Employees 30–50
Employees over 50

1527

1820

1963

1538

20%

20%

19%

17%

5090

5992

6748

6253

65%

65%

66%

67%

1185

1379

1546

1517

15%

15%

15%

16%

Total women
Full-time womenPart-time womena
Temporary women

Total employees

4973

5668

6342

5559

Full-time employees

4954

5650

6324

5550

Part-time employees

19

18

18

9

Contingent workers

971

884

726

576

APAC
Total employees

1883

2238

2456

2384

Full-time employees

1882

2238

2456

2383

Part-time employees

1

0

0

1

Contingent workers

164

588

726

605

EMEA
Total employees

946

1285

1459

1365

2021*

2022*

2023*

3334

4076

4596

4189

43%

45%

45%

45%

3293

4036

4543

4142

43%

45%

45%

45%

41

40

53

47

79%

76%

86%

87%

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

571

746

898

865

39%

42%

41%

43%

Leadership
Women in leadershipb
Women in executive leadershipc

AMR2019 baseline

112

174

217

210

33%

38%

38%

38%

3

3

3

3

33%

33%

33%

27%

AMR

2071

2474

2813

2453

APAC

847

1037

1124

1130

EMEA

416

565

659

606

AMR

404

506

613

575

APAC

95

135

153

157

EMEA

72

105

132

133

Women on Board of Directors

Total women by region

Women in leadership by region

Functional group

Full-time employees

913

1249

1415

1321

Part-time employees

33

36

44

44

Women in revenue-generating roles

41%

48%

48%

46%

Contingent workers

112

175

186

194

Women in revenue-generating roles—management

35%

42%

42%

44%

Women in STEM-related roles (% of total STEM roles)

37%

39%

39%

40%

Women in IT roles

24%

24%

24%

24%

Women in engineering roles

37%

29%

29%

30%

Footnotes:

General notes:* Denotes data has been assured.
aPercentage of all part-time employees.
b
Leadership: Manager, equivalent, and above.
c
Executive leadership: Director and above.

• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• Some segments may not add up to total due to rounding.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix69

Disclosures

Key performance indicators
Learn more: Federal Employer Information EEO-1 Report

Nurture our people and communities continued
Percentage female of each EEOC category (US)2019 baseline

2021*

2022*

2023*

EEOC minority summary (US)2019 baseline

2021*

2022*

2023*
2818

White/Caucasian

41%

43%

44%

43%

Total employees identifying in minority race and ethnicity statistics

2429

2830

3213

Native Hawaiian or Other Pacific Islander

31%

33%

31%

32%

Minority of total employeesa

49%

50%

52%

52%

American Indian or Native Alaskan

50%

50%

50%

50%

Non-Minority of total employeesa

46%

45%

44%

44%

Asian

44%

45%

46%

46%

Decline to state of total employees

5%

5%

4%

4%

Hispanic or Latino

39%

44%

43%

42%

Black or African American

37%

45%

46%

50%

Representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more communities in workforce

17%

17%

18%

18%

2 or More

45%

51%

51%

52%

Choose not to self disclose

40%

41%

37%

36%

Representation of URMs (Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more communities in leadership)b,d

10%

12%

13%

12%

Minority representation in executive leadershipc

21%

27%

30%

29%

2019 baseline

2021*

2022*

2023*

2284

2514

2756

2407

46%

45%

44%

44%

62

67

64

53

1%

1%

1%

1%

10

13

15

13

<1%

<1%

0%

0%

1601

1863

2097

1838

32%

33%

34%

34%

447

510

588

529

9%

9%

9%

10%

121

130

146

122

2%

2%

2%

2%

188

248

303

263

Percentage male of each EEOC category (US)2019 baseline

2021*

2022*

2023*

White/Caucasian

59%

57%

56%

57%

Native Hawaiian or Other Pacific Islander

69%

67%

69%

68%

American Indian or Native Alaskan

50%

50%

50%

50%

Asian

56%

55%

54%

54%

Hispanic or Latino

61%

56%

57%

58%

Black or African American

63%

55%

54%

50%

2 or More

55%

49%

49%

48%

Choose not to self disclose

60%

59%

63%

64%

Percentage gender by level 2023*

Male 2023*

Female 2023*

Undisclosed 2023*

Support to Entry Professional

50%

49%

0%

Intermediate to Senior Professional

56%

44%

1%

Supervisor to Assoc Director

54%

45%

1%

Director and Senior Director

61%

39%

1%

VP

64%

34%

1%

SVP / C suite

55%

45%

0%

Board of Directors

73%

27%

0%

Footnotes:*Denotes data has been assured.
a
Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those who choose not to specify a race/ethnicity.
b
Leadership: Manager, equivalent, and above.
c
Executive leadership: Director and above.
d
URM defined as underrepresented minorities (US) including: Black, Native, Pacific Islander, Hispanic or Latino, two or more.

General notes:• Some segments may not add up to total due to rounding.

EEOC minority by category (US)White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose
VeteranDisabled

a

4%

4%

5%

5%

240

294

241

197

5%

5%

4%

4%

143

145

157

125

3%

3%

3%

2%

248

230

223

157

5%

4%

4%

3%

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix70

Disclosures

Key performance indicators
Learn more: Federal Employer Information EEO-1 Report

Nurture our people and communities continued
EEOC data by level (US)2019 baseline

2021*

2022*

2023*

261

264

255

192

24%

23%

23%

23%

Support to entry professional

EEOC data by level (US)2019 baseline

2021*

2022*

2023*

Manager to associate director

White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

29

34

29

19

3%

3%

3%

2%

3

3

4

3

<1%

<1%

<1%

0%

489

514

485

361

45%

45%

44%

42%

173

185

191

160

16%

16%

17%

19%

48

38

36

30

4%

3%

3%

4%

57

65

83

72

5%

6%

7%

8%

38

35

26

14

3%

3%

2%

2%

1403

1555

1721

1512

50%

48%

46%

45%

Native Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose
Footnotes:

General notes:* Denotes data has been assured.

• Some segments may not add up to total due to rounding.

Native Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

413

452

508

453

54%

55%

54%

53%

11

11

12

13

1%

1%

1%

2%

2

1

0

0

<1%

<1%

0%

0%

182

214

243

234

24%

26%

26%

27%

65

70

82

75

9%

8%

9%

9%

17

22

26

20

2%

3%

3%

2%

22

23

28

19

3%

3%

3%

2%

46

51

49

45

6%

6%

5%

5%

Director and above

Intermediate to senior professional
White/Caucasian

White/Caucasian

22

21

22

20

1%

1%

1%

1%

4

7

9

8

<1%

<1%

<1%

0%

895

1078

1292

1162

32%

33%

34%

35%

199

243

300

281

7%

7%

8%

8%

51

63

75

65

2%

2%

2%

2%

105

150

181

163

4%

5%

5%

5%

143

191

147

121

5%

6%

4%

4%

White/CaucasianNative Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose

207

243

272

250

75%

70%

67%

66%

0

1

1

1

0%

<1%

<1%

0%

1

2

2

2

<1%

1%

<1%

1%

35

57

77

81

13%

16%

19%

21%

10

12

15

13

4%

3%

4%

3%

5

7

9

7

2%

2%

2%

2%

4

10

11

9

1%

3%

3%

2%

13

17

19

17

5%

5%

5%

4%

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix71

Disclosures

Key performance indicators

Nurture our people and communities continued
New hire data
New hire by age group2019 baseline

2021*

2022*

2023*

458

990

860

309

Employees under 30
Employees 30–50
Employees over 50

New male employee hires

APAC new employee hires
EMEA new employee hires

Native Hawaiian or Other Pacific Islander

2022*

2023*

1502

2583

2436

1372

54%

44%

20%

Promotion rate by EEOC (US)2019 baseline

2021*

2022*

2023*

1,358

1,320

419

14%

23%

20%

7%

White/Caucasian

22%

34%

26%

14%

89

156

140

51

Native Hawaiian or Other Pacific Islander

19%

34%

24%

21%

8%

11%

9%

3%

566

1185

1049

407

17%

29%

23%

10%

684

1262

1240

365

15%

25%

22%

7%

707

1479

1315

316

14%

26%

21%

6%

376

621

621

345

20%

28%

25%

14%

180

404

384

118

19%

31%

26%

9%

Percentage new hire per EEOC (US)White/Caucasian

2021*

716

New hire by region
AMR new employee hires

2019 baseline30%

New hire by genderb
New female employee hires

Promotion data
Total number of employees promoted

a

44%

40%

39%

38%

1%

1%

1%

<1%

American Indian or Native Alaskan

0%

33%

21%

0%

Asian

23%

37%

25%

15%

Hispanic or Latino

19%

34%

17%

16%

Black or African American

14%

33%

25%

14%

2 or More

20%

37%

38%

18%

Choose not to self disclose

21%

35%

21%

14%

2019 baseline

2021*

2022*

2023*

4908

5561

6210

5422

Number of employees as defined by the federal government
as meeting the criteria for protected veteran status

87

90

92

74

Number of veteran and active-duty employees,
regardless of protected status

143

145

157

125

Veteran data (US)
Number of US employees, regardless of whether
they have any military connection

Number of disabled veteran employees

2

3

3

0

Number of women veteran employees

24

26

27

22

Number of minority veteran employees—minority veterans include,
but are not limited to, people of color, women, LGBTQIA+, and (non)religious minorities

67

75

80

75

Percentage of Veterans (US)

3%

3%

3%

2%

2023*

American Indian or Native Alaskan

<1%

<1%

<1%

<1%

Asian

32%

34%

35%

34%

Other identities self reported (us)2019 baseline

2021*

2022*

Hispanic or Latino

10%

10%

11%

14%

LGBTQ (US)

1%

2%

3%

3%

Black or African American

2%

2%

3%

3%

Disabilities (US)

3%

4%

4%

10%

2 or More

7%

7%

6%

7%

Choose not to self disclose

5%

6%

4%

4%

Footnotes:

General notes:* Denotes data has been assured.
aPercentage data for new hire by age represents the percentage of the total age group headcount for the reporting year.
b
Represents percentage of new hires out of all female employees.

• For all gender statistics, percentage of women is based on number of employees who identify as male or female, not total number of Illumina employees.
• Some segments may not add up to total due to rounding.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix72

Disclosures

Key performance indicators

Nurture our people and communities continued
Employee turnover data

2019 baseline

2021*

2022*

2023*

Total number of employee turnover

856

1154

1246

1734

Rate of employee turnover

11%

14%

13%

18%

Total number of voluntary turnover

644

1048

1050

674

Rate of voluntary turnover

9%

12%

11%

7%

Total turnover

Employees 30–50
Employees over 50
Voluntary employee turnover under 30
Voluntary employee turnover 30–50
Voluntary employee turnover over 50

2019 baseline

2021*

2022*

2023*

530

763

646

1098

11%

14%

11%

18%

223

251

405

417

12%

12%

17%

17%

103

140

195

219

11%

12%

14%

16%

Total turnover by region
AMR
APAC
EMEA

Turnover by age
Employees under 30

Employee turnover data

229

246

308

362

15%

15%

16%

21%

489

749

787

1090

10%

13%

12%

17%

Voluntary turnover by region
AMR

701

586

368

8%

13%

10%

6%
192

188

224

315

10%

11%

13%

8%

72

123

149

114

8%

11%

11%

8%

White/Caucasian

8%

13%

9%

6%

Native Hawaiian or Other Pacific Islander

11%

5%

17%

9%

0%

25%

7%

0%
6%

138

159

151

282

12%

12%

10%

18%

195

233

279

176

13%

15%

15%

10%

366

686

654

429

7%

12%

10%

7%

82

129

117

69

7%

10%

8%

5%

American Indian or Native Alaskan
Turnover by level

384

APAC
EMEA

Voluntary turnover percentage by EEOC (us)

Asian

7%

13%

11%

Voluntary turnover support to entry professional

11%

14%

16%

9%

Hispanic or Latino

8%

14%

10%

5%

Involuntary turnover support to entry professional

3%

1%

2%

15%

Black or African American

11%

16%

12%

6%

Voluntary turnover intermediate to senior professional

8%

12%

9%

6%

2 or More

6%

21%

9%

7%

Choose not to self disclose

6%

13%

13%

6%

Involuntary turnover intermediate to senior professional

2%

1%

2%

10%

Voluntary turnover manager to associate director

6%

11%

10%

6%

Involuntary turnover manager to associate director

4%

2%

1%

9%

Voluntary turnover director and above

6%

17%

9%

6%

Involuntary turnover director and above

4%

3%

2%

9%

Footnotes:* Denotes data has been assured.

General notes:• Some segments may not add up to total due to rounding.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessPeople

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix73

Disclosures

Key performance indicators

Nurture our people and communities continued
Parental leavea

2019 baseline

2021

2022

2023

4714

5302

5916

5641

Total number of employees who took parental leave,by gender

Female 116
Male 65

Female 173
Male 89

Female 236
Male 128
Blank 1

Female 176
Male 192
Blank 1

Total number of employees who returned to work in thereporting period after parental leave ended, by gender

Female 116
Male 65

Female 166
Male 123

Female 226
Male 121
Blank 1

Female 170
Male 192
Blank 1

Total number of employees who returned to work afterparental leave ended that were still employed 12 months
after their return to work, by gender

Female 100
Male 54

Female 150
Male 107

Female 192
Male 102
Blank 1

Female 160
Male 180
Blank 1Return to Work:
Female 100%
Male 98%

Return to Work:
Female 98%
Male 99%

Return to Work:
Female 97%
Male 100%Return to Work:
Female 96%
Male 100%

Total number of employees who were entitled toparental leave

Return to work and retention rates of employees who
took parental leave, by gender

Retention:
Female 86%
Male 83%

Benefit plan and other retirement
Percentage of salary contributed by employee
or employer
Level of participation in retirement plans, such as
participation in mandatory or voluntary schemes,
regional or country-based schemes, or those withfinancial impact

Employee bonus and stock program

2019 baseline

Retention:
Female 93%
Male 89%

Retention:
Female 85%
Male 84%

2021

2022

Retention:
Female 91%
Male 93%2023

US 401(k): Employee elected between 0–80%, Illumina matching
contribution of 50% up to the first 6% employee election (3% of
eligible salary)
US 401(k): 97% employee
voluntary participation

2019 baseline

US 401(k): 98% employee
voluntary participation

2021

2022

Employees eligible for annual VCP bonus

All employees

Employees eligible to participate in employee stock
purchase plan

All employees

2023

Footnotes:

Performance & career development review

2019 baseline

2021

2022

2023

Percentage of employees receiving regularperformance and career development reviews(includes all administrative, production, technical,
middle management, and senior management)

100%

100%

100%

100%

2019 baseline

2021

2022

2023

89%

80%

86%

88%

Employee surveyb
Participation rate for employee iPulse survey

Average compensation ratio—women to men

2019 baseline

2021

2022

2023

100%

100%

99%

98%

Support to entry professional

102%

101%

100%

97%

Intermediate to senior professional

100%

99%

99%

98%

Supervisor to associate director

98%

100%

99%

97%

Director and above

101%

99%

98%

100%

Across all employee categories

Annual compensation ratio

2019 baseline

2021

2022

2023

Ratio of annual total compensation for the organization's highest-paid
individual in each region to the median annual total compensation for
all employees

Refer toProxy Filing

Refer toProxy Filing

Refer toProxy Filing

Refer toProxy FilingTraining2019 baseline

2021

2022

2023

Average hours of training per employee per year

60

64

62

62

Hours of training by gender: Male

60

66

63

65

Hours of training by gender: Female

61

63

60

60

Hours of training by employee category: Individual Contributor

64

68

66

66

Hours of training by employee category: Middle Management

71

76

70

77

Hours of training by employee category: Senior Management

38

44

39

41

Hours of training by employee category: Executive Leadership

22

30

26

28

Hours of training by functional category: Commercial Operations

50

52

51

45

Hours of training by functional category: General Operations

23

27

25

28

Following the birth of a child or placement of a child for adoption or foster care, we provide 100% pay continuity to eligible US-based employees for up to
six weeks to help ensure peace of mind during this essential time. In some cases, a mother could receive up to 28 weeks of pay continuity depending on the
combination of leaves associated with childbirth.
b
Employee survey participation rates in 2019 are calculated using an average of two surveys per year (Q2 and Q4 of each year). For 2020, the participation rateis based on an average of three quarterly surveys (Q2–Q4). For 2021, the participation rate is based on an average of four quarterly surveys (Q1-Q4).

Hours of training by functional category: Manufacturing

91

98

96

101

Hours of training by functional category: Research & Development

53

62

58

59

Total number of hours devoted to training on human rights

1737

3333

4726

3081

General notes:

Applicable employees certified to Code of Conduct

99%

97%

97%

96%

a

• For all training hour metrics, the values include only regular Illumina employees, not contingent workers.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix74

Disclosures

Key performance indicators

Nurture our people and communities continued
Health & safety
Global recordable injury or illness incident rate (incident per
100 employees)

2019 baseline

2021

2022

2023

0.52

0.54

0.23

0.27

Safety workers who are not employees but whose work
and/or workplace is controlled by the organization

2019 baseline

2021

2022

2023

Number of work-related fatalities

0

0

0

0

Lost time incident rate

0.74

0.23

0.12

0.10

Rate of work-related fatalities

0

0

0

0

Days Away Restricted Time (DART)

0.34

0.43

0.17

0.20

Environment, Health & Safety notices of violations

0

0

0

0

The number of high-consequence work-related injuries andillnesses (excluding fatalities)

0

2

3

0

Environmental fines

0

0

0

0

0

0.13

0.18

0

3611

1452

2054

4135

The rate of high-consequence work-related injuries and illnesses(excluding fatalities)
The number of recordable work-related injuries and illnesses

0

2

3

0

2019 baseline

2021

2022

2023

Number of work-related fatalities

0

0

0

0

The rate of recordable work-related injuries and illnesses

0

0.13

0.18

0

Rate of work-related fatalities

0

0

0

0

The number of high-consequence work-related injuries andillnesses (excluding fatalities)

49

51

23

29

Ergonomics,
Strains,
Contusions,and Sprains

Fracturesand strains

Ergonomics,
strains,
contusions,and sprains

N/A

0.62

0.16

0.24

0.27

2,741,396

2,986,473

3,296,423

2,687,619

Prevention reporting statistics

Employee safety

The rate of high-consequence work-related injuries andillnesses (excluding fatalities)
The number of recordable work-related injuries and illnesses

49

51

23

29

0.62

0.16

0.24

0.27

The main types of work-related injury and illness

Ergonomics,
strains,
contusions,and sprains

Ergonomics
and strains

Ergonomics,
strains,
contusions,and sprains

Slips, trips,
ergonomics,
strains,
and sprains

The number of hours worked

15,647,395

15,946,780

19,462,592

18,055,184

The rate of recordable work-related injuries and illnesses

General notes:• Recordable injury and illness rate calculated using total hours worked from employees + contingent workers.
• Lost time incident rate calculated using total hours worked from employees + contingent workers.
• DART: Days Away, Restricted, or Transferred.
• Notice of violation reporting does not include minor observations from local municipalities.
• High-consequence work-related injuries are defined as all recordable injuries.
• Ergonomic injuries include repetitive stress injuries.
• Contingent workers: workers who are not employees but whose work and/or workplace is controlled by the organization.
• Rates have been calculated based on 200,000 hours worked.

The main types of work-related injury and illness
The number of hours worked

Environmental, health & safety training
Total hours of EHS training
Average hours per employee

26,75843,06645,02243,067

3.7

4.1

4

4.1

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Assurance statements

Sustainability

Responsibility

Appendix75

Disclosures

Key performance indicators

Integrate sustainability
Energy consumption (Units: Gigajoules)

2019 baseline

2021*

2022*

2023*

247,576

403,211375,516357,299

0

0

0

0

1566

2417

2966

2837

503,658

581,067

375,516357,299

1566

9077

231,678

236,358

505,224590,144

607,194593,658

2019 baseline

2021*

2022*

2023*

Total electricity (purchased + generated)

257,648

187,297

231,678

236,358

Purchased electricity

256,082

184,882

228,712233,521

1566

2417

2966

2837

Total fuel consumption from nonrenewable sources
Total fuel consumption from renewable sources
Generation from renewable sources consumed by the organization
Total energy consumption from nonrenewable sources
Total energy consumption from renewable sources
Total energy consumption

Energy consumption by activity and region (Units: Gigajoules)

Generated electricity (onsite solar)

Emissions (Units: Metric Tons CO2e)

2019 baseline

2021*

2022*

2023*

Total Scope 1 & 2 (market-based) GHG emissions

34,40426,265

18,902

17,993

Total Scope 1 & 2 (location-based) GHG emissions

34,40436,91439,924

39,130Gross direct GHG emissions (Scope 1)

12,48920,296

18,902

17,993Gross market-based energy indirect GHG emissions (Scope 2)

21,915

5,968

0

0

Gross location-based energy indirect GHG emissions (Scope 2)

21,915

16,61821,022

21,137

Regional emissions market-based (Units: metric tons co2e)

2019 baseline

2021*

2022*

2023*

Scope 1 & 2 AMR region

22,90325,06018,15917,173

Scope 1 & 2 EMEA region

3,014

864

743

820

Scope 1 & 2 APAC region

8,488

341

743

0

2019 baseline

2021*

2022*

2023*

Total fuel247,576

403,211375,516357,299

Natural gas

247,576

403,211375,516357,299

Total steam

0

0

0

0

China

0

0

0

0

Netherlands

73

74

55

82

Country-specific scope 1 emissions (Units: metric tons co2e)

Electricity, heating, cooling, steam sold

0

0

0

0

Total energy consumption AMR region

380,106

469,104

476,860

452,895

Singapore

0

0

0

0

1132

768

688

738

11,284

19,454

18,15917,1732019 baseline

2021*

2022*

2023*

388

0

0

0

Total energy consumption EMEA region

47,77936,35836,30839,282

United Kingdom of Great Britain and Northern Ireland

Total energy consumption APAC region

75,752

84,681

94,026

101,481

United States of America

2019 baseline

2021*

2022*

2023*

Country-specific scope 2 market-based emissions (Units: metric tons co2e)

Percentage of global electricity consumption that is renewable

0.6%

59%

100%

100%

China

Onsite solar generation

0.6%

1%

1%

1%

Netherlands

384

8

0

0

Renewable electricity purchased

0%

3%

37%

39%

Singapore

8099

341

0

0

Covered by Renewable Energy Credits

0%

55%

62%

60%

Renewable electricity consumption

Footnotes:* Denotes data has been assured.

General Notes:• Boundary definition for energy and greenhouse gas emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D
activities. These sites represent our jurisdictional control plus material locations. This scope accounts for 96% of our total 2019 estimated baseline footprint.
• Refrigerant-specific data is not included.
• Some segments may not add up to total due to rounding.
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology to collect activity data and calculate Scope 1 andScope 2 emissions.
• Renewable energy credits purchased for all non-renewable electric consumption bringing our collective market-based scope 2 emissions to 0.

United Kingdom of Great Britain and Northern Ireland

1425

14

0

0

United States of America

11,6195605

00

Table of contents
2023 CSR Report

CEO message

About this report

2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix76

Disclosures

Key performance indicators

Integrate sustainability continued
Facility-specific emissionsa,b(Units: Metric Tons CO2e)

Scope 1

Scope 2Market-Based

Scope 3 emissions (units: metric tons co2e)

Scope 2
Location-Based2019 baseline

2021*

2022

2023*

Purchased Goods and Services (Category 1)

72,915

138,563

131,929

115,187

Capital Goods (Category 2)d39,94079,53083,071

61,677

6956

9048

8590

7039

46,327

68,93485,99386,429

236

1055

1275

1483

d

2021*

2022*

2023*

2021*

2022*

2023*

2021*

2022*

2023*

Cambridge, United Kingdom

749

681

731

0

0

0

903

971

1035

Eindhoven, Netherlands

72

Moved toSteenoven, Netherlands

203

Foster City, California

1359

1506

990

1403

0

0

1403

1906

1456

Waste Generated in Operations (Category 5)

Hayward, California

634

624

598

592

0

0

592

673

656

Business Travel (Category 6)d19,3503959

20,04010,884Madison, Wisconsin

1458

1554

1253

2138

0

0

2138

2695

2542

Employee Commuting (Category 7)d18,0127616

15,0278954

Northcoast, Singapore

N/A

0

0

N/A

0

0

N/A

247

1105

Upstream Leased Assets (Category 8)

1480

547

830

1502

15,24813,91013,883

1291

0

0

1580

3443

3778

Downstream Transportation & Distribution (Category 9)

San Diego Headquarters, California

Moved toSteenoven, Netherlands

0

Moved toSteenoven, Netherlands

Fuel- and Energy-Related Activities (Category 3)
Upstream Transportation & Distribution (Category 4)dAssessed, not relevant

756

564

449

134

0

0

200

325

171

Processing of Sold Products (Category 10)

San Diego Warehouse, California

0

0

0

47

0

0

74

96

76

Use of Sold Products (Category 11)

6968

Shanghai, China (Commercial)

0

0

0

0

0

0

358

220

492

End-of-Life Treatment of Sold Products (Category 12)

2368

Shanghai, China (Manufacturing)N/A (new facility)299

Downstream Leased Assets (Category 13)

San Diego i3, Californiac

00

N/A (new facility)

N/A (new facility)

Assessed, not relevant
9221

11,865

5764

5230

31

107

Assessed, not relevant

Steenoven, Netherlands

2

55

82

8

0

0

218

541

424

Franchises (Category 14)

Watson, United Kingdom

19

7

7

14

0

0

23

26

24

Investments (Category 15)d

23,559000Woodlands, Singapore

0

0

0

341

0

0

8927

9556

9079

Total Scope 3 Emissions

238,110

323,702358,651

299,0252019 baseline

2021*

2022*

2023*

Greenhouse Gas Breakdown (Units: Metric Tons CO2e)

Assessed, not relevant2019 baseline

2021*

2022*

2023*

Scope 3 emissions: % of total scope 3 emissions

CO2 Scope 1

12,47519,884

18,518

17,628Purchased Goods and Services (Category 1)

31%

43%

37%

39%

CH4 Scope1

7

375

349

332

Capital Goods (Category 2)d

17%

25%

23%

21%

N20 Scope 1

6

37

35

33

Fuel- and Energy-Related Activities (Category 3)

3%

3%

2%

2%

Upstream Transportation & Distribution (Category 4)d

19%

21%

24%

29%
0%

Emission intensity ratios (scope 1 & 2)d2019 baseline

2021*

2022*

2023*

Waste Generated in Operations (Category 5)

0.1%

0.3%

0%

GHG emission intensity per million dollars revenue

9.8

5.8

4.2

4.1

Business Travel (Category 6)d

8%

1%

6%

4%

GHG emission intensity kgCO2e/square feet

13.8

10.4

7.5

7.0

Employee Commuting (Category 7)d

8%

2%

4%

3%

GHG emission intensity per employee

4.4

2.9

1.8

1.9

Upstream Leased Assets (Category 8)

0.6%

0.2%

0%

1%

Emission intensity ratio (scope 3)

2019 baseline

2021*

2022*

2023*

72.6

66.1

78.8

65.4

GHG emission intensity per million dollars revenue

Use of Sold Products (Category 11)

3%

3%

3%

2%

End-of-Life Treatment of Sold Products (Category 12)

1%

2%

0%

0%

Investments (Category 15)d

10%

0%

0%

0%

Footnotes:

General Notes:*Denotes data has been assured.
aFacilities included in Scope 1 & 2 GHG Scope Boundary.
bEnergy emission factor for fuel based on 2018 Climate Registry Default Emission Factors. Metric tons
CO2e; GWP Reference: IPCC Fifth Assessment Report (AR5 – 100 year).
c
Illumina vacated San Diego i3 location August 2023.
d
Scope 3 material categories included in SBTi emission reduction and net zero targets• Boundary definition for energy and greenhouse gas emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities. These sites
represent our jurisdictional control plus material locations. This scope accounts for 96% of our total 2019 estimated baseline footprint.
• Refrigerant-specific data is not included.
• Some segments may not add up to total due to rounding.
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology to collect activity data and calculate Scope 1 and Scope 2 emissions.
• Renewable energy credits purchased for all non-renewable electric consumption bringing our collective market-based scope 2 emissions to 0.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Assurance statements

Sustainability

Responsibility

Appendix77

Disclosures

Key performance indicators

Integrate sustainability continued
Watera (Units: Megaliters)

2019 baseline

2021*

2022*

2023*

Interactions with water: total water withdrawal (potable + recycled)

225

268

256

277

Non-hazardous waste

Water withdrawal (potable)

147

195

213

267

Non-hazardous waste total

Water withdrawal (recycled)

78

74

43

10

Percentage of total water withdrawal in water-stressed regionsb

63%

70%

66%

49%

Recycling

Water intensity (kiloliters by rentable square feet for core locations)c

0.10

0.11

0.10

0.13

Composting% water consumption in AMR

97%

97%

92%

73%

Recovery (including energy recovery)% water consumption in EMEA

2%

1%

2%

2%

Incineration% water consumption in APAC

1%

2%

6%

25%

Effluent & waste by type and disposal method

Reuse

Deep well injection
Landfill

Total waste (Units: Metric Tons)
Total (hazardous + non-hazardous)
Global average non-hazardous diversion from landfilld(Units: Metric Tons) 2019 baseline

2021

2022

2023*

3494

4421

6119

5964

0

0

0

0

887

937

3338

2701

149

259

267

336

760

977

366

303

0

0

0

0

0

0

0

0

1698

2247

2224

2624

2019 baseline

2021

2022*

2023*

Onsite storage

0

0

0

0

4934

5975

7503

7336

Other

0

0

0

0

51%

49%

64%

63%

2019 baseline

2021

2022*

2023*

1440

1554

1383

1372

0

0

0

0
206

Hazardous waste

Regional waste data AMR (Units: Metric Tons)
Non-hazardous waste total

2619

3326

4802

Hazardous waste total

4724

Reuse

Hazardous waste total

902

605

594

546

Recycling

413

332

65

Madison Site % diversiond

39%

43%

43%

47%

Composting

0

0

0

0

850

1169

943

1079

62

41

47

44

Deep well injection

0

0

0

0

Landfill

37

6

8

43

54%

49%

66%

60%

Recovery (including energy recovery)

Hayward % diversiond

32%

22%

70%

33%

Incineration

San Diego % diversiond

33%

31%

42%

49%

Foster City % diversiondRegional waste data EMEA (Units: Metric Tons)
Non-hazardous waste total
Hazardous waste total

2019 baseline

2021

2022*

2023*

451

590

569

589

67

55

79

64

Cambridge, UK % diversiond

100%

100%

100%

100%

Netherlands % diversiond

100%

100%

100%

100%

2019 baseline

2021

2022*

2023*

424

504

750

651

Regional waste data APAC (Units: Metric Tons)
Non-hazardous waste total
Hazardous waste total

471

894

710

762

Singapore % diversiond

100%

100%

100%

100%

Footnotes:* Denotes data has been assured.
a2023 water data includes a re-statement from previous years due to accounting updates identified for water usage related to cooling towers at Singapore
NorthTech facility.

b

Onsite storage

0

0

0

0

Other

77

4

12

0

Water-stressed regions listed on page 45.
Core locations: San Diego HQ, i3 and Warehouse, Hayward, Foster City, Madison, Netherlands, Cambridge, and Singapore.
d% Diversion calculated using nonhazardous waste and % diverted from landfill.
cTable of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix
78

Disclosures

Key performance indicators

Operate responsibly
Governance2019 baseline

2021

2022

2023

Noncompliance with environmental laws and regulations; Significant
fines and non-monetary sanctions for noncompliance withenvironmental laws and/or regulations

0

0

0

0

Number of substantiated complaints concerning breaches ofcustomer privacy and losses of customer data

0

0

0

0

Number of public legal cases regarding corruption brought against
the organization or its employees during the reporting period

0

0

0

0

Antitrust cases2

See notes 1, 2

See notes 1, 2

See notes 1, 2

Nature and total number of critical concerns communicated to highest
governance body regarding CSR topics
Total employees covered by collective bargaining agreements
Incidents of discrimination and corrective actions taken

Transparency Reporting Law Enforcement & National
Security Requests

00

See note 3

0

0

0

0

See note 4

See note 4

See note 4

See note 42021 Privacy

2022 Privacy

2023 Privacy

Transparency

Transparency

Transparency

ReportReportReportN/A

Security personnel are trained in organization’s policies or procedures
concerning aspects of human rights that are relevant to operations.

N/A

The organization is unaware of any operations in which there is asignificant risk for incidents of child labor.

N/A

The organization is unaware in which there is a significant risk forincidents of forced or compulsory labor.

0

N/A

N/A
N/A
N/A

Yes
Confirmed
Confirmed

Yes
Confirmed
Confirmed

1. O
 n January 11, 2021, Complete Genomics, Inc., BGI Americas Corp., and MGI Americas, Inc. (collectively BGI) filed a complaint in the
US District Court for the Northern District of California alleging that Illumina violated federal antitrust and state unfair competition laws,
based on a patent infringement suit Illumina filed against BGI in the same court. Illumina denies the allegations, which are without merit.
On July 14, 2022, we entered into a settlement and license agreement with BGI resolving litigations between the parties, resulting
in the dismissal of BGI's antitrust and unfair competition claims. None of the parties made an admission of liability in entering into
the agreement.
2. O
 n March 30, 2021, the United States Federal Trade Commission filed an administrative complaint alleging that Illumina’s acquisitionof GRAIL, Inc. violates federal antitrust laws. Illumina denies the allegations. Following a full trial on the merits, the FTC’s Chief
Administrative Law Judge (ALJ) rejected the FTC’s complaint and found in favor of Illumina. On April 3, 2023, the FTC Commissioners
overturned the ALJ’s decision in Illumina’s favor, and the FTC Commissioners issued an opinion and order requiring Illumina todivest GRAIL. Illumina appealed to the US Court of Appeals for the Fifth Circuit, which on December 15, 2023, found that the FTC
Commissioners applied the wrong legal standard. The Fifth Circuit vacated the FTC’s order to divest GRAIL and remanded the caseto the FTC to reconsider the matter under the correct legal standard as articulated by the Fifth Circuit. In parallel proceedings, theEuropean Commission also issued orders prohibiting Illumina’s acquisition of GRAIL, and instructed Illumina to divest GRAIL. On July 12,

CSR governance topics

Position

Corporate Social Responsibility / CSR
Environment, Health & Safety, Supply Chain,
Facilities, Operations

Level from CEO

Level from Board

SVP, Chief People Officer

1

2

SVP, Chief of Global Operations

1

2

People, Employment, Diversity, Equity, and Inclusion

SVP, Chief People Officer

12Compliance, Ethics, Legal

SVP, General Counsel

1

2

Product

SVP, Chief Technology Officer

1

2

Cybersecurity

SVP, Chief Information Officer

1

2

Finance, Investor Relations, Internal Audit

SVP, Chief Financial Officer

1

2

Board of Directors (BoD)2023

BoD level oversight for CSR and CSR (including themes of sustainability and climate action; diversity, equity, andinclusion; human rights; cybersecurity; data privacy; and ethical and responsible business practices)

Yes

Clawback provision

Yes

Commitment to gender diversity on BoDYes

BoD composition by gender (% female)27%

BoD composition by racial/ethnic minority representation

9%

Number of directors

11

Number of independent directors
Average Board tenure

10
4 years2023, the European Commission issued a fine pursuant to Article 14(2)(b) of the EU Merger Regulation of approximately €432 million,
based on the allegation that Illumina consummated the acquisition of GRAIL during the pendency of the European Commission’s review.
Illumina denies the allegations and is appealing the European Commission’s decisions relating to the GRAIL acquisition. While the appeals
are pending, Illumina has announced it will divest GRAIL in accordance with the EU’s order.
3. Illumina treats this data as confidential company information. Supplemental references: Proxy Filing; Code of Conduct
4. D uring the past 12 years, neither the EEOC nor any court or administrative agency has issued a finding against Illumina in a claim
involving discrimination. No incidents were filed during the reporting period. The matters that were pending during the last reporting
period have been resolved. We do not tolerate acts of discrimination, and promote an open culture to report concerns (including
anonymously). Illumina takes all reports of misconduct seriously and has a strict non-retaliation policy. If a report is substantiated, thecompany would respond as it deems appropriate or necessary, consistent with the law, and will act swiftly to correct the problem anddeter future occurrences. Depending on the circumstances, this may include training and/or disciplinary action up to, and including,termination. Individuals may also be subject to civil or criminal prosecution for violating the law

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

TCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix79

Disclosures

Key performance indicators

Operate responsibly continued
Supply chain

2019 baseline

2021

2022

2023

Spend with direct suppliers$440 million$585 million$694 million$648 million

Supplier Code of Conduct in place
Geographic location of suppliers

A description of the organization’s supply chain

Countries: AE, AM, AR, AT, AU, BE, BS, CA, CH, CL,
CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, ID,
IE, IL, IN, IS, IT, JP, KR, LT, LU, MO, MX, MY, NL, NO,
NZ, PA, PE, PH, PL, PT, RO, RU, SE, SG, SI, TH, TR,
TW, UA, US, UY, VN, ZA

Estimated monetary value of payments made to suppliers
Number of active diverse suppliers (US)Diverse supplier spend

YesCountries: US, DE, CA, GB, SG, CH, JP, PL, FR,
AU, ZA, BE, NZ, IT, CN, NL, DK, NO, MY, IN,
ES, IS, SE, IL, PT, AR, HK, AM, KR, UA, IE, BN,
ID, BD, EC, AT, FI, TW, MO, LU, VN, TR, LK, AE,
MX, CZ, RU, RO, TH, BR, LV, CR, PH, BY, UY,
SA, HU, SI, GR, PK, CY, BG, LT, RS, BO, PY, NG,
KY, GT, PA, SV, KE, EE, PE, CL, CO

Countries: AU, BE, CA, CH, CN, CZ, DE, DK,
ES, FR, GB, HK, IE, IT, JP, KR, LT, MX, MY, NL,
SE, SG, TH, TW, US, VN, ZA

Illumina’s global supply chain consists of suppliers, subcontractors, channel partners, manufacturing sites, distribution centers, and customers

Types of suppliers
Number of suppliers engaged by organization

Countries: AE, AM, AR, AT, AU, BE, BG, BR,
CA, CH, CN, CO, CZ, DE, DK, ES, FI, FR, GB,
GH, HK, ID, IE, IL, IN, IT, JP, KR, LK, LT, LU, LV,
MY, NL, NO, NZ, PL, RO, RU, SA, SE, SG, SI,
TH, TR, TW, US, ZA

Yes

Direct, indirect, strategic, finished medical device, custom spec, off the shelf, and services
3891

3798

3323

4533

>$1 billion>$1 billion>$1 billion>$1 billion

>400

517

919

872

$190 million$209 million$269 million$107 million

Percentage of total PO spend with diverse suppliers (US)

19%

17%

18%

11%

Percentage of total PO spend with total diverse suppliers (Global)

N/A

N/A

13%

8%

Percentage of strategic suppliers that have committed to minimizing theirenvironmental footprint

N/A

84%

100%

100%

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

AccessSASB index

People

TCFD index

Sustainability

Assurance statements

Responsibility

Appendix80

Disclosures

Key performance indicators

Operate responsibly continued
Political contributions

2019 baseline

2021

2022

2023

$50,000

$0

$0

$0

Total monetary value of financial and in-kind political contributions
made directly and indirectly by the organization by country andrecipient/beneficiary

Trade association & memberships

U.S. trade association memberships
World 50, Inc.

2021

2022

2023

Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of theseorganizations may utilize a portion of membership fees for non-deductible state and federal lobbying and political expenditures. As part ofour transparency practices, we disclose trade memberships for which we contribute at least $5,000 annually in fees.

$393,766$240,850$183,670

US Chamber of Commerce$150,000$160,000$360,000

Coalition for Access to Prenatal Screening (CAPS)$100,000$100,000$75,000

Access to Comprehensive Genomic Profiling Coalition$80,813$75,000$75,000

Procurement Leaders$57,000$58,710$0

Biocom$56,300$57,500$67,500

American Clinical Laboratory Association (ACLA)$50,000$50,000$50,000

Coalition for 21st Century Medicine$50,000$50,000$0

Personalized Medicine Coalition (PMC)$32,000$32,000$38,000

California Chamber of Commerce$25,000$0$0

San Diego Economic Development Corp. (SDEDC)$25,000$25,000$25,000

EMEA trade association memberships

National Association of Manufacturers (NAM)$24,500$24,500$0

All.Can (ASBL)$35,000$32,204$31,752

AdvaMed$19,950$19,950$19,950EUCOPE$27,892$19,322$19,034

American Cancer Society—Cancer Action Network (ACS-CAN)a$10,000$0$0

US Qatar Business Council$10,000$10,000$10,000

San Diego Regional Chamber of Commerce (SD Chamber)

$7650

$7650

$7900

US Saudi Arabian Business Council$10,000$10,000$10,000

Industrial Environmental Association (IEA)

$6000

$6000

$6000

Healthcare Business Women's Association (HBA)

$5000

$5000

$0

Trade and industry group memberships above $5,000 threshold annually
GlobalWorld Economic ForumUS UAE Business Council
International Quality Network for Pathology (IQN Path)$330,000$330,000$0$10,000$10,000$10,000

$5000

$0

$5439

American European Community Association (AECA)

For the US trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under
Section 162(e)(1)(B) of the Internal Revenue Code, such as payments to organizations designated as 501(c)(4) and 501(c)(6) associated withstate and federal lobbying efforts annually.

$5634

APJ and greater China trade association memberships
US India Business Council
Pathology Technology Australia$27,500$20,000

Organization$0

Total annual membership fee% Membership fees
used for state orfederal lobbying

2021

2022

2023

2021

2022

2023

2021

2022

2023

Dollars applied to state or federal
lobbying from membership fees

$7309

$20,868$0

US Chamber — China$25,000$25,000$0

US-China Business Council (USCBC)$15,000$15,000$15,000

US Chamber of Commerce$161,625$160,000$360,000

25%

35%

35%

$40,406$56,000$126,000

US-ASEAN$11,686$14,500$18,850

$7413

$4026

$4007

Coalition for Access toPrenatal Screening (CAPS)$100,000$100,000$75,000

25%

0%

25%

$25,000$0$18,750

American Clinical Laboratory
Association (ACLA)$50,000$50,000$50,000

33%

30%

59%

$16,500$29,500$29,500

Biocom$56,300$57,500$67,500

10%

10%

10%

$5630

$5750

$6750

Coalition for 21stCentury Medicine$50,000$50,000

$0

*

30%

0%

*

$15,000$0

AmCham China

45%$22,500

Footnotes:
For the trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under Section 162(e) (1)(B) of theInternal Revenue Code, such as payments to organizations designated as 501(c)(4) and 501(c)(6) associated with state and federal lobbying efforts annually.

a

General notes:• Updated data to reflect most current information.

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

GRI index
GRI description
Description

GRI section
Section

CSR at Illumina
GRI index

SASB index

AccessTCFD index

Illumina
Illumina ReportreportGRI 1 reference

Illumina has reported in accordance with the GRI Standards forthe period 1st January 2023
2022 to 31st December 2022
2023
GRI 1

GRI 1: Foundation
GRI 1: Foundation
2021
2021

GRI 2: General disclosures
Disclosures 2021
Organizational details

GRI 2-1

Pages: 8, 9,Introduction,
89
Appendix

Entities included in the organization, sustainability reporting

GRI 2-2

Page: 86

Introduction, Appendix

Reporting period, frequency and contact pointGRI 2-3

Page: 86

About this report

information
Restatements of information*

GRI 2-4

Page: 86

About this report

External assurance

GRI 2-5

Page: 108

Assurance Letter

GRI 2-6

Pages:
8-9, 13-15,CSR
22-22,
27-31, 51-52,
80Introduction,
at Illumina,
Access,83,Sustainability,
89, 101
Responsibility, Appendix

Activities, value chain and other business relationships

Sustainability

Assurance statements

Responsibility

Appendix81

Disclosures

GRI description
Description

GRI section
SectionIllumina
Illumina ReportreportGRI 3: Material topics
TopicsGRI 1:
1:Foundation
Foundation2021
Statement of use

PeopleEmployees

GRI 2-7

Pages: 57-68,People,
93-99 Appendix

Workers who are not employees

GRI 2-8

Page: 93

Governance structure and composition

GRI 2-9

Pages:
12-17,
72, 100
CSR atIllumina,
Responsibility, Appendix

Nomination and selection of the highest governance body

GRI 2-10

Pages:
16,Illumina,
72, 100 Responsibility, Appendix
CSR atChair of the highest governance body
Chair of the highest governance bodyRole of the highest governance body in overseeing the management
Roleof the highest governance body in overseeing the managementof impactsof impacts
Delegation of responsibility for managing impacts
Delegation of responsibility for managing impacts
Role of the highest governance body in sustainability reporting
Role of the highest governance body in sustainability reporting
Conflicts of interest
Conflicts of interest
Communication of critical concerns
Communication of critical concerns
Collective knowledge of the highest governance bodyCollective knowledge of the highest governance body
Evaluation of the performance of the highest governance body
Evaluation of the performance of the highest governance body
Remuneration policies
Remuneration policies
Process to determine remuneration
Process to determine remuneration
Annual total compensation ratio
Annual total compensation ratio
Statement on sustainable development strategy
Statement on sustainable development strategy

GRI 2-11
GRI 2-11

Pages: 16, 72, 100
CSR at Illumina, Responsibility, Appendix

GRI 2-12
GRI 2-12

Pages: 16, 72, 100
CSR at Illumina, Responsibility, Appendix

GRI 2-13
GRI 2-13
GRI 2-14
GRI 2-14
GRI 2-15
GRI 2-15
GRI 2-16
GRI 2-16
GRI 2-17
GRI 2-17
GRI 2-18
GRI 2-18
GRI 2-19
GRI 2-19
GRI 2-20
GRI 2-20
GRI 2-21
GRI 2-21
GRI 2-22
GRI 2-22

Page: 16

Policy commitments
Policy commitments

GRI 2-23
GRI 2-23

Embedding policy commitments
Embedding policy commitments

GRI 2-24
GRI 2-24

Processes to remediate negative impacts
Processes to remediate negative impacts
Mechanisms for seeking advice and raising concerns
Mechanisms for seeking advice and raising concerns
Compliance with laws and regulations
Compliance with laws and regulations
Membership associations
Membershipassociationsengagement
Approach to stakeholder

GRI 2-25
GRI 2-25
GRI 2-26
GRI 2-26
GRI 2-27
GRI 2-27
GRI 2-28
GRI
GRI 2-28
2-29

CSR at Illumina
Pages: 16, 72, 100
CSR at Illumina, Responsibility, Appendix
Page: 72-76
Responsibility
Page: 100
AppendixPage: 16, 72-76, 100
Responsibility
Page: 72
Responsibility
Page: 72, Proxy
Responsibility, Proxy
Page: 72
Responsibility, Proxy
Page: 72
Responsibility, Proxy
Page: 2-3, 12-16
CEO Message, CSR at Illumina, Sustainability
Page: 13-17, 44, 52, 62, 68, 72, 73, 74, 77, 78,
CSR at Illumina, People, Sustainability,
79-84
Responsibility, ESG Hub
Page: 13-17, 44, 52, 62, 68, 72, 73, 74, 77, 78,
CSR
atIllumina, People, Sustainability,
79-84
Responsibility, ESG Hub
Page: 71-84, 100, 106
Responsibility, Appendix
Page: 71-84, 106
Responsibility, Appendix
Page: 68, 71-84, 100
People, Responsibility
Page: 17, 22, 29, 31, 41, 44, 86
CSR at Illumina, Access, People,
Page: 17 Sustainability, Appendix

Collective tobargaining
agreements
Approachstakeholder
engagement

GRI 2-29
2-30
GRI

Page: 100

Collective bargaining agreements

GRI 2-30

Appendix

CSR at Illumina
Appendix

Process to determine material topics

GRI 3-1

Page: 12-17

CSR at Illumina

List of material topics

GRI 3-2

Page: 14,17

CSR at Illumina

GRI 3-3
3-3
GRI

CSR atPage: 12-17,
72Illumina, Access, People,
Sustainability, Responsibility

GRI 3-3
GRI 3-3
GRI 201-1
GRI 201-1
GRI 201-2
GRI 201-2
GRI 201-3
GRI 201-3

Page: 12-17

GRI 3-3
GRI 3-3
GRI 202-1
GRI 202-1
GRI 202-2
GRI 202-2

Page: 12-17
Introduction, CSR at Illumina, Access
Page: 62, 98
People, Appendix
Page: 63
PeopleGRI 3-3
GRI 3-3
GRI 203-1

Page: 12-17, 19, 36, 57, 71
Introduction, Access, People,
Page: 19,Sustainability,
22-23, 25, 26,Responsibility
30, 37, 40-41, 54-55
Access,Page: 19,Introduction,
22-23, 25, 26,
30, 37,People,
40-41, 54-55
Sustainability, Appendix

Management ofof materialmaterial topics
topicsManagement
GRI 201: Economic Performance 2016
GRI 201: Economic performance
Management of material topics
Management of material topics
Direct economic value generated and distributed
Direct economic value generated and distributed
Financial implications and other risks and opportunities due toFinancial
implications and other risks and opportunities due toclimate change
climate change
Defined benefit plan obligations and other retirement plans
Defined benefit plan obligations and other retirement plans
GRI 202: Market Presence 2016
GRI 202: Market presence 2016
Management approach: Market PresenceManagement approach: Market Presence
Ratios of standard entry level wage by gender compared to local
Ratiosof standard
entry level wage by gender compared to local
minimum
wage
minimum wage
Proportion of senior management hired from the local community
Proportion of senior management hired from the local community
GRI 203: Indirect Economic Impacts
GRI 203: Indirect economic impacts
Management approach: Indirect Economic Impacts
Management approach: Indirect Economic Impacts
Infrastructure investments and services supported

Page: Proxy

CSR at Illumina

Proxy
Page: 44-45, 51, 53-54, 107
Sustainability, Responsibility, Appendix
Page: 67, 98
People, Appendix

Significant indirect
economic
impacts
Infrastructure
investments
andservices supported

203-2
GRI 203-1

GRI
204: Procurement
PracticesSignificant
indirect economic
impacts
Management approach: Procurement PracticeGRI 204: Procurement practices
Proportion of spending on local suppliers
Management approach: Procurement PracticeGRI 203-2
GRI 3-3

Access, People, Sustainability
Page: 12-17, 71, 80-81

GRI 204-1
GRI 3-3

Page: 82, 101
CSR at Illumina, Responsibility, Appendix

GRI 204-1
GRI 3-3

Responsibility, Appendix
Page: 12-17, 71

GRI 205-1
GRI 3-3

Page: 71-76, 80-81, 100
CSR at Illumina, Responsibility, Appendix

GRI 205-1
205-2

Page: 73-74,
80, 81, 100 Appendix
Responsibility,

205-3
GRI 205-2

Page: 100 Responsibility, Appendix

GRI 205-3
GRI 3-3

Page: 12-17

206-1
GRI 3-3

Page: 100
CSR at Illumina, Responsibility

GRI
205: Anti-corruption
Proportionof spending on local suppliers
Management approach: Anti-corruption
GRI 205: Anti-corruption
Operations assessed for risks related to corruption
Management approach: Anti-corruption
Communication and training about anti-corruption policies
Operations
assessed for risks related to corruption
and procedures
Communicationand training
aboutandanti-corruption
policies
Confirmed incidentsof corruption
actions taken
and procedures
GRI 206: Anti-competitive
Behavior
Confirmed
incidents of corruption
and2016
actions taken

Management approach: Anti-competitive
GRI 206: Anti-competitive behavior
Legal actions for anti-competitive behavior, anti-trust, andManagement
approach: Anti-competitive
monopoly practices
Legal actions for anti-competitive behavior, anti-trust, andmonopoly practices

GRI 206-1

Appendix

AppendixFootnotes:
 restatement of water data occurred in this 2023 reporting period due to accounting updates identified for water usage related to coolingA
towers at Singapore NorthTech facility.

*

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix82

Disclosures

GRI index continued
GRI description
Description

GRI section
SectionIllumina
Illumina Reportreport

GRI description
Description

GRI section
SectionIllumina
Illumina ReportreportGRI 306: Waste

GRI 301: Materials

Management approach: Waste

GRI 3-3

CSR atIllumina,
Sustainability
Pages: 12-17,
43,
48

Waste generation and significant waste-related impacts

GRI 306-1

Appendix
Pages: 43,Sustainability,
48-50, 92

GRI 302: Energy

Management of significant waste-related impacts

GRI 306-2

Sustainability
Pages: 43, 48-50

Management approach: Energy

GRI 3-3

CSR atIllumina,
Pages: 12-17,
43-45,
46 Sustainability

Waste generated

GRI 306-3

Appendix
Pages: 48, Sustainability,
92

Energy consumption within the organization

GRI 302-1

Sustainability,
Pages: 43-44,
46, 51, 90, Appendix
91, 107

Waste diverted from disposal

GRI 306-4

Appendix
Pages: 48, Sustainability,
92

Energy consumption outside of the organization

GRI 302-2

Sustainability,
Pages: 43-44,
49, 51, 52, Appendix
91,107

Waste directed to disposal

GRI 306-5

Appendix
Pages: 48, Sustainability,
92

GRI 308: Supplier environmental
Environmental assessment
Assessment

Management approach: Materials

GRI 3-3

CSR atIllumina,
Sustainability
Pages: 12-17,
43,
49

Reclaimed products and their packaging materials

GRI 301-3

Page: 49

Sustainability

Energy intensity

GRI 302-3

Appendix
Pages: 46, Sustainability,
91

Reduction of energy consumption

GRI 302-4

Sustainability,
Pages: 43-44,
46, 50-51, Appendix
55, 90-91

Management approach: Supplier Environmental Assessment

GRI 3-3

CSR at 12-17,
Illumina,
Responsibility
Pages:
43,Sustainability,
52, 71

GRI 302-5

Pages: 49-50, 53-55
Sustainability

New suppliers that were screened using environmental criteria

GRI 308-1

Appendix
Pages: 81, Responsibility,
89

Negative environmental impacts in the supply chain and actions taken

GRI 308-2

Pages: 50-51

Management approach: Water and EffluentsGRI 3-3

CSR atIllumina,
Sustainability
Pages: 12-17,
43,
47

GRI 401: Employment

Interactions with water as a shared resource

GRI 303-1

Appendix
Pages: 47, Sustainability,
92

Management approach: Employment

GRI 3-3

CSR
Pages: 12-17,
57 at Illumina, People

GRI 401-1

Page: 96

Reductions in energy requirements of products and services
Effluents
GRI 303: Water and effluents

Sustainability

Management of water discharge-related impacts

GRI 303-2

Pages: 47, Sustainability,
92
Appendix

New employee hires and employee turnover

Water withdrawal

GRI 303-3

Pages: 47, Sustainability,
92
Appendix

Pages: 67, 98 People, Appendix

GRI 303-4

Pages: 47, Sustainability,
92
Appendix

Benefits provided to full-time employees that are not provided totemporary or part-time employees

GRI 401-2

Water discharge
Water consumption

GRI 303-5

Pages: 47, Sustainability,
92
Appendix

Parental leave

GRI 401-3

Page: 98

GRI 3-3

CSR 43-45
at Illumina, Sustainability
Page: 12-17,

Management approach: Health and Safety

GRI 3-3

CSR
Pages: 12-17,
57 at Illumina, People

Occupational health and safety management system

GRI 403-1

Pages: 68, 99 People, Appendix

Hazard identification, risk assessment, and incident investigation

GRI 403-2

Pages: 68, 99 People, Appendix

Occupational health services

GRI 403-3

Appendix
Pages: 67-68,People,
99

Worker participation, consultation, and communication on
occupational health and safety

GRI 403-4

Page: 68

Worker training on occupational health and safety

GRI 403-5

Pages: 68, 99 People, Appendix

Promotion of worker health

GRI 403-6

Pages: 67-68 People, Appendix

Prevention and mitigation of occupational health and safety impacts
directly linked by business relationships

GRI 403-7

Pages: 68- 69People, Appendix

Workers covered by an occupational health and safety
management system

GRI 403-8

Pages: 68, 99 People, Appendix

Work-related injuries

GRI 403-9

Pages: 68, 99 People, Appendix

Work-related ill health

GRI 403-10

Pages: 68, 99 People, Appendix

GRI 304: Biodiversity
Management approach: Biodiversity
Operational sites owned, leased, managed in, or adjacent to,protected areas and areas of high biodiversity value outside
protected areas

GRI 304-1

Significant impacts of activities, products and services on biodiversity

GRI 304-2

Page: 45

Habitats protected or restored

GRI 304-3

Page: 45-46, 53-55
Sustainability

IUCN Red List species and national conservation list species with
habitats in areas affected by operations

GRI 304-4

Page: 45, 46

Page: 45-46

Sustainability
Sustainability

Sustainability

GRI 305: Emissions
Management approach: Emissions

GRI 3-3

CSR 43-45
at Illumina, Sustainability
Page: 12-17,

Direct (Scope 1) GHG emissions

GRI 305-1

Sustainability,
Page: 43-44,
46, 90-91 Appendix

Energy indirect (Scope 2) GHG emissions

GRI 305-2

Sustainability,
Page: 43-44,
46, 90-91 Appendix

Other indirect (Scope 3) GHG emissions

GRI 305-3

Page: 43-44,
51, 91
Sustainability,
Appendix

GHG emissions intensity

GRI 305-4

Page: 46, 91
Sustainability, Appendix

Reduction of GHG emissions

GRI 305-5

Page: 43-44,
46, 50-51, 55,
90-91
Sustainability,
Appendix

Emissions of ozone-depleting substances (ODS)

GRI 305-6

Page: 91

Appendix

Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant
air emissions

GRI 305-7

Page: 91

Appendix

Appendix

People, Appendix

GRI 403: Occupational health
Health andand safety
SafetyPeople, Appendix

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix
83

Disclosures

GRI Index continued
GRI description
Description

GRI section
SectionIllumina
Illumina Reportreport

GRI description
Description

GRI section
SectionIllumina
Illumina ReportreportGRI 414: Supplier social
Social assessment
Assessment

GRI 404: Training and education
Education
Management approach: Training and Education

GRI 3-3

CSR
Pages: 12-17,
57 at Illumina, People

Management approach: Supplier Social Assessment

GRI 3-3

CSR at12-17,
Illumina,
Responsibility
Pages:
52, Sustainability,
71, 80

Average hours of training per year per employee

GRI 404-1

People, Appendix
Pages: Introduction,
6, 63, 98

New suppliers that were screened using social criteria

GRI 414-1

Page: 101 Responsibility, Appendix

Management approach: Public Policy

GRI 3-3

CSR atResponsibility
Pages: 12-17,
71,Illumina,
84

Political contributions

GRI 415-1

Appendix
Pages: 84, Responsibility,
102

Management approach: Marketing and Labeling

GRI 3-3

CSR12-17,
at Illumina,
Pages:
71, 76 Access, Responsibility

Requirements for product and service information and labeling

GRI 417-1

Access, Appendix
Pages:Responsibility,
76, 106

noncompliance concerning
Incidents of non-complianceconcerningproductproductand
andservice
service
information and labeling

GRI 417-2

Page: 106

Appendix

noncompliance concerning
Incidents of non-complianceconcerningmarketing
marketingcommunications
communications

GRI 417-3

Page: 106

Appendix

Management approach: Customer Privacy

GRI 3-3

CSR12-17,
at Illumina,
Pages:
71, 75, Access,
78-79 Responsibility

Substantiated complaints concerning breaches of customer privacy
and losses of customer data

GRI 418-1

Page: 100Programs for upgrading employee skills and transition
assistance programs

GRI 404-2

Pages: 61, 63-66

Percentage of employees receiving regular performance and careerdevelopment reviews

GRI 404-3

Pages: 64, 98 People, Appendix

PeoplepolicyGRI 415: Public Policy

labeling
GRI 417: Marketing and Labeling

Equal opportunity
Opportunity
GRI 405: Diversity and equalManagement approach: Diversity and Equal Opportunity

GRI 3-3

at Illumina,
Pages:CSR
12-17,
57, 60 People, Appendix

Diversity of governance bodies and employees

GRI 405-1

Responsibility,
Pages:People,
57-59, 93-97,
72, 100 Appendix

Ratio of basic salary and remuneration of women to men

GRI 405-2

Pages: 98

Management approach:GRI 3-3

CSR
Pages: 12-17,
57,at
62Illumina, People

Incidents of discrimination and corrective actions taken

GRI 406-2

Pages: 100

Management approach: Freedom of Association andCollective Bargaining

GRI 3-3

CSR
Pages: 12-17,
57 at Illumina, People

Operations and suppliers in which the right to freedom of associationand collective bargaining may be at risk

GRI 407-1

Page: 106Management approach: Child LaborGRI 3-3

CSR at71,
Illumina,
Responsibility
Pages: 12-17,
77

Operations and suppliers at significant risk for incidents of child labor

GRI 408-1

Page: 77

Management approach: Forced and Compulsory LaborGRI 3-3

CSR atIllumina,
Pages:
12-17,
71, 77,Responsibility,
80, 81, 100 Appendix

Operations and suppliers at significant risk for incidents of forced orcompulsory labor

GRI 409-1

Appendix
Pages: 77, Responsibility,
81, 100

Management approach: Security PracticeGRI 3-3

Pages: 12-17

CSR at Illumina

Security personnel trained in human rights policies or procedures

GRI 410-1

Page: 100

Appendix

Management approach: Local Communities

GRI 3-3

CSR
Pages: 12-17,36at Illumina, People

Operations with local community engagement, impact assessments,
and development programs

GRI 412-1

Pages: 36-41 People, Access

Appendix

GRI 406: Non-discrimination
People, Appendix

GRI 407: Freedom of association
Association andand collective
Collectivebargaining
Bargaining

Appendix

GRI 408: Child labor
Labor
Responsibility

GRI 409: Forced or compulsory
CompulsorylaborLabor

GRI 410: Security practices
Practices

GRI 413: Local communities
Communities

privacyGRI 418: Customer Privacy

AppendixTable of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix84

Disclosures

SASB index

The Sustainability Accounting Standards Board (SASB) is an independent standards-setting organization that promotes disclosure of material sustainability information to meet investor needs. Illumina is classified officially in
the Health Care Sector and Medical Equipment & Supply Industry. We have also chosen to add relevant sections from the industry categories of Biotechnology & Pharmaceuticals as well as Software & IT Services.

Dimension

Disclosure Topic

Code

Accounting MetricResponse

PRIMARY SICS SECTOR: HEALTHCARE | Primary SICS industry: medical equipment & supplies
Access & affordability

SocialcapitalProduct quality & safety

Selling practices &product labeling

Product design &lifecycle management
Businessmodel &
innovation
Supply chain management

Leadership &governanceBusiness ethics

Other

Activity metrics

Affordability and pricing

HC-MS-240a.1

Ratio of weighted average rate of net price increases to the annual increase in the U.S. Consumer Price Index

Access p21

Affordability and pricing

HC-MS-240a.2

Description of how price information for each product is disclosed to customers or to their agents

Access p21

Product safety

HC-MS-250a.1

Number of FDA recalls issued, total units recalled

Responsibility

Product safety

HC-MS-250a.2

List of products listed in the FDA’s MedWatch safety alerts for human medical products database0

Product safety

HC-MS-250a.3

Number of fatalities related to products as reported in FDA Manufacturer and User Facility Device Experience

0

Product safety

HC-MS-250a.4

Number of FDA enforcement actions taken in response to violations of Current Good Manufacturing Practices (cGMP)

0

Ethical marketing

HC-MS-270a.1

Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

0

Ethical marketing

HC-MS-270a.2

Description of code of ethics governing promotion of off-label use of products

Product design &lifecycle management

HC-MS-410a.1

Discussion of process to assess and manage environmental and human health considerations associated with chemicals
in products, and meet demand for sustainable products

Product design &lifecycle management

HC-MS-410a.2

Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipmentand (2) supplies

Sustainability, Appendix

Supply chain management

HC-MS-430a.1

Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing
and product quality

Responsibility, Appendix

Supply chain management

HC-MS-430a.2

Description of efforts to maintain traceability within the distribution chain

Responsibility, Appendix

Supply chain management

HC-MS-430a.3

Description of the management of risks associated with the use of critical materials

Responsibility, Appendix

Business ethics

HC-MS-510a.1

Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption

Business ethics

HC-MS-510a.2

Description of code of ethics governing interactions with health care professionals

Activity metrics

HC-MS-000.A

Number of units sold by product category

Employee recruitment,
development & retention

HC-BP-330a.1

Discussion of talent recruitment and retention efforts for scientists and R&D personnel

Employee recruitment,
development & retention

HC-BP-330a.2

1) Voluntary and 2) involuntary turnover rate for a) executive/senior managers b) mid-level managers c) professionals d)
all others

Appendix

TC-SI-330a.3

Percentage of gender and racial/ethnic group representation for 1) management 2) technical staff 3) all other employees

People, Appendix

Responsibility, Illumina Code of Conduct
Sustainability

Appendix
Responsibility, Integrity Code for Interactions
with Healthcare Professionals andGovernment Officials
Not currently disclosed

Supplemental SICS industry: biotech & pharma
Humancapital

Employee engagement,
diversity & inclusion

People, Appendix

Supplemental SICS industry: software & IT services
Human capital

Employee engagement,
diversity & inclusion

Recruiting & managing
a global, diverse &skilled workforce

Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleAssurance statements

Sustainability

Responsibility

Appendix

Disclosures

Task force on climate-related financial disclosures (TCFD) index
TCFD voluntary climate-related disclosure recommendations have been used to guide our reporting. We believe addressing climate change is key to achieving a sustainable, just, and resilient future for all.
We are committed to transparency and will continue to share progress in our annual CSR Report and CDP submissions.
TCFD disclosure element

Illumina response

Governance: Describe organization's governance around climate-related risks and opportunities
1

Governance
TheIllumina
IlluminaCEO
is a memberof theof(Board)
Directors(Board)andforis directing
responsiblefor directing
allstrategy,
aspectsof
In addition
to the full Board
oversight,
remit oftheGovernanceCommittee
the byThe
CEO
is a memberof the Board
ofBoardDirectors
and isresponsible
all aspectsof company
planning,and operations.
Climate-related
issues andprojects theassociatedwith
theNominating/Corporate
reduction of our environmental
footprint are
reviewed at assists
least annuallycompanyplanning,
Climate-related
andprojects
associatedreductionBoard
in overseeing
the company’s
material environmental, social, and governance matters, except as specificallythefull Boardstrategy,
and can be
escalated andto theoperations.
Board throughIllumina’s CEO andissues
the CEO's
directreports.
Each direct with
reportthemanages
responsibilities
associatedwith their functionalarea.
of our environmental footprint are reviewed at least annually by the full Board and can be escalated to the Board

delegated to another Board committee.

The Board provides oversight to the CSR program covering environmental, social, and governance (CSR) topics, including climate-related issues. The Board receives updates at least annually on current performance and future strategic plans, with additional updates provided if
through Illumina’s CEO and the CEO's direct reports. Each direct report manages responsibilities associated with
The Compensation Committee continues to oversee and provide input to management on diversity and inclusionmaterial changes occur.

1.1

Board oversighttheir functional area.

matters, and the Audit Committee continues to oversee cybersecurity.
The Board provides oversight to the CSR program covering environmental, social, and governance topics,
We govern CSR at the highest level with oversight from the full Board of Directors. This strong leadership supportsInaddition toclimate-related
the full Board oversight,
theTheremitBoardof the Nominating/Corporate
Committee
assists theBoard in overseeing
the company’s material environmental, social, and governance matters (CSR), except as specifically delegated to another Board committee.
includingissues.
receives updates atGovernanceleast annuallyon current
performanceand future
the management of material environmental, social, and governance issues, including climate action, diversity,
strategicplans, Committeewith additional
updates
provided
if material
occur.
The
Compensation
continues
to overseeand provide
input to changes
management
on diversity and inclusion matters, and the Audit Committee
continues
to oversee humancybersecurity.
equityand inclusion,rights, cybersecurity, and ethical, responsible business practices.
The Board provides oversight, guidance and direction on CSR risk and opportunities that have potential impact on reputation and long-term economic viability, including climate action.

The
Board
providesoversight,
guidance
onof
CSR
risk andthat
have thepotential
impactonWegovernCSR
at the highest
level withoversightand
fromdirection
the full Board
Directors.
Thisopportunities
strong leadershipsupports
managementof material
environmental, social, and governance issues, including climate action, diversity, equity and inclusion, human rights, cybersecurity, andreputationand long-term
economic viability, including climate action.
ethical,responsible
business practices.

The Executive CSR Steering Committee comprises a team of senior leaders from across the organization, including

1.2

Management role

progress. A council of leaders from each CSR strategic focus area report to the CSR Executive Committee on a

The Executive CSR Steering Committee comprises a team of senior leaders from across the organization, including the General Counsel, Chief of Global Operations, Chief People Officer, Chief Technology Officer, Chief Marketing Officer, Global Head of CSR, and VP of Investor
the General Counsel, Chief of Global Operations, Chief People Officer, Chief Technology Officer, Chief Marketing
regular basis with progress updates. Reports to the broader CEO staff are scheduled as needed to provide updates
Relations. The CSR Executive Committee has overall responsibility for reviewing company activities related to CSR, including climate change programs. The CSR Executive Committee sets the strategy for environmental sustainability including establishing reduction targets andOfficer, Global Head of CSR, and VP of Investor Relations. The CSR Executive Committee has overall responsibility
on status regarding CSR elements including environmental matters. On at least an annual basis, updates on CSR
monitoring annual progress. A council of leaders from each CSR strategic focus area report to the CSR Executive Committee on a regular basis with progress updates. Reports to the broader CEO staff are scheduled as needed to provide updates on status regarding CSR elements
for reviewing company activities related to CSR, including climate change programs. The CSR Executive Committee
projects are provided to the full Board of Directors and the Nominating/Corporate Governance Committee.
including environmental matters. On at least an annual basis, updates on CSR projects are provided to the full Board of Directors and the Nominating/Corporate Governance Committee.

sets the strategy for environmental sustainability including establishing reduction targets and monitoring annual

85

Table of contents
2023 CSR Report

About this report

TCFD disclosure element

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix

Disclosures

Illumina response

Strategy: Disclose the actual and potential impacts of climate-related risks and opportunities on the organization's businesses, strategy, and financial planning where such information is material.
2

2.1

Strategy

Climate risk andopportunities timeline

The Illumina
CEO is To
a memberthehitBoardof Directors(Board)andpathis responsiblefor directing
all aspects
company strategy,
InIllumina
additioncommits
to the full Board
oversight,
the remitof the 1Nominating/Corporate
GovernancethebaseBoardyear.
in overseeing
Short(0–5 years)
ensureofwe
criticalmilestones
on ourto net-zero,we createdshort-,ofmedium-,and longto reducing
absolute
Scope
and 2 GHG emissions
46% byCommittee
2030 fromassistsa 2019We also the
Short (0–5 years) To ensure we hit critical milestones on our path to net-zero, we created short-, medium-, and long-term targets. These climate commitments include Science Based Targets initiative (SBTi) verified targets aligned to the 1.5 °C pathway. Our short term target outlines aplanning,and operations.
Climate-related
issuesand projects
associatedwith the initiative
reduction(SBTi)of our environmental
footprint
areto thecompany’s
environmental,social, andgovernanceelectricity
matters (CSR),
exceptdelegated
to another
Board committee.
termtargets.
These climate
commitments
includeScience
Based Targets
verified targets
alignedcommit tomaterial
increase
annual sourcingof renewablefrom
0.6%asinspecifically2019 to 100%by 2030.
We further
commit to
4% annual reduction in Scope 1, 2 and 3 emissions on our path towards 46% Scope 1, 2 and 3 emissions reduction by 2030.
reviewed
at least Ourannually
bytermthe fullBoard
and canabe
escalatedto the Boardand the CEO's
1.5°C pathway.
shorttargetoutlines
4%
annual reduction
inthroughScope Illumina’s
1, 2 and 3CEO
emissionson ourdirect
pathreports.
towards
reducing
absolute
scope 3continues
GHG emissions
from
most
material
categories
of purchased
goodsmatters,
and services,
capitalThe
Compensation
Committee
to oversee
and theprovideinput
to management
on diversity
and inclusion
and the Audit
Under
the recommendations
ofresponsibilities
SBTi Net-Zero
Standard,
companies
go beyondmitigateupstream
climate change
by undertaking
or makinginvestments
thatemployee
generate additionalco-benefits
for people andnature.
To
Each Scope
directreportmanages
associatedwith theirshould
functional
area. their near- and long-term science-based targets to further
46%
1, 2 and
3 emissions
reductionby 2030.
goods,
andactions
distribution,businesstravel,commutingand investments
46%
by 2030
Committee
continuestransportation
to oversee cybersecurity.
further facilitate beyond value chain mitigation, Illumina has invested in Nature Based Green-e Certified Carbon Credits while on our journey to net
zero.
have
appliedcarbonoffsets
for ourgastoscope
as climate
a temporary
mitigation.
enabledverified
us to reach
from
a We
2019
base
year.
These
targets
arenaturalaligneda 1.51°C
ambitionandThisexternallybycarbon
SBTi. neutrality in
The Board
oversight to of
theSBTi
CSR Net-Zeroprogram covering
environmental,
and
(CSR)
topics,climateUnder
theprovides
recommendations
Standard,
companiessocial,shouldgogovernancebeyond theirnearandincluding
long-term
We govern CSR at the highest level with oversight from the full Board of Directors. This strong leadership supports the management
our direct operations (Scope 1 & 2) for 2022 and 2023.
related issues. The
Board toreceives
at least
annually
on current
performanceand future
strategicplans, with that
additional
science-basedtargets
furtherupdates
mitigateclimatechangeby undertaking
actionsor makinginvestments
generateLong
termtargets are social,alignedwith
UN Sustainable
Development
Goalsdiversity,(SDG) 2030
and science-based
emissionofmaterial
environmental,
andgovernanceissues, including
climate action,
equitytimeline
and inclusion,
human rights,
Environmental
performance
metricsaremonitored
consistently
andreportedquarterly.
Functionalgroupsestablish
projects
to
meet
these
short-termgoals. approach
Energy or carbon
reduction
projects
are reported
project
scoping
level withexpected
impacts and timeline for returns
updates provided
if material
occur.
additionalco-benefits
for changes
people andnature. To further facilitate beyond value chain mitigation, Illumina has invested in
reduction
resultin functional
group
projectsatandgoals
for shorter
term
timeline.
cybersecurity,and ethical,
responsible
businesspractices.
oninvestment.
NatureBased
Green-eCertified
Creditswhile
ourjourney tothat
nethavezero.
We haveappliedcarbonoffsets
for our
The Board
providesoversight,
guidanceCarbon
and direction
on CSRriskonandopportunities
potential
impacton reputation
andlong-termLong (8–28 years) With our commitment to responsible and sustainable practices, we have established targets tonaturalscope
1aligned
as a climate
temporary
mitigation.
This enabled
us to 2030
reachtimeline
carbonneutrality
in ouremission
direct operations(ScopeLongtermgastargetsarewith UN
Sustainable
Development
Goal (SDG)
andscience-based
reduction approacheconomic
viability,
includingaction.
prioritize the implementation of sustainable solutions in our facilities and products, as well as across our supply and1 & 2) for 2022 and 2023.

value chain.
Medium (5–8 years) Illumina has established a Climate Action Plan to prioritize the implementation of sustainable solutions in our facilities and products,
as well as across our supply and value chain. We expanded our 2030 climate action targets to minimize risk associated with climate
Environmental
performance
metrics
are monitoredconsistently
andreported quarterly. Functional groups establish
change,build resilience,and identify
opportunities
for long-termsustainablegrowth.
We set a long-term target of net-zero emissions by 2050 across our operations and value chain (Scopes 1, 2 and 3).
projects to meet these short-term goals. Energy or carbon reduction projects are reported at project scoping level withThis target
has beenverifiedSBTi
and tois 100%alignedwith themost aggressive
climateactionscope
goals3ofkeeping
globalIllumina commits to reducing absolute Scope 1 and 2 GHG emissions 46% by 2030 from a 2019 base year. We also commit to increase annual sourcingof renewableelectricity
fromby0.6%
in 2019
by 2030.
We further
commit to reducing
absolute
GHG
emissionsfrom theexpected impacts and timeline for returns on investment.
warming andto 1.5°C. On thepath
to net-zero,ourbasemilestone
targets
forare2030
will toensurewe
hit critical
milestones.
These
most material categories of purchased goods and services, capital goods, upstream transportation and distribution, business travel, employee commuting
investments
46%
by 2030
from a 2019
year. Thesetargetsaligneda 1.5 °Cclimateambitionand externallyverifiedMediumtargets have been verified by SBTi and include: 46% absolute reduction in Scope 1, 2 and 3 emissions; and 100%by
SBTi. (5–8 years) Illumina has established a Climate Action Plan to prioritize the implementation of sustainable
solutions in our facilities and products, as well as across our supply and value chain. We expanded our 2030 climate
action targets to minimize risk associated with climate change, build resilience, and identify opportunities for long-termsustainable growth.

renewable electricity.

Long term targets are aligned with UN SDG 2030 timeline and science-based emission reduction approach result in functional group projects and goals for shorter term timeline.

2.2

Climate risk andopportunities impact

We have also committed to 90% landfill diversion and 10% reduction in water intensity at core sites.

Illumina
definesa substantive
financialor strategic
as onewith afinancial
potential
financial
impactgreaterthan
5% ofThis couldTobeunderstandthe potential
risks andopportunities
climatechange,Illumina
conducted
an factors
assessment
using
the theIllumina
definesa substantive
financialor strategic
impact asimpact
those witha potential
impactgreaterthan 5%of revenue
impact.
the result of businessinterruption
due toclimate relatedofrisk
or business
operational
impact.
Additional
considered
includerevenue
impact.
Thiswould
could
be theresult ofbusinessandinterruption
to climate
related risk or business operational
recommendations of the TCFD. The assessment measured impact utilizing the following definitions:climaterelatedrisk thatcause
a businessinterruption
exposure todue
criticaloperations.
impact.
Additional
factors
considered
includeclimaterelatedrisk
that would
cause a businessand of the Task· Low
Ability to Financial
absorb financial,
and reputational
impact.
To
understandthe potentialrisks
and opportunitiesof theclimatechange,Illumina
conducted
an assessment
using theinterruption
recommendations
ForceImpacton Climate-related
Disclosuresoperational,(TCFD). The assessment
measured
impact utilizing the following definitions:
toAbility
criticaloperations.
· Moderate Impact - Some impact to finances, operations, and reputation.
· exposure
Low Impactto absorb
financial, operational, and reputational impact.
· High Impact- Substantive financial, operational, strategic, and reputational impact.
· Moderate Impact - Some impact to finances, operations, and reputation.
The climate change elements that have most influenced our strategy are physical risk to operations, supply chain impact, and reputation. These risks have been incorporated into business continuity planning, future product development, redundancy in supply chain where possible, andThe climate change elements that have most influenced our strategy are physical risk to operations, supply chain impact,
Under the 3°C scenario, we assume a world in 2030 facing a slow global economy with fraught geopolitical alliances.
site selection for future growth. We are actively reviewing opportunities to further integrate climate into our processes and path to further expand resilience. Examples of incorporation include: targets to align with the UN Sustainable Development Goals and utilize the Science Basedand reputation. These risks have been incorporated into business continuity planning, future product development,
Accelerating automation with uneven benefits leads to a focus on inequality. Society is slow to react to climate impacts,
Targets initiative (SBTi) methodology for a well below 2°C scenario (2DS); holistic goals of reducing the environmental footprint of our products throughout the life cycle; incorporation of Design for Environment into our new product design; and addition of a new logistics location to
redundancy in supply chain where possible, and site selection for future growth. We are actively reviewing opportunities
distracted by larger economic concerns. Carbon emissions have started to decline slightly: energy efficiency andour network on the east coast resulting in cost savings, improved supply chain planning, and a reduction of air emissions. We have implemented redundant planning and maintained safety stock to provide resilience during severe weather events. For financial planning, we include risk
to further integrate climate into our processes and path to further expand resilience. Examples of incorporation include:
renewable gains are easily offset by increased use of energy-intensive tech. This scenario causes some physicaland opportunities evaluated through our standard budget planning. Investment in energy-reduction projects that require capital expenditures are evaluated through the Capital Committee planning process. Potential indirect cost associated with supply chain, future tax, or increased
targets to align with the UN SDGs and utilize the SBTi methodology for a well below 2°C scenario (2DS); holistic goals ofclimate impacts by 2030. This model utilizes data from RCP 6.0 and SSP 4 (low challenges to mitigation, high challenges
operating costs from extreme weather would connect with these internal workstreams.

2.3

Targets to manage climate
risk and opportunities

reducing the environmental footprint of our products throughout the life cycle; incorporation of Design for Environment

to adaptation).

In 2020, we evaluated three 2030 climate scenarios linked to global warming by 2100. Our goal was to better

spur coordinated risk-containment efforts. While some physical impacts are already locked in, the pace of change slows

In
2020,
evaluated
three
2030 climate
scenarios
global warming
by 2100.
goal wastothe
betterunderstandthe implications
change for our business and identify opportunities to build resilience. Climate scenario analysis was completed using three plausible
into
ourwe
new
product
design;and addition
oflinkeda newtologistics
locationto ourOur
networkoneast
coast resulting
in cost of climate
Under
the well below 2°C scenario, we assume a world in which global cooperation leads to economic recovery that fully
narrative
representationsof ourplanning,
operating environment
respectivelyaligned to a well below 2°C, a 3°C , and a 4°C level of warming. To map assumptions for each trajectory, we utilized standardized third-party climate modeling data, such as the Shared Socioeconomic Pathways
savings,future
improved
supply chain
and a reductionof air emissions.
embraces the low-carbon transition, with strong climate policy and regulatory action. Some severe climate impacts felt
(SSPs) and the Intergovernmental Panel on Climate Change (IPCC) Representative Concentration Pathways (RCP).
Under
the 4°C thescenario,
global warming
reaches
4°C byfor
2100,
to pre-industrial
temperatures.
In 2030,
we assume
a geopoliticallywith thelimitedflows
orbelowknowledge,a challenging
situation,worsenedby disinformation
generalunderstand
implicationsof climatechangeourrelative
businessand identify
opportunities
to build
resilience.
Climate fragmented
andworld
by 2050
world
isof
ongoods
a well
2°C andtrajectory.
This economic
model utilizes
datafrom RCP
2.6 and SSP and
1 (lowchallenges
mistrust.
Limitedactionon completed
climate policy
will betakenplausible
and a doubling
down future
on fossil-basedenergy sources
result. Morefrequent climate-related
weather events impact most regions by 2030. This scenario utilizes data from RCP 8.5 and SSP 3 (high challenges to mitigation
scenario
analysis
was
using
three
narrative
representationsof ourwill
operatingenvironment
to mitigation/adaptation).
andadaptation).aligned to a well below 2°C, a 3°C , and a 4°C level of warming. To map assumptions for each trajectory, we
respectively

The scenarios were reviewed in a cross-functional workshop that included key stakeholders across various business

utilized
third-party
climatemodelingsuch asthe Shared
Socioeconomic
Pathways(SSPs) and
the
Under
thestandardized
3°C scenario, we
assume a worldin 2030
facing adata,
slow global
economywith fraught
geopolitical alliances.
Accelerating
automation
withunits.
unevenbenefits
leads to aforfocus
on scenario
inequality.wereSociety
is slow to react
to climate impacts,
distracted
largereconomic concerns.
The
implications
each
discussed
and participants
identified
risk byandopportunity
hot spotsCarbon
toIntergovernmental
on Climate
Change(IPCC) and
Representative
Concentration
Pathways(RCP).
emissionshave startedPanelto decline
slightly: energy
efficiency
renewable gains
are easily offset
by increased
use of energy-intensive tech. This help
scenario
causessomeintegration
physical climate
impacts byplanning2030. Thismodel
utilizes
data fromand SSP 4 (lowchallenges
mitigation,
directfurtherof resilience
and
embed
climateintoRCPour6.0developing
enterpriserisktomanagement
highchallenges
adaptation).
Under
the 4°Ctoscenario,
global warming reaches 4°C by 2100, relative to pre-industrial temperatures. In 2030, we assume program. We will be utilizing the climate scenario insights to expand influence on our climate planning evolution anda geopoliticallyfragmented
worldwith limitedof goods
or knowledge,a challenging
situation,businessUnder
the well below
2°C scenario,
we assumea worldflows
in whichglobal cooperation
leads andto economic
recoveryeconomic
that fully embraces
the low-carbon
transition,continuity
with strongplans.
climate policy and regulatory action. Some severe climate impacts felt spur coordinated risk-containment efforts.
worsenedby disinformationand general
actionclimatepolicywill isbe
a 2°C
doubling
down
onmodel utilizes data from RCP 2.6 and SSP 1 (low challenges to mitigation/adaptation). The scenarios were reviewed in a cross-functional workshop
Whilesome physicalimpacts are alreadylocked mistrust.
in, the paceLimitedof change
slowsonandby 2050
the world
ontakena well andbelow
trajectory.
This
fossil-basedenergysources
will various
result. business
More frequentclimate-related
weather
eventsmostby 2030.
This
that
included key
stakeholders
acrossunits. The
implications for eachscenario
wereimpact
discussed
andregions
participants
identified
risk and opportunity hot spots to help direct further integration of resilience planning and embed climate into our developing enterprise risk
scenario utilizes
data
RCP
8.5 and
SSP 3scenario(high challenges
to mitigation
andmanagement
program.
Wefromwill beutilizing
the climate
insights to expand
influenceon adaptation).
our climate planning evolution and business continuity plans.

86Table of contents
2023 CSR Report

About this report

TCFD disclosure element

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleAssurance statements

Sustainability

Responsibility

Appendix

Disclosures

Illumina response

Risk Management: Disclose how the organization identifies, assesses, and manages climate-related risks.
3

Risk management

3.1

Process to identify
climate risk

3.2

Process to manage
climate risk

3.3

Process to integrate
climate risk in overallrisk managementToof annual
the Task
Force onFinancial
Disclosures(TCFD).
Weby
evaluated
2030
climateTounderstandunderstandthe
thepotential
potentialrisks
risksandandopportunities
opportunitiesofofclimate
climatechange,change,weweconductedconductedan
anassessment
assessmentinin2020
2020usingusingthe recommendations
and increasing
sourcing
ofClimate-related
renewable electricity
from
0.6% in 2019
to 100%2030. Tothreeaddress
ourScope 3
scenarios
linked to global
byWe
2100.
Our goal
was2030
to betterunderstandthe
implications
climate bychangeand identify
to build
resilience.
Climatescenario
completed
using
three
plausible
the recommendations
ofwarming
the TCFD.
evaluated
three
climatescenarios
linkedto globalofwarming
2100.for our businessemissions,
we are opportunities
working with eachfunctionalgroup
on projects
to analysis
continuewas
to drivedown the
value
chain
impact.
narrativeof ourenvironmentalignedto a well2°C,
a 3°C , andto
a 4°C levelInitialof warming.
map
assumptions
forinclude
each trajectory,
weutilized
standardized
third-party climate
modelling
data,
such
Our goalfuture
was torepresentations
better understandtheoperating
implicationsof climaterespectively
change for ourbusinessand below
identify
opportunities
projectsTo
andsampleinitiatives
updates toourinvestment
policy, communication
campaign
to oursupplier
asbuild
the Shared
Socioeconomic
Pathways(SSPs)
the Intergovernmental
Panel narrativeon Climate
Change(IPCC) Representative
Concentration(RCP).
resilience.
Climate scenario
analysis
was andcompletedusing three plausible
futurerepresentationsof ourbase, supplierPathways
mapping optimization,
expanding green travel policy, and shifting purchased goods from air to ocean

operatingenvironment
respectively aligned
toIllumina
a well below
2°C, a 3°C, and impact
a 4°C level
warming.
assumptions
freight
whereverpossible. Illumina
createda 2030target for
100% ofstrategic
suppliersassessment,
to have a commitment
To
identify andmanage climate-related
issues,is integratingclimateinto ofourexisting To
riskmap
management
structureusing
the Environment,
Health &has
Safetyteam
management
system,the
CSR materiality
businessfor each trajectory,
we utilized standardized
climatemodellingdata,
as theAs
SharedSocioeconomic
to reduce
theirenvironmental
associatedwithchange
our investments
accounted
forcontinuity
program management,
supply chainthird-party
risk reviews,
and internalauditrisksuchprogram.
our enterpriserisk management
programevolves,
we plan tofootprint.
integrateAdditionally,
climate as athe
keyemissions
component.
The climate
elements thathave mostPathwaysour(SSPs)and thePanel on supply
Climatechain
Change(IPCC)
Representative
Concentration
10%intoof theimpactcontinuity
in our value
chain infuture
our 2019
baselinestudy and redundancy
was one of the
top fivechain
areaswherecontributing
toand
our site
influenced
strategy
areIntergovernmental
physical risk to operations,
impact,andreputation. Theserisks have been incorporated
businessplanning,
product
development,in supply
possible,
Pathways
3 greenhousegas inventory. Following review of the Scope 3 data, we modified our investments policy toselectionfor(RCP).
future growth. We are actively reviewing opportunities to further integrate climate into our processes and path toScope
further
expand resilience.
investingin Energy
andUtilities sector
unless1.5°C
the associatedissuance
is identified
as aGreen,
Social or
To identify
manage climate-related
Illumina
is integratingclimateimpact intoGoals
our existingrisk management
Examplesof andincorporation
include: targetsissues,
to align
with theUN Sustainable
Development
and utilizationof the Science eliminate
Based Targets
initiative(SBTi)
methodology
for abonds
well below
scenario; holistic
goals
of reducing
theenvironmental
Sustainability(GSS)
Bond. and a reduction of air emissions.
structure
the Environment,
Health& Safety
team management
system,the CSR materiality
footprint
ofusing
our products
throughout
the life
cycle; incorporationof Designfor Environment
into ourassessment,
new productbusinessdesign; improved
supply chain
planning;

continuity
program management,
supply chain
risk reviews,
and stockinternal
riskresilience
program.during
As oursevere
enterpriserisk events. For
In 2022
we planning,received approval
fromour long-termtarget toreach net-zero
GHG budget
emissions
acrossInvestment
our direct inWehave implemented
redundant planningand maintained
safetyto audit
provideweatherfinancial
we include
riskSBTi
andon
opportunities
evaluatedthroughour standard
planning.
management program
evolves,
we planto integrate
climateareas evaluateda key component.
climate Committeechange elements
that
operations
and ourvalue
chain bywith
2050
from chain,a 2019futurebase year.
energy-reduction
projects
that require
capitalexpenditures
through The
the Capitalplanning
process. Potential
indirectcost
associatedsupplytax, or increased operating costs from extreme weather would
have mostour strategy
are physical risk to operations, supply chain impact, and reputation. These risks have
Additional processes for identifying, assessing, and responding to climate-related risks and opportunities have beenconnect
withinfluenced
these internal
workstreams.
been incorporated into business continuity planning, future product development, redundancy in supply chain wheredeveloped.
utilize
our enterpriserisk management
program,emergency
preparedness& response
Inpossible,
early 2021,
Illumina
launched
our
first
Scope
3
emission
inventory
assessment
acrossall
relevant
categories
for
our
value
chain.
Of theWe
fifteencategories
assessed,
we selected themost material
categories
contributing
to our program,emission ourand site selection for future growth. We are actively reviewing opportunities to further integrate climate into
environmental
management
system, and ourcontinuity
programto leverage
existing
workflows.
inventory
that represented
or morewereresilience.
defined as material and account for 92% of our total Scope 3 footprint. These categories
include,upstream transportation
andbusiness
distribution,purchased
goods
and services,
capitalgoods be the focus ofour processes
and path to7%
further
expandWe reviewfrom
the environmental
systemframework
annuallyreduction
as part ofapproach
the globalaligned
aspectto
andimpacts
clause.
our reduction efforts, investments, business travel, employee commuting. In September of 2021, we successfully received verification
Science Basedmanagement
Targets initiative(SBTi)
on our emission
a 1.5°C pathway.
Examplesincorporation
include: targets
to Scopealign with
SDG3andutilization
ofby
the2030
SBTicomparedmethodology
for aandwellincreasing
Outputfromsourcing
this dataofinfluences
performanceand
GHG reduction
objectives.
Illumina
also
uses our weOurverifiedof
targets
include reducing
absolute
1, 2 the
andUN
Scope
emissions46%
to 2019
annualrenewableenvironmental
electricity from
0.6% in 2019
to 100%by 2030. To
address ourScope
3 emissions,below
1.5°Cwithscenario;
holistic goals
of on
reducing
thetoenvironmental
footprint
products
thelife cycle;
ISO14001
environmental
management
system as
one ofcommunication
the mechanisms
to monitor
andsupplierreduce ourenvironmental
areworkingeach functional
group
projects
continue to drive
down oftheourvalue
chain throughout
impact. Initialprojects
and sample
initiatives
include updates
to our investment
policy,campaign
to ourbase,
supplier mapping
incorporationof Designgreen
for Environment
into
our
new productdesign;improved
supplychain
planning;
and apossible.
reductionIllumina
impacts
from GHG
emissions.
optimization,
expanding
travel policy,
andshifting
purchased
goodsfrom airto oceanfreight
whereverhas createda 2030target for 100% of strategic suppliers to have a commitment to reduce their environmentalof air emissions.
footprint.
Additionally, the emissions associated with our investments accounted for 10% of the impact in our value chain in our
2019baselinestudy andwas onerelatedof the top
five areas
contributing
to ourScope 3 greenhousegasat
inventory.
Following
The
EHS
team monitors
legislation
to climatechangeand generalenvironmental
regulations
the global,
We have
implemented
redundantplanning
maintained
safetystock to provide
resilienceduringsevere sector
weather
reviewof theScope 3 data,
we modified
our andinvestments
policyto eliminate
investingin Energy
and Utilities
bonds unlessthe associatedissuance
is identified
as a Green,or Sustainability
Bond.during the RFP process, newregional,country, andlocal level.
Supply chain
data isSocial
reviewed
through data(GSS)
collection
Forreceived
financialapprovalplanning,
we include
opportunities
throughouremissions
standard budget
planning.
supplier
onboarding,regular
supplier
Input from government affairs, EHS, regulatory, and compliance
Inevents.
2022 wefrom
SBTi on risk
our andlong-term
target toevaluatedreach net-zero
GHG
across our
direct operations
and ourvalue chainandby 2050froma 2019reviews.
base year.
Investment in energy-reduction projects that require capital expenditures are evaluated through the Capital Committee
teams
isutilize
also incorporated
toriskoverallrisk culture
and various
workstream
assessments.
Addressing
risk atthe site level
Additional
processes
for
identifying,assessing,andresponding
toclimate-related
risks
and
opportunities
have
been
developed.
We
ourenterprisemanagement
program,emergency
preparedness& response
program,ourplanning process. Potential indirect cost associated with supply chain, future tax, or increased operating costs fromis performed by our site emergency management cross functional group which plan for and react to immediate andenvironmental
management
system,andourbusiness
continuity
programtoleverageexisting
workflows.
extreme weather would connect with these internal workstreams.
near-term physical risks caused by climate change.
Wereview
the environmental
management
systemframework
annuallyas part of the
globalandimpacts clause.
Output from this data influences environmental performance and GHG reduction objectives. Illumina also uses our ISO14001
In early
2021,
Illumina launched
our first Scope
3 emission
inventory
assessment
acrossall aspect
relevant
categories
for
The following definitions apply to our assessment:
environmental
management
systemas oneassessed,of the mechanisms
to monitor
reduceour environmental
impacts
our value chain.
Of the fifteen
categories
we selected
the mostandmaterial
categories
contributing
to ourfrom GHG emissions.
· Time Horizon:
years),
years),Long (8–28
years) during the RFP process, new supplierThe
EHS team
monitors
relatedtomoreclimatechangeandenvironmental
regulations
at thecountry,
and localShortlevel.(0–5
SupplychainMedium
data is (5–8
reviewed
throughdata collection
emission
inventory
thatlegislation
represented
7% or
were
definedasgeneralmaterial
and account for
92% of our
totalglobal,
Scoperegional,
3· Likelihood:
Not likely,
As likelyand
as various
not, Morelikely thanassessments.
not, Likely, Virtuallycertainonboarding,and regularsupplier
reviews.
Input transportationfrom government
EHS, regulatory,complianceteams
is also incorporated
to overallrisk culture
workstream
Addressing
risk at the site level is performed by ourfootprint. These
categories
include,upstream
andaffairs,
distribution,purchasedandgoods
and services,
capitalsite
emergency
management
cross functionalgroup which businessplan for andreact
to immediateand near-term
physicalby climatechange.to absorb financial, operational, reputational impact), Moderate (some impact to finances,
goods
be the focus
of our reduction
efforts, investments,
travel,employeecommuting.
In Septemberof risks caused· Impact:
Low (ability
2021,
we successfully
from SBTi on our emission reduction approach aligned to a 1.5 °C pathway.
operations, reputation), High (substantive financial, operational, strategic, reputational impact).
The
following
definitionsreceived
apply toverification
our assessment:
Our verified targets include reducing absolute Scope 1, 2 and Scope 3 emissions 46% by 2030 compared to 201987

Table of contents
2023 CSR Report

About this report

TCFD disclosure element

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleSustainability

Assurance statements

Responsibility

Appendix

Disclosures

Illumina response

Metrics & Targets: Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.

4

Metrics & Targets

4.1

Climate-related metrics

As a science-based organization, we are compelled to ensure our reduction targets are aligned and verified to a sciencevalidation
fromInSBTi.
Ourtargetthe
includesall material
chain
categories:
purchased
and services,science-based
approach.
2022,
wenet-zerowere among
first companies
in value
the worldand
our industry,
and thegoods
first genomics
company
based
approach.
In 2022,
we2050werenet-zeroamong thefirst companies
in the world
and
our industry,
the first
genomics
capital goods,
transportationand distribution,businesstravel,employeecommuting,
We by
to receive
verificationof ouremissionstargets by
Science
Based
Targets andinitiative
Corporate
Net-Zero Standard.
In 2021,upstream
our Scope
1, 2, and 3 emission
targets werealignedto a 1.5°C climate
ambition andand investments.
externally verified
company
to receive
verification
our 2050
net-zeroemissionstargetsby thecarbon
SBTi Corporate
Net-Zerohave
identified
material
as all relevantthat represented
7% or moreof our total
3
Science Based
Targets
initiativeof(SBTi).
We seta long-termtargetof net-zeroemissionsby 2050Standard.
across ourInoperations
andvalue chain
whichcategories
received validation
fromcategories
SBTi. Our net-zerotarget includes
all materialvalue2019
chainScope
categories:
2021,
our Scope2, and3 emission
targets
werealignedtransportation
to a 1.5 °C climate
ambition andbusinessexternallyverifiedby SBTi.
emissionsinventory baseline.
material
categories
represented
92% categories
of Illumina’sthat
2019
Scope 3 emissions
andof ourpurchased
goods1,andservices,
capitalgoods,
upstreamand distribution,
travel,employeecommuting,and investments.
We have These
identified
material
categories
as all relevant
represented
7% or moreWe
a long-termtarget of net-zerocarbonemissions2050 across
our operations
and
value
chain which
established
our baseline.
totalset2019
Scope 3 emissions
inventorybaseline.
These bymaterial
categories
represented
92%
of Illumina’s
2019received
Scope 3 emissions
and established
our baseline.

4.2

GHG emission data

Detailed current and historical greenhouse gas emission data is available in Key Performance Indicators· Reach net-zero GHG emissions across Illumina’s direct operations (Scope 1 ,2) and our value chain (Scope 3) by 2050 from 2019 baseline levels

4.3

Targets to manage climate
risk and performance
to targets· Reduce Scope 1, 2 absolute GHG emissions 46% by 2030 from 2019 baseline· Reduce absolute GHG emissions from material Scope 3 categories 46% by 2030 from 2019 baseline· Reduce Scope 1, 2 absolute GHG emissions 90% by 2050 from 2019 baseline· Reduce absolute GHG emissions from material Scope 3 categories 90% by 2050 from 2019 baseline· Increase annual sourcing of renewable electricity to 100% by 2030 from 2019 baseline

88Table of contents
2023 CSR Report

About this report

CEO message
2030 targets

Introduction

Key performance indicators

CSR at Illumina
GRI index

SASB index

AccessTCFD index

PeopleAssurance statements

Sustainability

Responsibility

Appendix89

Disclosures

Independent limited assurance report to Illumina, Inc.
ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance
engagement in accordance with ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s 2023 Corporate Social
Responsibility Report (“2023 CSR Report”) for the period beginning January 1, 2023, and ending December 31, 2023 (CY2023).

Our Responsibilities
Our responsibility is to express a limited assurance conclusion in accordance with ISAE 3000 and ISAE 3410 whether the Reported Information
has been properly prepared in accordance with the Reporting Criteria and to provide this in a report to Illumina.

We have performed our limited assurance engagement in accordance with the International Standard on Assurance Engagements

Work Performed
The procedures we performed were based on our professional judgment. Our work included, but was not limited to:(ISAE3000),
Assurance
Independent Limited3000
Assurance
Reportto Illumina,
Inc. other than Audits or Reviews of Historical Financial Information, as well as the International Standard
on Assurance Engagements 3410 (ISAE 3410) Assurance Engagements on Greenhouse Gas Statements, issued by the International Auditing andBackground and introduction
Assurance Standards Board. The engagement covered all entities and all facilities under the operational control of Illumina.
ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited assurance
engagement in accordance with ISAE 3000 and ISAE 3410 covering select information reported within Illumina’s Corporate
Our review was limited to the data reported in the Key Performance Indicator Summary sections (pages 64 – 88) marked with the symbol “*”Social Responsibility Report CY ’22 (“CY22 CSR Report”) for the period beginning January 1, 2022, and ending December 31,(“Reported
2022(“CY22”). Information”), comprising of the following metrics and their respective segmentations:
We have performed our limited assurance engagement in accordance with the International Standard on Assurance
Integrating
Environmental
Sustainability:
NurturingEngagements
3000 (ISAE
3000), Assurance otherthan Audits or Reviews of Historical Financial Information,
as well as theOur People:
International Standard on Assurance Engagements 3410 (ISAE 3410) Assurance Engagements on Greenhouse Gas Statements,
Workforcedata
issuedby the International
Auditing and Assurance Standards Board. The engagement covered all entities•andall facilities under• Energy
consumption
the operational control of Illumina.
• Gender data

• Energy consumption by activity and region
Our review was limited to the data reported in the Key Performance Indicator Summary sections (pages 90
marked withfemale and male of each
• –P95)
ercentage• Renewable electricity consumption
the symbol “*” (“Reported Information”), comprising of the following metrics and their respective segmentations:
EEOC category (US)• Emissions
Integrate Sustainability:
Nurturing Our People:• EEOC minority summary (US)• Regional emissions
Energy Consumption
Workforce Data
• EEOC minority by category (US)•Energy
Greenhouse
Consumptiongas breakdown
Gender Data
Country, and Facility Emissions
EEOC Minority Summary (US)• EEOC data by level (US)•Regional,
Country-specificScope 1
Emission Intensity
New Hire Data
• New hire data
1 and 2 Emissions Scope 2 market-based
Promotion Data
•ScopeCountry-specificScope 3 Emission
Veteran Data (US)• Percentage new hire per EEOC (US)
•WaterFacility-specific emissions
Employee Turnover Data
• Promotion data
Other Identities Self-Reported (US)• Emission intensity ratios• Promotion date by EEOC (US)• Scope 3 emissions
We have not performed any procedures with respect to other information included in the Illumina CY22 CSR Report and,• Veteran data (US)• Scope 3 emissions: % of total Scope 3 emissions• Employee turnover data
• Other identities self-reported(US)• Parental leave• Benefit and employee bonus/
stock plan
• Performance review andemployee survey• Compensation ratio• Training• Health & safety

therefore, no conclusion on the Report as a whole is expressed.

• Water waste

Reporting criteria
The reporting criteria are the standards identified in the CY22 CSR Report – Reporting Overview (“Reporting Criteria”).

We havenot performed any procedures with respect to other information included in the Illumina 2023 CSR Report and, therefore, no conclusion
Inherent
uncertainty
Theof non-financial
the methods used to determine non-financial information, allow for different, but
on nature
the Reportas a information
whole isandexpressed.
acceptable measurement techniques which can result in materially different measurements and can impact accuracy andcomparability.
ReportingFurthermore,criteria the nature and methods used to determine such information, as well as the measurement criteria
andthereporting
precision thereof,
may change
overstandards
time.
The
criteria
are theidentified in the 2023 CSR Report – Reporting Overview (“Reporting Criteria”).
The Reported Information has been measured applying the Reporting Criteria which has been adopted solely for the purpose ofprovidingthis uncertainty
non-financial information. As such the Reported Information may not be suitable for another purpose. Where
Inherent
significant assumptions or deductions are utilized, they are disclosed. Where direct data was unavailable, the company used
The nature of non-financial information and the methods used to determine non-financial information, allow for different, but acceptableindustry standards as estimates. The assurance provided therefore does not guarantee or provide certainty over themeasurement
techniques
which can result in materially different measurements and can impact accuracy and comparability. Furthermore, thecompletenessof reported
data.

• Assessing the appropriateness of the Reporting Criteria for the Reported Information.
• Carrying out interviews or reviewing questionnaires from key personnel to understand the systems and controls in place during the reporting period.
• Assessing the systems, processes, and controls to collate, aggregate, validate and report the data.
• Reviewing a selection of factors and formulae used and calculations performed over the Reported Information.
• Considering the appropriateness of the Reported Information provided by Illumina and any third-party data management system service providers.
• Testing a sample of records against underlying records which were either individually material or where there was potential for errors to accumulate tomaterial amounts included:• Testing of energy consumption, scope 1 and 2 emissions, water and waste consumption at 13 company facilities in scope of the reporting.
• Testing of scope 3 emissions across the 10 calculated scope 3 emissions categories.
• Testing of human capital data aggregated across three regions and 28 countries where company operates, including against EEO-1 reporting for US
operations.
• Reperforming a selection of calculations of the Reported Information.

The relative effectiveness and significance of specific control procedures at Illumina and their effect on assessment of control risk at a facility
level are dependent on their interaction with the controls and other factors present at individual facilities. We have not performed any proceduresto evaluate the effectiveness of controls at individual facilities. We have not conducted any work outside the agreed scope and therefore restrict
our conclusion to the above-mentioned subject matter.
Restriction of Use
This assurance report is made solely to Illumina in accordance with the terms of our engagement, which include agreed arrangements fordisclosure. Our work has been undertaken so that we might state to Illumina those matters we have been engaged to state in this limited
assurance report and for no other purpose. Our limited assurance report should not be regarded as suitable to be used or relied on by any party
wishing to acquire rights against us other than Illumina for any purpose or in any context. Any party other than Illumina who obtains access to ourlimited assurance report or a copy thereof and chooses to rely on our limited assurance report (or any part thereof) will do so at its own risk. To
the fullest extent permitted by law, we accept or assume no responsibility and deny any liability to any party other than Illumina for our work, forthis independent limited assurance report, or for the conclusions we have reached.
Conclusion
Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believethat the Reported Information, noted in the Key Performance Indicator Summary (pages 64-88) for CY2023 (ending on December 31, 2023), has
not been prepared, in all material respects, in accordance with Illumina’s Reporting Criteria.

nature and methods used to determine such information, as well as the measurement criteria and the precision thereof, may change over time.

Illumina’s responsibilities
The Company’s management are responsible for:

The Reported Information has been measured applying the Reporting Criteria which has been adopted solely for the purpose of providing this•The accuracy
and completenessthe information
containedInformationin the Reported Information.
non-financial
information.
Asofsuch
the Reported
may not be suitable for another purpose. Where significant assumptions or deductions•
The design, implementation, and maintenance of internal controls relevant to the preparation of the report toare utilized,
they are disclosed. Where direct data was unavailable, the company used industry standards as estimates. The assurance provided
provide reasonable assurance that the report is free from material misstatement, whether due to fraud or error.
therefore
does
guarantee
providecertainty
thecompletenessof reported
data.
•
Ensuring
the not
Reported
Informationor
is fairly
stated inaccordance overwith theapplicable
criteria (“Reporting
Criteria”) andfor the content and statements contained therein.

Illumina’s responsibilities
The Company’s management are responsible for:
• The accuracy and completeness of the information contained in the Reported Information.
• The design, implementation, and maintenance of internal controls relevant to the preparation of the report to provide reasonable assurance thatthe report is free from material misstatement, whether due to fraud or error.
• Ensuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting Criteria”) and for the content andstatements contained therein.

Brian Noveck
CSAP Practitioner for, and on behalf of, ISOS Group, Inc.
April 8, 2024

Lauren Anderson
ACSAP Practitioner for, and on behalf of, ISOS Group, Inc.
April 8, 2024

We have not performed any procedures with respect to other information included in the Illumina 2022 Corporate Responsibility Report and, therefore, no conclusion on the Report as a whole is expressed.

Learn More: 2023 Assurance Letter

Disclosures
This report may contain forward-looking statements that involve risks and uncertainties.
Among the important factors to which our business is subject that could cause actual
results to differ materially from those in any forward-looking statements are: (i) changes
in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer
orders among our products and services; (iii) our ability to adjust our operating expenses toalign with our revenue expectations; (iv) our ability to manufacture robust instrumentationand consumables; (v) the success of products and services competitive with our own; (vi)challenges inherent in developing, manufacturing, and launching new products and services,
including expanding or modifying manufacturing operations and reliance on third-party
suppliers for critical components; (vii) the impact of recently launched or pre-announced
products and services on existing products and services; (viii) our ability to modify ourbusiness strategies to accomplish our desired operational goals; (ix) our ability to realize
the anticipated benefits from prior or future actions to streamline and improve our R&D
processes, reduce our operating expenses and maximize our revenue growth; (x) our
ability to further develop and commercialize our instruments, consumables, and products;(xi) to deploy new products, services, and applications, and to expand the markets forour technology platforms; (xii) the risks and costs associated with our ongoing inability tointegrate GRAIL due to the transitional measures imposed on us by the European Commission
as a result of their prohibition of our acquisition of GRAIL and orders issued by the European
Commission and the Federal Trade Commission requiring that we divest GRAIL; (xiii) therisks and costs associated with the expected divestment of GRAIL, including the possibility
that the terms on which we divest all or a portion of the assets or equity interests of GRAIL
are materially worse than those on which we acquired GRAIL; (xiv) our ability to satisfy thenecessary conditions to consummate the divestiture of GRAIL on a timely basis or at all, due
to the requirements set by the European Commission; (xv) the risk that disruptions from theconsummation of our acquisition of GRAIL and associated legal or regulatory proceedings,
including appeals, or obligations will harm our business, including current plans andoperations; (xvi) the risk of incurring additional fines associated with the consummation of ouracquisition of GRAIL; (xvii) our ability to obtain approval by third-party payors to reimburse
patients for our products; (xviii) our ability to obtain regulatory clearance for our products
from government agencies; (xix) our ability to successfully partner with other companies
and organizations to develop new products, expand markets, and grow our business; (xx)uncertainty, or adverse economic and business conditions, including as a result of slowing
or uncertain economic growth or armed conflict; (xxi) the application of generally accepted
accounting principles, which are highly complex and involve many subjective assumptions,estimates, and judgments and (xxii) legislative, regulatory and economic developments,
together with other factors detailed in our filings with the Securities and Exchange
Commission, including our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which are released beforehand. We
undertake no obligation, and do not intend, to update these forward-looking statements, toreview or confirm analysts’ expectations, or to provide interim reports or updates.

Stay up to date on recent news, stories, and more byconnecting with us.

Sam, director of public relations, sharing
the power of genomics to the next
generation of changemakers in China.

+1.800.809.4566 toll-free (US) +1.858.202.4566 tel
www.illumina.com©2024 Illumina, Inc.
All rights reserved. All other names, logos, and other trademarks are theproperty of their respective owners.